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Interleukin 6 (IL6) is associated with arterial disease development, progression and 
surgical outcome. Raised levels of IL6 may play a causal role in disease development 
or may be the effect of pathology. An IL6 single nucleotide polymorphism (SNP) G-
174C has been identified and reported to associate with IL6 expression. However, 
conflicting results have emerged and both the relationship between IL6 and vascular 
disease and the precise effect of SNP G-174C in vivo in humans remains obscure. 
 The aim of this study was to establish the effect of SNP G-174C in humans, in vivo 
in different tissues. Varicose vein surgery patients donated adipose tissue, skeletal 
muscle, vein and blood samples. Patients were genotyped for SNP G-174C. A new 
pre-mRNA assay was developed, using gel electrophoresis, restriction digest and 
fluorescence quantification, to measure the ratio of heterozygous allelic pre-mRNA 
transcription. IL6 mRNA expression in different tissues was also measured using 
relative real time PCR (RT-PCR) to assess effect of tissue type on expression profiles. 
mRNA expression within tissues was compared between G-174C genotypes, to 
further quantifying the association of SNP G-174C with transcript levels.  
  The pre-mRNA assay showed higher expression for the C-allele, though not 
statistically significant.  The pre-mRNA assay needed to detect low levels of intron 
retaining allelic pre-mRNA isoforms. Replicates and controls for residual genomic 
DNA were used to monitor assay precision. Adipose tissue gave the greatest 
precision in the pre-mRNA assay. In the RT PCR assay adipose tissue expressed 
significantly more IL6 mRNA than all other tissues examined. In vein and leukocytes 
subjects with the CC genotype expressed significantly higher levels of IL6 mRNA 
than subjects with GC or GG genotypes. There was a trend towards higher 
expression for the CC genotype in all tissue types. A significant though weak 
correlation between IL6 mRNA expression and age was demonstrated for vein and 
leukocytes.  
 Adipose tissue may be an important source of IL6 compared to other tissues. This 
may be relevant for obesity associated diseases. Subjects with G-174C genotype CC 
showed a trend towards higher IL6 RNA expression. Further studies are necessary to 
clarify the effect of genotype on IL6 expression.   3 
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1  Introduction 
1.1  Interleukin 6 (IL6) 
Interleukin 6 (IL6) is regarded by many as one of the most important cytokine in the 
acute phase response (1-3). Besides its physiological role in immune defence, it has 
been associated with a wide range of diseases such as atherosclerosis (4), cancer, 
diabetes,  asthma,  rheumatic  diseases,  inflammatory  bowel  disease  and  a  host  of 
other pathological processes (5-9).  
 
Cytokines  such  as  IL6  are  proteins  that  act  as  intercellular  mediators.  They  are 
produced by a variety of tissues and cells and generally act locally in a paracrine or 
autocrine manner. IL6 is a predominantly pro-inflammatory cytokine. It is expressed 
by  macrophages/monocytes,  T-lymphocytes,  adipocytes,  endothelial  cell,  vascular 
smooth muscle cells, fibroblasts, osteoblasts, chondroblasts and myocytes (10-12). 
IL6  plays  a  central  role  in  host  defence  through  the  induction  of  acute  phase 
response  proteins,  maturation  of  B-cells  into  antibody  producing  cells  and 
stimulation of  proliferation and differentiation of cytotoxic T-cells  (13). In addition 
to this role in immune response, IL6 has a positive effect on haematopoiesis and 
plays a role in regulating cell numbers and neuronal function in the central nervous 
system (14;15).  
 
This study focused on IL6 because of its potential role in vascular disease 
development as well as outcome from vascular surgery. Numerous association 
studies have linked raised levels of interleukin 6 to the development and progression 
of atherosclerosis, however the causal nature of this association is still in doubt (see 
section 1.5). Genetic variation may have an effect on circulating levels of IL6; 
therefore genetic studies could potentially be used to investigate causality (see 
section 1.7). The experimental design of this study aimed to clarify the effect of a 
genetic variant on IL6 gene expression.  
The following introduction will summarise the background information important in 
understanding the potential regulatory mechanisms of this protein. It will summarise 
existing evidence of association between IL6 and aspects of vascular disease 
development as well as outcome from vascular surgery.   21 
1.2  The IL6 Gene 
The  gene  for  IL6  was  first  mapped  to  chromosome  7  in  1986  (16).  Subsequent 
studies  further  localised  the  gene  to  the  short  arm  of  the  chromosome  (position 
7p21-p15) (17;18). The gene contains five exons. Exons are regions of a gene that 
are expressed i.e. are translated into protein (19) (see Figure 1-1). 
 
 
 
Figure 1-1: Schematic representation of IL6 gene (not to scale) showing promoter region (control 
point for regulated gene transcription), untranslated regions (region of gene transcribed into RNA 
but not translated into protein), introns (region of the gene transcribed into RNA but spliced out 
before translation into protein occurs) and exons (protein coding regions). 
 
1.3  IL6 Expression 
The plasma level of IL6 is determined by the rate of IL6 gene expression and 
subsequent release into the circulation as well as the plasma clearance rate (20;21). 
The activity and half-life of circulating IL6 is affected by the presence of interleukin 6 
receptor (IL6R) which in turn is determined by factors such as exercise (22;23). 
Thus the levels of biologically active circulating IL6 are regulated at various steps of 
which gene expression is the first. Gene expression is the process by which the DNA 
sequence of a gene is converted into a functional protein starting with transcription 
during which the coding DNA strand sequence is copied into ribonucleic acid (RNA) 
and ending with post translational changes of the protein substrate.  
Expression of IL6 is induced by a variety of inflammatory stimuli such as interleukin 
1β (IL1β), tumour necrosis factor α (TNFα), platelet derived growth factor, 
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transforming growth factor β, bacterial products (e.g. lipopolysaccharides) and viral 
infection (12;24). IL6 expression by monocytes is inhibited by IL4 and IL13 (25). 
 
Gene expression is regulated at various levels. The first and most important is the 
primary control of transcription. Subsequent levels of regulation are alternative 
splicing, RNA editing, regulation of translation and post translational changes of the 
protein substrate (25;26). 
 
Transcription is tightly regulated by transcription factors. Transcription factors form 
part of the transcription initiation complex which binds to the promoter region of the 
gene. They can act as activators, such as nuclear factor IL6 (NF-IL6) and nuclear 
factor κB (NF-κB) or as inhibitors, e.g. glucocorticoid receptor (24). Experiments 
have shown the region -180 to -123 in the promoter region of the IL6 gene to be 
important for transcription induction by IL1 (24;27;28).  Genetic variation within this 
region may therefore affect gene expression. 
Primary transcription of the gene results in a precursor RNA copy of the DNA 
sequence called heterogeneous nuclear RNA (hnRNA). hnRNA contains untranslated 
regions (UTRs) as well as exons and introns. Before RNA is translated into protein it 
undergoes splicing. Splicing removes introns from the RNA sequence and binds 
consecutive exons together. This process occurs in the nucleus. Splicing is catalysed 
by the spliceosome, a large RNA/protein complex composed of small nuclear 
ribonuclear proteins (snRNP) [snRNP= small nuclear ribonucleic acids (snRNA) and 
ribonuclear proteins (RNP)]. Catalysis results in a series of biochemical reactions 
between the RNA nucleotides leading to the removal of introns from the RNA 
message and ultimately to the formation of messenger RNA (mRNA) (25;26) (see 
Figure 1-2).    23 
 
Figure 1-2: Primary transcription of DNA into hnRNA followed by cleavage of  5' splice site with 
lariat formation and cleavage of 3' splice site. End product is mRNA which does not contain the 
intron region. The spliced intron is debranched and degraded. 
 
In the human transcriptome alternative splicing is a frequent phenomenon. There 
are four major types of alternative splicing: exon skipping, alternative 3’ splice site, 
alternative 5’ splice site and intron retention (29;30). Exon skipping seems to be the 
most frequent type of alternative splicing (31). During exon skipping exons are 
removed together with the intronic regions. This leads to non-consecutive exons 
being joined together. Alternative splicing allows multiple mRNA and in turn protein 
isoforms to be generated from one gene. This process is important as the alternative 
products may or may not maintain their biological activity. Whether or not they do, 
will depend on the function of the domain that was lost/maintained during 
alternative splicing and on how the tertiary structure of the protein is altered.  
To date several alternative splice products for IL6 have been described, though the 
relative abundance of the different isoforms has not been clearly established. 
Alternative splicing in IL6 predominantly leads to the loss of exon two. Two distinct 
isoforms seem to exist, both missing exon two (IL6∆2). One of these exerts IL6 
inhibitory properties on proliferation and differentiation (32), while the other does 
not appear to serve as a significant inhibitor to IL6 (33). IL6∆2 encodes a 
predominantly intracellular protein which could provide an explanation for the cell   24 
surface receptor-independent IL6 signalling seen in a variety of cell systems 
(21;34). There is no evidence to date that intron retention occurs in IL6 RNA, 
however other isoforms, missing part of exon 2, arising from alternative promoters 
and truncated versions have been described (35).  
RNA editing and translation occurs in eukaryotes. RNA editing involves chemical 
modification of mRNA (2). Following any post-transcriptional changes the mature 
mRNA is translated into protein. Translation of mRNA may be affected globally by 
phosphorylation of eIF-2a, a translation factor or by transcript specific regulatory 
mechanism (2), however these regulatory mechanisms have not been specifically 
investigated in IL6. 
The IL6 protein consists of 184 amino-acids and a 28 amino-acid-hydrophobic signal 
sequence (36). The protein undergoes post translational changes involving 
glycosylation and phosphorylation which affect the tertiary structure and the 
biological activity of IL6. These post translational changes appear to be tissue 
specific (37;38). As a result of the post transcriptional as well as the 
posttranslational changes, IL6 is secreted as a set of proteins that are 
heterogeneous, with varying molecular mass (39).  
 
1.4  Signaling Pathways for IL6 
There appears to exist one intracellular and one extracellular IL6 inducible signalling 
pathway. The details of the intracellular pathway are yet to be defined, but 
alternative splice products (see section 1.3), have been postulated to play a crucial 
role (21;34).  
The extracellular pathway is known to act via the IL6 receptor (IL6R) complex 
containing two distinct transmembrane molecules: the ligand binding subunit IL6 
receptor and the signal transducing protein gp130 (40-42). The IL6 receptor 
complex is under the control of several regulatory mechanisms. The IL6R subunit is 
up regulated by dexamethasone and down regulated by IL6 and granulocyte 
macrophage colony-stimulating factor (43). Tumour necrosis factor, IL1 and 
dexamethasone up regulate gp130 (43). 
The IL6R exists in membrane bound and soluble form (sIL6R). sIL6R is generated 
either by proteolytic cleavage (shedding) of the membrane bound IL6R or by 
alternative splicing of the IL6R mRNA (40;44;45). Many cells, e.g. endothelial cells, 
are unresponsive to IL6 as they miss the membrane bound IL6 receptor(45). 
However the presence of the soluble IL6 receptor (sIL6R) enables these cells to   25 
mount an inflammatory response to IL6 via the interaction of the soluble IL6 
receptor/ IL6 complex (sIL6R/IL6) with membrane bound gp130 (45). This process 
is called trans-signalling (46). Gp130 trans-signalling is not exclusive to IL6. Other 
members of the IL6 family also trans-signal through gp130, a phenomenon termed 
receptor redundancy (47;48). It is important to take receptor redundancy into 
account, when considering IL6 blockade for therapeutic purposes. Gp130 may be 
activated by other members of the IL6 family, thus rendering isolated IL6 blockade 
ineffective. 
Recent evidence has been found for a soluble gp130 receptor which may exhibit 
antagonistic properties. However neither the in vivo control nor the functional 
significance of soluble receptors is clearly understood (49). 
Signal transduction via the gp130 receptor results in activation of the janus kinase 
(JAK)/signal transducers and activator of transcription (STAT) pathway (12) (see 
Figure 1-3). Gp130 receptors associate with members of the janus kinase family. 
Binding of IL6/IL6R to the gp130 receptor induces dimerisation of the liganded 
receptor, which induces tyrosine phosphorylisation of the associated JAKs. The JAKs 
in turn phosphorylate tyrosine residues in the receptor endodomain. These 
phosphorylated tyrosines are recognized by the SH2 domains of STAT1, STAT3 and 
SPH2 tyrosine phosphatase which are recruited to the activated receptor complex. 
Once a STAT molecule is bound to the receptor, JAK catalyses its tyrosine 
phosphorylation, which leads to hetero or homo dimerisation. The dimerised STAT is 
translocated to the nucleus. Here it binds to a specific DNA response element in the 
promoter region of the target gene, activating gene expression (50). Seven types of 
STATs have been identified. Of these, STAT3 appears to be vital for the signalling of 
IL6 (51). 
On the other hand SPH2 has a negative regulatory effect on STAT activation. In 
addition it acts as an adaptor protein that links IL6 to the Ras/ERK pathway. ERK has 
a positive effect on STAT nuclear translocation and activates transcription factors 
such as NF-IL6 and ELK1.    
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Schematic representation of the IL6 signalling pathway  
(from http://www.biocarta.com/pathfiles/h_il6Pathway.asp): 
  
Figure 1-3: The IL6R/IL6 complex is shown binding to the gp130 receptor subunit. This leads to 
activation of JAK, which in turn leads to activation of STAT3, which dimerises and translocates to 
the nucleus were it binds to the response unit of target genes. The activated JAK also induces a  
SHP2/GAB  mediated  ERK/MAPK  pathway  leading  to  activation  of  ELK1  and  inhibition  of  the 
JAK/STAT pathway. (Abbreviations: JAK=Janus Kinase; STAT= signal transducers and activators 
of transcription; SPH2=a Src homology 2-containing tyrosine phosphatase; GAB= Grb2 associated 
binder;  ERK=  extracellular-signal-regulated  kinase;  MAPK=  mitogen-activated  protein  kinase 
APRE=acute phase response element; EBS=EST binding site; CRE= cAMP regulatory element) 
 
The JAK/STAT signalling cascade has been studied extensively (52). If adequate 
control of this IL6 signalling pathway is to be maintained a negative regulatory 
mechanism for the cytokine response must exist. Functional studies have provided 
evidence that suppressors of cytokine signalling (SOCSs) may play an important role 
(53).  
   27 
Having summarised the regulatory mechanisms of transcription and IL6 signalling 
pathways, the following chapters will discuss the relevance of IL6 to arterial disease. 
 
 
1.5  IL6 and Aspects of Arterial Disease Development  
1.5.1  IL6 and Atherosclerosis 
IL6 has been implicated in a variety of diseases, one of which is atherosclerosis (54). 
Atherosclerotic disease is the most common cause of death in the western world (4).  
It represents a chronic  inflammatory process which has been shown to be 
associated with increased levels of circulation pro-inflammatory cytokines such as 
IL6, IL1β and TNFα (12). IL6 has been named as the most consistent biomarker of 
peripheral arterial disease to date (55). Many of the effects of IL6 relating to the 
vascular system are known and it is possible to delineate pathways through which 
IL6 may causally affect the development of atheroma. 
 
IL6 pathways in atherosclerosis 
The earliest manifestation of the atherosclerotic lesion is the  ‘fatty streak’ (56). 
Fatty streaks are characterized by the presence of macrophages and T-cells in the 
intima. Cell adhesion molecules are implicated in leukocyte recruitment into the fatty 
streak and have been shown to be up regulated in lesion prone sites in the arterial 
tree (57). These include vascular cell adhesion molecule 1 (VCAM1), intercellular 
adhesion molecule 1 (ICAM1)  and e-selectin (58;59). Both IL6 and TNFα can induce 
expression of these adhesion molecules in endothelial cells (12;60;61). VCAM1, 
ICAM1  and e-selectin interact with specific ligands on circulating leukocytes to 
facilitate their adhesion to the vessel wall (12). After binding to the endothelium, 
leukocytes migrate into the sub-endothelial space. This migration is driven by 
chemoattractants such as oxidised low density lipoproteins (oxLDL), lipoprotein(a) 
(Lp(α)),monocyte chemotactic protein 1 (MCP1), IL1 and tumour necrosis factor 
alpha (TNFα) (62).  IL6 is able to induce MCP1 and influence levels of TNFα and may 
therefore exert some control over this migration process. (see Figure 1-4)   28 
 
Figure 1-4: From AJ Lusis, Nature 2000. Inflammatory pathways in atherosclerosis. 
 
Once inside the intima, monocytes differentiate into macrophages. This process is 
partially controlled by IL6 and ultimately leads to the formation of lipid laden cells 
called foam cells. Foam cells are one of the characteristic components of the 
atherosclerotic plaque. The transition of macrophages into foam cells through lipid 
uptake is mediated by TNFα, IL1β and IFNγ which activate monocyte-macrophages 
to increase their mobility, phagocytosis and enzyme levels (12).  
The more advanced atherosclerotic lesion contains macrophages, T-cells, smooth 
muscle cells (SMC), extracellular lipid and matrix deposit (63). The cellular 
components of the advanced plaque contribute to the ongoing inflammatory process 
that drives plaque progression by expressing a variety of mediators involved in 
intercellular signalling. These mediators are involved in the proliferation of smooth 
muscle cells, a characteristic histological feature of a mature atherosclerotic lesion. 
IL6 and its soluble receptor have been shown to be released from human 
macrophages. The ensuing IL6/sIL6 receptor complex stimulates up regulation of 
gp130 in cultured human SMC and ultimately drives these cells into a proliferative 
state (64). As both macrophages and smooth muscle cells are a characteristic   29 
histological feature of a mature atherosclerotic lesion, it is possible that IL6 plays an 
important role in determining the cellular structure of the mature plaque.  
 
IL6 down regulates TNFα and IL1 expression, whereas transcriptional activity of IL6 
is increased in response to TNFα (12;24). IL6 and TNFα both have an effect on the 
expression of other mediators of atherosclerosis. IL6 and TNFα induce, among 
others, MCP1, a powerful chemo attractant involved in leukocyte adhesion and 
migration. Thus IL6 may have a direct effect on plaque development and an indirect 
effect through modulation of the expression of other mediators. 
In addition to the autocrine and paracrine effects of IL6 within the arterial lesion 
itself, IL6 is able to induce hepatic acute phase response proteins such as C-reactive 
protein (CRP) and fibrinogen. Increased levels of fibrinogen lead to a state which 
favours atherothrombosis (65).  
 
Besides this evidence for the involvement of IL6 in molecular processes leading to 
atherosclerosis, clinical studies also suggest a role for IL6 in the atherosclerotic 
disease process. 
 
IL6 and Atherosclerosis: Clinical Evidence 
Interleukin gene transcripts have been found to be expressed in human 
atherosclerotic lesions with atherosclerotic arteries showing a 10-40-fold higher level 
of IL6 mRNA than non-atheromatous vessels (54), suggesting a fundamental 
involvement of IL6 in plaque development (46).  Elevated levels of circulating IL6 
are found in patients  with abdominal aortic aneurysms and chronic limb ischemia 
(66-71). Furthermore raised levels of IL6 are associated with coronary, peripheral 
and carotid atherosclerosis (72) and risk of death in patients with cardiovascular 
disease (9;73;74). 
Low echogenicity of carotid plaques is a known risk factor for plaque rupture and 
ischaemic stroke. IL6 levels have been shown to be inversely related to plaque 
echogenicity (75). This association could relate to IL6 induced monocyte recruitment 
with subsequent expression of matrix metalloproteinases leading to plaque rupture 
(76;77). Thus IL6 seems to be associated with both chronic vascular disease and 
acute vascular events. 
 
Raised IL6 levels also appear to have some predictive value for vascular disease. 
Circulating levels of IL6 have been shown to be associated with evidence for sub-  30 
clinical atherosclerosis, independent of traditional risk factors (78). In the Edinburgh 
Artery Study serum IL6 at baseline was found to be the most reliable predictor of 
arterial disease progression as assessed by ankle brachial pressure index (ABPI) of 
all the inflammatory markers examined (79). ABPI in turn predicts future 
cardiovascular risk as has been shown in several large scale trials (80;81). Elevated 
levels of circulating IL6 are also associated with an increased risk for future 
myocardial infarction in healthy individuals (82). A prospective study of healthy men 
compared 202 participants who developed myocardial infarction within the follow up 
period of 6 years with 202 asymptomatic matched controls. A correlation between 
raised IL6 levels at baseline and increased cardiovascular risk over a prolonged 
period of time was found (82) (see Table 1.9-1 & Figure 1-5).   31 
Table 1.9-1: Table from PM Ridker (Circulation 2000) showing crude and adjusted relative risk 
(RR) of future myocardial infarction among apparently healthy men according to baseline level of 
IL6. (Fully adjusted models additionally controlled for total and HDL cholesterol, body mass index, 
diastolic blood pressure, diabetes, family history of premature coronary artery disease, alcohol use, 
and exercise frequency.)  
Quartile of IL-6 (range, pg/mL) 
 
  1 (<1.04)  2 (1.04–1.46)  3 (1.47–2.28)  4 (>2.28)  P for Trend 
Crude analysis 
 
Total cohort           
RR  1.0  1.4  2.8  2.3  <0.001 
95% CI  ...  0.7–2.6  1.6–5.1  1.3–4.3   
P  ...  0.3  0.001  0.005   
Nonsmokers           
RR  1.0  1.4  2.5  2.6  0.001 
95% CI  ...  0.7–2.7  1.4–4.7  1.3–4.8   
P  ...  0.3  0.003  0.01   
Total and HDL cholesterol adjusted 
 
Total cohort           
RR  1.0  1.5  2.9  2.3  0.003 
95% CI  ...  0.7–2.9  1.6–5.4  1.2–4.3   
P  ...  0.3  0.001  0.01   
Nonsmokers           
RR  1.0  1.6  2.6  2.5  0.003 
95% CI  ...  0.8–3.1  1.4–5.1  1.3–5.1   
P  ...  0.2  0.004  0.01   
Fully adjusted 
 
Total cohort           
RR  1.0  1.9  3.5  2.3  0.01 
95% CI  ...  0.9–3.9  1.8–6.9  1.1–4.6   
P  ...  0.08  0.001  0.03   
Nonsmokers           
RR  1.0  2.1  3.1  2.7  0.009 
95% CI  ...  1.0–4.5  1.6–6.7  1.1–5.7   
P  ...  0.06  0.002  0.02   
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Figure 1-5: Graph from PM Ridker (Circulation 2000) showing relative risk of future myocardial 
infarction associated with each increasing quartile of baseline IL-6 concentration according to 
months of follow-up. The figure demonstrates an increased risk associated with increased IL6 levels, 
which is stable over a prolonged time period. 
 
The fact that raised levels of IL6 can precede clinical disease development or 
progression could suggest that IL6 is causally involved in atherosclerosis and thus 
could be clinically relevant. However it could equally be argued that an increase in 
circulating IL6 may merely be the result of an inflammatory process in the arterial 
wall which has not yet become clinically detectable. Thus the question of causality 
remains unanswered. 
One facet of the potentially causal relationship between IL6 and atherosclerosis is 
the suggestion that IL6 may form part of a link between risk factors and 
atherogenesis.  
1.5.2  IL6 and Risk Factors for Atherosclerosis 
It has been hypothesised that IL6 is not only associated with arterial disease itself 
but may in fact be part of the pathway that links risk factors with arterial disease 
development. 
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Hypertension  
Clinical trials have shown a significant association between hypertension and 
atherosclerosis however the exact underlying mechanism for the association remains 
uncertain (83-86). With increased understanding of the cellular and molecular 
processes involved, it has become apparent that certain mechanisms are common to 
both hypertension and atherosclerosis (83). It has been suggested that the bridge 
connecting these two conditions is inflammation (84).  In this respect Angiotensin II, 
part of the Renin Angiotensin System (RAS) important in blood pressure (BP) 
control, appears to play a major role (87-94). Angiotensin II stimulates nicotinamide 
adenine dinucleotide phosphate (NADPH)/nicotinamide adenine dinucleotide (NADH) 
oxidase in the components of the vessel wall, leading to the generation of reactive 
oxygen species. This in turn, leads to up regulation of NF-κB which stimulates IL6 
expression and thus contributes to a pro-inflammatory state (83;84;89;92;95-98). 
Therefore factors involved in initiating hypertension such as Angiotensin II may via 
pro-inflammatory factors such as IL6 also influence the development of 
atherosclerosis. A recent paper has defined a positive feed back loop, that 
demonstrates how vascular inflammation can become self sustaining (87). The local 
production of Angiotensin II in the vessel wall leads to the induction of IL6 
expression which in turn leads to up regulation of angiotensinogen production by the 
liver via the Janus Kinase (JAK)/signal transducer and activator of transcription 
(STAT) pathway. This supplies more substrate to the activated vascular renin 
angiotensin system leading to further production of Angiotensin II - perpetuating 
vascular inflammation (87).  
 
The importance of the IL6 mediated effects of the RAS on the atherosclerotic process 
is demonstrated by clinical studies showing that a variety of antihypertensive agents 
can exert an anti-atheromatous effect independent of blood pressure reduction 
(87;89;99;100). This effect has been put down to inhibition of the expression of 
inflammatory mediators such as IL6. Other clinical studies have shown that high IL6 
levels correlate with increased blood pressure in men (82;101). Recent studies in IL6 
knock out mice have demonstrated hypertension caused by angiotensin II and high 
salt diet as well as the acute hypertensive response to stress significantly depends 
on the presence of IL6 (102;103). This suggests that IL6 may mediate both the 
hypertensive effect as well as the atherosclerotic effect of Angiotensin II. 
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Type II Diabetes  
Atherosclerotic disease occurs at a significantly higher rate in individuals suffering 
from diabetes than in the general population (104-107). Atherosclerotic disease has 
been regarded as the sequel of longstanding diabetes. However, recent evidence 
shows that markers of sub clinical vascular disease can predict future risk of Type II 
diabetes and that cardiovascular disease (CVD) can precede the onset of diabetes by 
up to 15 years (108;109). This has lead to the theory that both Type II diabetes and 
CVD share a common pathophysiology, possibly reduction in nitric oxide (NO) (110) 
(111). Reduction in NO appears to occur in hyperglycaemia and insulin resistance as 
well as arterial plaque development (111-114). It occurs via down regulation of 
endothelial nitric oxide synthase and chemical reaction of NO with reactive oxygen 
species (115). The local production and release of nitric oxide is crucial to normal 
endothelial function, as NO is a powerful vasodilator  and inhibitor of platelet 
aggregation, leukocyte adhesion and vascular smooth muscle cell proliferation 
(116;117). Decreased production of NO has been shown to be associated with the 
increased activation of transcription factor NF-κB (118-122). NF-κB in turn increases 
expression of pro inflammatory cytokines such as IL6, IL1 and TNF thereby creating 
a pro-atherogenic environment (116).  
A rise in IL6 can also promote insulin resistance. In human hepatocytes insulin 
receptor signal transduction is impaired by IL6 and in fat cells IL6 may promote 
insulin resistance via induction of suppressor of cytokine signalling (SOCS)-3 
(123;124). Therefore reduction in NO may via increase in IL6 create both an athero- 
and a diabetogenic environment.  However, the effect of IL6 on glucose metabolism 
may be tissue specific. Inhibition of insulin receptor substrate 1 (IRS-1) and 
induction of SOCS-3 thought to induce insulin resistance could only be demonstrated 
in the liver but not the muscle of IL6 treated mice (125). In fact IL6 may improve 
glucose uptake in muscle cells (125). Thus the overall effect of IL6 on glucose 
metabolism remains controversial, as does the theory of a joint developmental 
pathway for diabetes and vascular disease via IL6. 
 
Hypercholesterolemia  
The association between raised cholesterol levels and vascular disease is well 
described. Oxidised low density lipoprotein (oxLDL) can decrease endothelial nitric 
oxide synthase (eNOS) expression and thus nitric oxide bioavailability which leads to 
endothelial dysfunction (126;127). One pathway through which oxLDL may mediate 
reduction in eNOS expression is through binding to the lecithin-like oxLDL receptor 1   35 
(LOX1) present on human endothelial cells. The binding of oxLDL to LOX1 on 
endothelial cells leads to activation of intracellular signalling pathways such as 
mitogen-activated protein kinase (MAPK) (128) which may  induce inhibition of eNOS 
expression (129). It has also been shown in bovine aortic endothelial cells that 
activation of the LOX1 receptor by oxLDL leads to increase in the production of 
reactive oxygen species (ROS) such as superoxide anions (130). These can react 
with and deactivate nitric oxide also leading to a reduction in its bioavailability. 
Another effect of binding of ox-LDL to LOX-1 is an increase in NF-κB expression. This 
may also be mediated via the MAPK cascade or possibly an increase in ROS 
(128;131). NF-κB  in turn leads to up regulation of IL6 and other inflammatory 
mediators, as well as endothelial vasoconstrictors and growth factors producing a 
pro-atherogenic environment in the vascular wall (117). Hypercholesterolemia may 
therefore induce atherosclerosis in part via a pathway involving IL6.  
Clinical evidence supports the view that inflammation and its mediators are involved 
in the association between hypercholesterolemia and arterial disease (132). Statin 
drugs, which are known to reduce the morbidity and mortality from cardiovascular 
events, appear to have anti-inflammatory activity (133;134) (135;136). Carotid 
plaques from patients receiving statin therapy have been shown to contain less IL6 
than plaques from untreated patients (132). Simvastatin and atorvastatin have been 
shown to reduce IL6 levels in the first 7 days following the start of treatment 
(137;138) and the beneficial effect of statins on cardio-vascular disease are thought 
to be in part mediated by this reduction (139). 
 
Smoking 
Though the underlying mechanism is not fully understood, smoking is associated 
with accelerated atherosclerosis and cardiovascular disease (140;141). One possible 
mechanism is via increased generation of reactive oxygen species (ROS), which has 
been shown to occur in smokers (141;142). This encourages oxidation of low density 
lipoproteins which have been shown to have a pro-atherogenic effect (see above) in 
part through reducing nitric oxide (NO) bioavailability resulting in endothelial 
dysfunction as well as induction of IL6 expression (141;143-145). Indeed serum 
levels of IL6 in current smokers and former smokers have been found to be 
significantly higher than in non-smokers (140;146-148). Other factors that may 
potentially mediate the atherogenic effect of smoking are increased platelet turnover 
and activation and increase in circulating fibrinogen (149;150). It has been shown 
that smoking increases fibrinogen levels in healthy volunteers and in patients with   36 
coronary artery disease (CAD) (151-154). IL6 is important in regulating fibrinogen 
levels, leading to up regulation of fibrinogen synthesis in the liver (152). An IL6 
response element exists in the promoter region of the β-fibrinogen gene and, as 
production of β-fibrinogen is thought to be the rate limiting step in fibrinogen 
synthesis, IL6 may directly influence the rate of fibrinogen production (155) 
(156;157). It is therefore possible that the increase in fibrinogen in smokers is 
mediated through IL6. One study investigated fibrinogen levels in healthy controls 
and patients with coronary artery disease (CAD) (152). Both groups were further 
subdivided into smoker and non smokers. This study demonstrated a significant 
difference in IL6 levels between smoking and non smoking CAD patients. No 
difference was seen  in healthy volunteers (152). However, coronary artery disease 
had a greater effect on fibrinogen levels that smoking (152). Thus smoking may 
increase IL6 levels in patients who already suffer from arterial disease, but the 
increase in fibrinogen in these patients does not appear to be mediated entirely 
through IL6 (152).  
Smoking may increase the development of vascular disease and its complications 
through a variety of pathways, however the relative importance of the individual 
effects is not clear (141).  
 
Obesity 
Obesity, particularly visceral obesity is associated with an increased risk for 
cardiovascular disease (158). Adipose tissue has traditionally been regarded as a 
passive energy store, however more recently it has become apparent that fat is an 
important endocrine organ (159). It secretes a variety of bioactive peptides involved 
in glucose and fat metabolism. These include leptin, adiponectin, resistin as well as 
interleukin 6 (160-162). Furthermore IL6 levels are increased in obese subjects and 
IL6 levels increase with increasing adiposity (163;164). It has therefore been 
suggested that obesity represents a low grade inflammatory state and that the 
associated increased levels of IL6 are the link between obesity and atherosclerosis 
(49;160;165;166).  
Studies looking at site of production of circulating IL6 suggest a greater contribution 
from visceral fat than from peripheral adipose tissue (167;168). Assuming IL6 
represents a link between atherosclerosis and obesity, this would correlate with the 
observation that visceral obesity constitutes a greater risk factor for atherosclerosis 
than peripheral adiposity (167;168). 
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It appears that IL6 is closely associated with arterial disease development. There is 
evidence for a potential role for IL6 in the cellular processes of plaque formation, as 
well as a link between risk factors and vascular disease. In addition IL6 may affect 
surgical treatment outcome and relevant evidence is discussed in the following 
chapters. 
 
1.6  IL6 and Vascular Surgery 
1.6.1  IL6 Response to Surgery in the early Post-operative Period 
1.6.1.1 Local IL6 Response 
IL6 may be involved in wound healing through stemming of infection and removing 
cellular debris through leukocyte infiltration (169). It may further be involved in 
angiogenesis through induction of vascular endothelial growth factor (VEGF) and 
may modulate matrix metalloproteinase (MMP) expression  (170-172). It is unclear 
whether IL6 overall plays a positive or negative role in wound healing as its effects 
are complex. MMPs are enzymes capable of degrading extracellular matrix deposits 
and thus play a major role in tissue remodelling and can potentially delay wound 
healing. IL6 may stimulate expression of matrix metalloproteinase 9 (MMP9), which 
when present in increased amount is associated with poor wound healing and 
chronic ulcers (173-176). However, delayed wound healing in glucocorticoid treated 
mice can be partially reversed by administration of recombinant (rm)IL6 (173). It is 
thought that rm-IL6 acts through suppressing MMP10 production, which is increased 
by glucocorticoids (177).  
Wound healing in IL6 knock out mice is significantly delayed when compared with 
wild type mice (170) and restored by administration of recombinant mouse IL6, 
while IL6 antibodies and (rm)IL6 delayed wound healing in wild type mice (178-
180). It is therefore possible that physiological levels of IL6 are necessary for normal 
wound healing, but raised IL6 levels have a negative effect on re-establishing tissue 
integrity following injury.  
IL6 may further influence wound healing by suppressing albumin production in 
hepatocytes (181). Low albumin levels in turn are thought to be associated with 
poor wound healing. 
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1.6.1.2 Systemic IL6 Response 
 
Systemic Inflammatory Response Syndrome and Multi Organ Failure 
Major surgery, such as aortic surgery, is accompanied by a systemic inflammatory 
response associated with an increase in circulating cytokines (182). The most 
consistently identified rise in cytokines is that of circulating IL6 (177;183). Studies 
into the IL6 response following aortic surgery, found that IL6 levels were 
significantly associated with major postoperative complications (184). A study 
looking at levels of  TNFα, IL1β and IL6 following abdominal aortic aneurysm (AAA) 
repair, found that those with adult respiratory distress syndrome (ARDS)/Multi-organ 
failure had significantly higher levels of IL6 then those without (177;183). An 
exaggerated post-operative IL6 response can precede the onset of clinical 
complications by 12 to 48 hours (71;169;185-187). Whilst consistent with a role for 
IL6 in causing post-operative complications, it remains possible that this association 
derives from a confounding effect, or that post-operative complications drive IL6 
synthesis before they become clinically manifest. 
 
Systemic inflammatory Response in Endovascular Aortic Repair 
It would appear that the characteristics of the surgical procedure influence the 
extent of the post-operative IL6 response. Both the extent of tissue trauma and the 
duration of the procedure have been cited as the determinant of the postoperative 
IL6 levels with evidence that the main determinant is extent of tissue injury (188). 
This is of interest when considering the impact of emerging endovascular techniques 
in which the reduction of tissue trauma could convey a major advantage. It has been 
shown that post-operative IL6 levels are reduced after endovascular aneurysm 
repair (EVAR) when compared to open AAA repair (189-193). However IL6 is not 
only release from injured tissues; the aortic mural thrombus itself has been shown 
to contain high amounts of IL6 which could be released during manipulation inside 
the thrombus during endovascular repair (194). Thus increases in IL6 may be part of 
the post-operative inflammatory response in both open and endovascular surgery, 
though one may induce a smaller response than the other.  
 
Ischaemia Reperfusion Injury 
Ischaemia reperfusion injury initiates an inflammatory response which is reflected in 
an increase in circulating cytokines, including IL6 (195). Hypoxia has been   39 
demonstrated to induce expression of IL6 in endothelial cells and a study looking at 
lower limb bypass surgery showed that circulating levels of IL6 were markedly raised 
following reperfusion compared to levels measured prior to clamping (71;192;196) . 
Studies on ischaemia reperfusion injury have also demonstrated high levels of 
cytokines in both the legs (IL6,IL8,IL10) and the gastrointestinal tract (IL6) 
compared with systemic levels following aortic clamping (197).  
Tissue ischaemia then results in accumulation of high levels of inflammatory 
mediators such as IL6, which on reperfusion are released into the systemic 
circulation (198-201). The activation of inflammatory pathways can result in injury 
to distant organs such as the lung and kidney through the vascular sequestration of 
activated neutrophils and damage by activated resident neutrophils (202).  
There is evidence from mouse models that IL6 directly contributes to the organ 
injury caused by ischaemia reperfusion I/R induced systemic inflammatory response. 
A study looking at renal ischaemia in IL6 knockout mice compared to wild type mice 
found evidence that IL6 enhances the degree of renal injury, dysfunction and 
inflammation following reperfusion (203). It was also shown that inhibition of NF-κB 
can prevent lung injury induced by intestinal I/R in mice (71). As NF-κB induces 
expression of IL6 and TNFα, it is possible that these play a causal role in the 
development of distal organ injury leading to multiple organ failure following I/R.  
 
Immunosuppression 
It is known that major surgery can lead to an immune suppressed state (185;204-
206). Major surgery is associated with an early hyper-inflammatory response 
characterised by the release of pro-inflammatory cytokines such as TNFα, IL1 and 
IL6 (43;205-207). It is thought that the rise in IL6 may paradoxically play a role in 
the post-operative immune depressed state (185). Although IL6 is generally 
regarded as a pro-inflammatory cytokine it also displays anti-inflammatory 
properties which are thought to be important in its function as an immune regulatory 
cytokine (43). The release of IL6 leads to up-regulation of major anti-inflammatory 
mediators e.g. by stimulation of macrophage expression of interleukin-1-receptor 
antagonist and a soluble TNF receptor (208). In addition IL6 is also able to directly 
inhibit expression of TNFα and IL1 (209-211). Another pathway through which IL6 
can contribute to the post-operative immune suppression is by stimulating the 
expression and release of strong anti-inflammatory mediators such as transforming 
growth factor β (211), prostaglandin E2 and glucocorticoids (210-212).  
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TNFα, IL1 and IL6 are all raised in the immediate postoperative period  
(183;204;213). However whereas the rise in TNFα and IL1β is relatively short lived 
(183;207;213), IL6 levels remain elevated for up to 7 days following surgery 
(183;214). This prolonged release of IL6 may lead to an imbalance between pro- 
and anti-inflammatory cytokines and ultimately contributes to the immune 
suppressed state seen after major surgery. This theory is supported by a study 
showing that high levels of IL6 in the early postoperative phase after 
oesophagectomy are associated with a late phase suppression of cellular immunity 
(204). Increased IL6 levels on day one following major tumour resection also 
correlate with Interleukin 1 receptor antagonist (IL1ra) levels (183;215;216).  
 
Besides its role in the early postoperative period IL6 also appears to influence long 
term outcome from vascular surgery. 
 
1.6.2  IL6 and Long Term Outcome after Vascular Surgery 
1.6.2.1 Graft Patency/Intimal Hyperplasia 
Intimal hyperplasia complicates all forms of arterial reconstruction (217;218). It is 
the principal cause of failure in vein and synthetic grafts and in atherosclerotic 
arteries that have been stented. Intimal hyperplasia involves a process in which 
smooth muscle cells migrate into the intima were they proliferate, accompanied by 
the secretion of matrix proteins. This leads to an increase in arterial wall thickness 
and narrowing of the lumen. It has been suggested that cytokines such as IL6 and 
TNFα  might contribute to the mesenchymal cell recruitment, proliferation and 
intimal hyperplasia seen in vascular grafts (219). IL6 and its soluble receptor have 
been shown to lead to cellular proliferation in cultured human smooth muscle cells. 
(220). IL6 has also been shown to induce VEGF (vascular endothelial growth factor) 
(220-222). Though the role of VEGF in neointimal hyperplasia is still controversial, it 
may have a role to play, as neovascularisation is part of the intimal hyperplastic 
process in models of angioplasty, arterial stenting and vein bypass grafting (223-
225). Also, administration of VEGF has been shown to increase intimal hyperplasia in 
an animal model of arterial injury (226). 
Studies in rats also suggest a role for IL6 in intimal hyperplasia. It was shown that in 
vivo  induction  of  toll  like  receptor  2  (Tlr2)  leads  to  increased  intimal  hyperplasia 
(227). Toll like receptors use a downstream NF-κB signalling pathway inducing the 
production  of  pro-inflammatory  cytokines  and  chemokines  (228-230).  This  is   41 
demonstrated in a study showing that vascular cells stimulated with a synthetic Tlr2 
ligand express  significantly more  IL6,  IL8 and MCP1 than control (231).  Another 
study investigating the NF-κB signalling pathway showed that inhibition of NF-κB in 
vivo reduces the development  of intimal hyperplasia in rats (232).  It is therefore 
likely that the intimal hyperplasia induction by Tlr2 is in part mediated via IL6.  
Further evidence for this comes from pharmacological studies. In a rat model the 
combined treatment with pravastatin and clopidogrel significantly decreased intimal 
hyperplasia following carotid endarterectomy. Pravastatin has been shown to reduce 
the expression of IL6 by smooth muscle cells (233). In addition endothelial cells pre-
treated with pravastatin show reduced IL6 synthesis (218). Clopidegril in turn could, 
through its antiplatelet effect, decrease cytokine release from activated platelets 
(218). It has therefore been proposed that the reduction in intimal hyperplasia seen 
in rats treated with pravastatin and clopidegril may in part be mediated by a reduced 
expression of cytokines such as IL6 (234).  
 
 
1.7  Proof of Causality and Mendelian Randomisation 
It has been demonstrated that IL6 levels are raised in patients suffering from 
atherosclerosis and that raised levels are associated with increase risk of developing 
cardiovascular disease as well as with poor outcome in the atherosclerotic patient. 
Pathways exist through which IL6 can modulate plaque development and become 
the link between risk factors for atherosclerosis and arterial disease itself. IL6 plays 
a major role in the inflammatory response to surgery and thus short term patient 
outcome, as well as long term outcome in terms of vascular graft patency. Thus IL6 
appears intricately involved in all aspects of atherosclerosis and vascular surgery, 
however final proof of causality has not been established.  
 
The association between increased in IL6 levels with aspects of the vascular disease 
process does not prove causality, as raised levels could equally be the result rather 
than the cause of pathology. Furthermore, much of the knowledge about IL6 has 
been gained from in vitro experiments. Although these provide good models, the in 
vitro effects cannot be assumed to be of relevance in vivo. The extent of redundancy 
in the cytokine system and the complexity of biological pathways involved in vivo, 
make it difficult to single out one mediator as the fulcrum in the disease process. 
Equally convincing arguments could be made for other mediators such as TNFα, IL1,   42 
NF-κB etc. being the likely essential link in the chain of events. Therefore before 
considering using immune modulation of IL6 to improve outcome for the vascular 
patient, IL6 has to be shown to have a causal effect that is clinically relevant. 
Studies aimed at showing causality using mouse models have given some insight; 
though interpreting the results is complex.  A study on atherosclerosis prone mice 
(ApoE-/-) demonstrated that exogenous administration of recombinant mouse 
interleukin-6 significantly enhanced fatty lesion development (235;236). This 
suggests that IL6 could indeed play a causal role in the development of vascular 
disease. However other studies, again using ApoE knock out mice but with an 
additional knock out of IL6 showed that life long deficiency of IL6 in ApoE knock out 
mice enhances atherosclerotic lesion development and increases cholesterol levels 
(237). This suggests that a certain level of IL6 is required to maintain a healthy 
vasculature but exogenous or excessive administration might be harmful. It is not 
clear whether exogenously administered IL6 will have the same effect as an 
intrinsically raised IL6 level and it is the intrinsic levels which are relevant in clinical 
terms. These considerations make interpretation of mouse models difficult.  
The ideal study to investigate the contribution of IL6 to arterial disease or outcome 
from arterial surgery would be to control IL6 levels in individuals over a prolonged 
period of time and assess the association of prolonged increased levels with 
increased plaque formation or increased complications form vascular surgery. 
Clearly, such a study could not be performed. However, in order to mimic the above 
conditions, scientists have recently employed Mendelian randomisation. Mendelian 
randomisation is the term applied to the random assortment of alleles at the time of 
gamete formation (238). This random assortment can lead to different individuals 
being genetically programmed to produce more or less of certain mediators at 
baseline or after stimulation. This variation in gene expression can be caused by 
polymorphisms within the gene. Polymorphisms are variations within a gene that 
occur in more than 1% of the population (239). Polymorphisms can affect the 
ultimate level of gene product in a variety of ways, e.g. promoter polymorphisms 
may affect the binding of the transcription initiation complex and thus the rate of 
primary transcription. Therefore if a genotype could be defined that would cause an 
individual to produce more IL6 than a person of a different genotype, this could be 
used to study the effects of IL6 in vivo.  
Using the example of IL6, Mendelian randomisation studies are based on the 
following principle: The level of IL6 has been found to correlate with arterial disease 
and disease/treatment outcome. However it is not possible to establish whether   43 
raised IL6 levels are cause or effect (reverse causation). If it can be shown that an 
individual’s genotype may influence levels of IL6 expression and proof is also found 
that this genotype is associated with disease development and outcome, than a 
strong case is made for a causal role of IL6 in this disease. The proof of causality 
relies on the fact that the association of genotype and disease is unidirectional i.e. 
must be based on the genotype influencing likelihood of disease outcome and 
progression. In other words – Genotype can influence disease, but disease cannot 
influence genotype. 
IL6 contains several common genetic variants but interest has focused on a single 
nucleotide polymorphisms (SNP) in the promoter region of the gene, which was 
defined in 1998 (238) (see Figure 1-6). This variant is a single nucleotide 
polymorphism (SNP) 174 base pairs upstream from the start of the untranslated 
region (UTR) were a guanine base is substituted for a cytosine base (SNP G-174C) 
(rs1800795). Although many studies have investigated SNP G-174C, its precise 
effect on IL6 gene expression remains unclear (see section 1.7.1). The reported 
allele frequencies vary widely in different populations (for the G allele 0.48 in the 
Finish population to 0.74 in an Italian population) (240). According to data from the 
HapMap project, genotype frequency in the Utah population of northern and western 
European ancestry is 0.53 for the G allele and 0.47 for the C allele. 
http://www.hapmap.org/cgi-perl/snp_details_B35?name=rs1800795&db=hm20 . 
However data from SeattleSNPs  http://pga.gs.washington.edu/finished_genes.html 
gives the frequency as 0.26 for the C allele and 0.74 for the G allele for a 
European/Afro American panel. 
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Figure 1-6: Schematic representation of the IL6 gene. The position of the promoter polymorphism is 
marked in light blue. 
 
The SNP G-174C promoter variant was shown to affect gene transcription in HeLa 
cells transfected with a construct of the 5’ region of the IL6 gene and a luciferase 
reporter gene. The -174C construct showing a 0.624 fold lower expression than the -
174G construct both with and without stimulation (238). The same study showed 
that circulating levels of IL6 were about twice as high in healthy subjects with the 
GG genotype then the CC genotype. A host of clinical studies followed the discovery 
of SNP G-174C, examining the association of the SNP and IL6 levels in human 
subjects as well as association of SNP G-174C genotype with disease development 
and progression. These have shown conflicting results. 
 
1.7.1  Mendelian Randomisation Studies: IL6 Promoter SNP G-174C 
A number of studies have tried to find evidence of an association between SNP G-
174C, varying IL6 expression and cardiovascular disease. Conflicting evidence has 
emerged from these studies.  
A number of studies confirmed the in vitro finding (238), that the GG genotype was 
associated with increases in IL6 expression. Circulating levels of IL6 were found to 
be higher in healthy subjects carrying the G-allele (238). The GG genotype was also 
found to be associated with higher levels of IL6 in patients who had undergone 
coronary artery bypass grafting (CABG) (241) and in Type II diabetic patients (242). 
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If IL6 plays a causal role in arterial disease development and the G-allele is 
associated with increased IL6 expression, then one would expect the GG genotype to 
be found more commonly amongst patients with vascular disease. Indeed it was 
shown that the combined genotype of SNP G-174C GG and another polymorphism in 
the promoter region of MMP3 (6A6A) was strongly associated with increased carotid 
intima media thickness, a marker for atherosclerosis, as assessed by ultrasound 
(243;244). A study which assessed endothelial function by means of reactive dilation 
of the brachial artery in a random number of individuals aged 20-28 found a trend 
towards poorer endothelial function in individuals carrying the G-allele (245). A 
study which assessed endothelial function by means of reactive dilation of the 
brachial artery in healthy young men found that smoking had a more detrimental 
effect on endothelial function in the GG genotype group than in the CC genotype 
(245). In a study comparing patients with peripheral arterial disease (PAD) with 
healthy controls found that the GG genotype as well as the G allele were significantly 
more common in patients with PAD (242;246). The GG genotype was more common 
in Type II diabetics with PAD then in those without (242). From this evidence it 
would seem that IL6 may indeed be causally involved in arterial disease 
development and that it is the SNP G-174C GG genotype that conveys a greater risk 
of atherosclerosis.  
The evidence in the literature however is conflicting. Other studies have shown that 
the C-allele is associated with higher plasma IL6 levels (247-249). In patients who 
underwent CABG surgery and in hypercholesterolaemic patients, those with the C-
allele were shown to have higher plasma levels of IL6 than those with the GG-
genotype (250;251). It has been suggested that the C-allele confers a risk of 
myocardial infarction in the elderly (252). There are a variety of studies which found 
the C-allele to be associated with an increased risk of cardiovascular disease, among 
them a study on 1109 random Australian subjects which showed a significant 
association between the C-allele and increased carotid intima-media thickness (IMT)  
(248;249;253-255). It was also found that in healthy men the C-allele was 
associated with 2.4-2.5% increase in blood pressure, equating to a 5% increase in 
risk for MI in genotype CC, when compared to subject carrying only the G-allele 
(249).  
Equally some studies have found no correlation between IL6 G-174C genotype and 
IL6 levels or disease. A study examining the interaction between the IL6 G-174C 
promoter polymorphism and risk of MI in male smokers, found that there was no 
association after adjustment for multiple comparisons (256). A study investigating if   46 
IL6 G-174C genotype affects IL6 production in vivo following elective aortic 
aneurysm repair, found no significant difference between genotypes (182). In a 
large population based study no difference in genotype distribution between a group 
of MI patients and a group of controls could be demonstrated (138). Moreover there 
was no association between cardiovascular risk factors and IL6 genotype (138). A 
large study on 6434 participants showed no influence of SNP G-174C on plasma 
levels of IL6 (257).  The same study found no association between IL6 G-174C 
genotype and risk of CVD or MI (257). Similarly other studies failed to show a 
significant influence of IL6 G-174C  genotype on risk of vascular disease 
(138;243;247;258;259).   
 
A clinically relevant causal role of IL6 in arterial disease processes cannot be 
assumed in the face of this evidence. However, neither can such a role be excluded, 
as there are a variety of reasons why these discrepancies may have occurred.  
 
Possible Reasons for conflicting Results from Genotype Studies 
When the IL6 G-174C genotype is used in association studies to prove causality, an 
assumption is made that the effect of this polymorphism in vivo is fully understood. 
There is no study to date however, that has satisfactorily investigated the in vivo 
effect of SNP G-174C on gene expression. The effect of the polymorphism has 
mainly been demonstrated in culture using constructs of the promoter region 
transfected into cell lines i.e. in an in vitro model (24;238).  
When using an in vitro model, potential regulatory sites may not form part of the 
constructs i.e. the model accounts for only part of the gene as adjacent areas, not 
transfected into the model, might influence gene expression in vivo e.g. by providing 
binding sites for inhibitory factors. This is demonstrated by two studies which 
investigated gene expression in HeLa cells transfected with different length 
constructs of the promoter region of IL6 (24;238) which showed discrepant results, 
possibly due to exclusion of a regulatory region from the construct by one or other 
study (182).  
Another limitation of in vitro studies is the use of known inducers of IL6 expression 
such as LPS. It is possible that the artificial induction of cytokines in vitro exerts a 
different effect on the cell as the induction of IL6 in vivo (24).  
The effect of SNP G-174C on gene expression in vivo has been investigated by 
measuring plasma levels of IL6 in subjects of different genotypes. Though these   47 
studies provide valuable in vivo data, one has to take into account certain factors 
which may influence the results. 
The plasma level of IL6 is the result of IL6 expression in a variety of tissues such as 
endothelium, leucocytes, adipose tissue and muscle. If the promoter SNP G-174C is 
functional, then the circulating levels of IL6 would be influenced by the sum of the 
effect of SNP G-174C in contributing tissue types. The result can only be interpreted 
accurately with regards to SNP G-174C effect, if the effect is the same in all tissue 
types. However it has not been established whether SNP G-174C influences 
transcription in vivo in humans equally in different tissues/cell types. It is possible 
that the effect of SNP G-174C on gene transcription is modulated by the tissue type 
in which the gene is expressed; thus circulating IL6 levels may give misleading 
results. It is likely that transcription is regulated differently in different tissue types 
through e.g. varying expression of transcription factors in different tissues (24). It is 
therefore difficult to draw conclusions from the overall plasma level to the exact 
effect of SNP G-174C.  
Another drawback of using plasma levels and genotype is that gene expression is 
regulated at several levels. The first and most important regulatory level is the 
primary control of transcription. The promoter variant SNP G-174C is likely to affect 
expression only at this level. However, subsequent levels of regulation with the 
capacity to influence final protein levels exist. Therefore a study investigating 
circulating protein levels takes into account all these levels of regulation as well as 
the effect of SNP G-174C on the primary transcription. Studying primary RNA 
expression patterns rather than measuring final protein product with regards to 
genotype would allow more precise insight into the effects of the promoter 
polymorphisms. 
Another reason for the discrepant observations may be that SNP G-174C was 
studied in isolation. The effect one polymorphism exercises on gene expression may 
be influenced by base pair changes at other polymorphic sites i.e. by haplotype. It is 
therefore possible that haplotype analysis rather than genotype analysis would give 
more consistent results. Other polymorphisms in the IL6 gene that may be 
investigated as part of a haplotype analysis, are SNP G-597A, G-572C (252;260-
263). These are also thought to affect gene transcription. However G-597A is in 
complete linkage disequilibrium (see final paragraph section 1.7.1 ) with G-174C 
(24). The G-572C polymorphism is relatively rare; making it therefore of use only in 
studies with large sample numbers (24).    48 
Further possible reasons for the discrepant observations in association studies is the 
fact that the association of the promoter polymorphism appears to be age 
dependent, therefore studies looking at population with a different age distribution 
may show conflicting results (252). 
Apart from these practical experimental considerations the inherent limitations of 
Mendelian randomisation also have to be taken into account when interpreting 
genetic association studies. The Mendelian randomisation approach may give 
erroneous results if the marker under examination is in linkage disequilibrium with 
another variant influencing disease risk (24;264). Linkage disequilibrium (LD) 
describes a scenario were two genetic variants are inherited together. If the marker 
SNP G-174C was in LD with another marker affecting a gene other than IL6, also 
able to influence disease risk, then demonstrating an association between SNP G-
174C and disease may not reflect a causal role of IL6 in the disease process; rather 
it would relate to the effect of the marker in LD with SNP G-174C. It has not been 
shown that linkage disequilibrium exists for SNP G-174C with a marker in another 
gene. However such a marker may be discovered in the future. As IL6 is located 
within a relatively gene poor part of the genome, and linkage disequilibrium is less 
common with increasing physical distance, this scenario appears unlikely. 
 
 
1.8  Summary 
IL6 is a cytokine that is associated with atherosclerotic risk factors, vascular disease 
development and progression and outcome from surgery and thus appears to play 
an important role in all aspects of vascular disease. Modulation of this protein could 
therefore offer a promising therapeutic strategy.  Before such a therapeutic option 
can be entertained, proof of causality needs to be established. Epidemiological 
studies employing the principle of Mendelian randomisation promise to be a useful 
tool to answer the question of causality, however they require the definition of a 
genotype that affects gene expression in vivo. SNP G-174C is thought to affect 
expression, but epidemiological studies have given conflicting results. This may be 
partially due to the methodology employed in investigating the effects of the IL6 
promoter SNP. Cell culture experiments may not provide adequate models for in vivo 
SNP effects on IL6 expression and protein levels are influenced by various levels of 
regulation, whereas promoter SNP G-174C is only likely to affect primary 
transcription.  RNA expression studies on human tissues may provide a more   49 
accurate answer to the effect of promoter SNP G-174C on gene expression. In 
addition, plasma levels do not take into account possible variation of the promoter 
SNP effect in different tissues. Plasma levels of IL6 are the result of IL6 secretion in 
a variety of tissues and cells. It is therefore important to understand the regulation 
of gene expression in the individual tissue types and also the relative contribution 
the individual tissues make to the circulating levels of IL6. Lastly, inter-individual 
comparisons are subject to confounding variables which may mask the effect of 
promoter SNP G-174C and may explain some of the discrepant observations in the 
literature.  
It is necessary to delineate the in vivo effect of this promoter polymorphism further, 
employing in/ex vivo investigations in human tissues.  
 
 
1.9  Hypothesis, Study Aims and Objectives 
 
Hypothesis:  
1. The magnitude of IL6 expression is determined by IL6 G-174C genotype.  
2. The magnitude of IL6 expression is determined by the tissue type in which the 
gene is expressed. 
 
Aims: The aim of this study was to investigate the effect of SNP G-174C genotype on 
IL6 gene expression in vivo in humans in different tissues. Delineating this effect 
could be useful in future studies investigating the nature of the IL6/arterial disease 
association. The second study aim was to assess levels of relative IL6 RNA 
expression in humans in different tissues. 
 
Objectives: Blood, vein, adipose and skeletal muscle tissue was to be collected from 
individuals free of diseases known to affect IL6 expression. The collected samples 
were to be investigated for levels of IL6 mRNA expression in the different tissues. 
The  effect  of  SNP  G-174C  genotype  on  expression  in  different  tissues  was  to  be 
investigated. A new assay was to be designed which would allow measurement of 
the relative IL6 hnRNA expression from the two alleles in heterozygous individuals.  
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2  Patients, Materials and Methods 
Please see Appendix A: for a list of materials used in this study. 
2.1  Study Outline 
The following sections will outline the study (see Figure 2-1) and the reasons for 
conducting the study in the manner in which it was performed. 
 
 
Figure 2-1: Flow chart of study. 
Patient Recruitment 
Sample Collection: 
1.  adipose tissue 
2.  vein 
3.  skeletal muscle 
4.  blood x 2 
 
Ethics Approval 
Genotyping SNP G-
174C (LightTyper) 
assay) 
Heterozygote 
tissue 
Homo- and 
heterozygotes tissue 
1.) Gel based 
allelic 
transcription assay 
quantifying 
relative 
contribution of the 
two alleles to IL6 
hnRNA in 
different tissues in 
individuals  
(intra-individual 
comparison) 
2.) Real time 
PCR analysis of 
IL6 mRNA in 
different tissues 
to establish 
relative 
expression 
comparison 
between tissues 
(inter-individual 
comparison) 
3.) Real time 
PCR analysis 
of IL6: 
Comparison of 
relative 
expression 
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genotypes 
(inter-
individual 
comparison) 
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2.1.1  Patient Recruitment and Tissue Selection 
Cell culture is only an approximate model of in vivo conditions (see section 1.7.1). In 
order to achieve an accurate measure of in vivo RNA expression ex vivo tissue 
samples were used in this study. Cardiovascular disease and a variety of other 
pathologies, such as acute inflammatory or malignant diseases, may affect IL6 tissue 
expression. The study therefore aimed to investigate individuals free of these 
systemic diseases. To study the effect of tissue type interaction with SNP G-174C 
genotype on IL6 expression, a variety of tissues had to be investigated. Tissues both 
known to express IL6 and accessible in patients treated in the vascular unit (vein, 
subcutaneous adipose tissue, muscle and leukocytes) were chosen for the 
investigation. Other tissues known to express IL6 i.e. neuronal tissue, cartilage and 
bone where not included in this study as access to these samples was not available 
in the study patients. Leukocytes rather than mononuclear cells were used, as the 
processes involved in isolating individual cell types from leukocytes may have 
caused alteration in the RNA profile of the cells. Most isolation methods involve 
prolonged centrifugation in a gradient solution. The RNA profile of cells once 
harvested may change over time. This study aimed to assess the in vivo RNA profile, 
thus avoiding time delay was important for accurate results. Patients undergoing 
varicose vein surgery in the day surgery unit were chosen for recruitment to the 
study for the following reasons: 
1.  Patients with significant systemic disease are precluded from day 
surgery. Therefore these patients are free from significant cardiac 
disease.  
2.  The groin dissection performed during the tying of the sapheno-
femoral junction for varicose vein surgery allows access to vein, 
adipose tissue and skeletal muscle without extension of the skin 
incision.  
Therefore varicose vein patients attending the Day Surgery Unit were ideally suited 
to donate samples for this study.  
Muscle and adipose tissue biopsies had not been previously performed routinely in 
varicose vein patients in this unit and concern was raised that these may lead to an 
increase in post-operative pain and bleeding complications. A follow up of the initial 
patients was therefore performed.  
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2.1.2  Effect of Promoter SNP G-174C on IL6 RNA Expression  
The promoter SNP G-174C is likely to affect transcription of DNA into RNA rather 
than translation of RNA into protein, therefore this study examined RNA expression 
levels rather than protein expression levels. Real time PCR analysis is a well 
described method for the analysis of RNA expression levels and this technique has 
previously been used to compare RNA expression between individuals of different 
genotypes. This inter-individual comparison however, is susceptible to confounding 
variables, such as age, smoking habits and medication. Therefore the initial stage of 
this study aimed to design an assay that would minimise the effect of such 
confounding variables. This assay was based on preferential allelic transcription. 
 
2.1.2.1 Preferential Allelic Transcription 
Diploid organisms have two copies of a gene, one maternal and one paternal copy. 
These two DNA coding sequences are referred to as alleles. Most genes are 
expressed from both alleles, except for genes subject to X-chromosome silencing or 
genomic imprinting (265). However, expression does not always occur in equal 
amounts from both alleles (266;267). A study looking at 602 genes showed that 326 
of these had preferential expression from one allele (265). Assuming SNP G-174C 
affects gene transcription one would expect an imbalance of expression from the two 
alleles in heterozygote individuals. The advantage of quantifying allelic transcription 
in heterozygous tissues lies in the fact that inter-individual confounding variables 
affect both alleles and thus are unlikely to influence the transcription ratio between 
the two alleles. Therefore measuring allelic transcription may provide an insight into 
the effect of promoter SNP G-174C on transcription while eliminating the influence of 
confounding variables. 
 
2.1.3  Ex Vivo Expression of IL6 RNA in different Tissues 
IL6 RNA expression may not only be influenced by genetic polymorphisms but also 
by the tissue type in which the gene is expressed. Raised circulating levels of IL6 
have been linked to aspects of vascular disease (see 1.5). IL6 is expressed in a 
variety of cells including monocytes/macrophages, adipocytes, endothelial cells, 
fibroblasts and myocytes. The circulating levels of IL6 are therefore the result of its 
secretion from various tissues. The relative contribution individual tissues make to 
the plasma IL6 level however is not known. Definition of the relative IL6 expression   53 
of individual tissues would allow research to focus on tissues expressing the most 
IL6 and thus are more likely to influence circulating levels. 
Levels of expression of IL6 have previously been investigated in tissue culture with 
and without stimulation. Levels of expression in individuals suffering from a variety 
of diseases have also been studied (24;268-271). The results obtained in these 
studies cannot be compared to assess the relative contribution individual tissues 
make, as experimental conditions varied, as did the samples used (i.e. cell culture, 
ex vivo tissue samples, plasma etc.). To date there is no study allowing a direct 
comparison of baseline IL6 expression in different tissues in vivo in the same 
individual. 
This study therefore aimed to gain further insight into the relative RNA expression of 
IL6 in different tissues by comparing relative IL6 transcription in a variety of tissue 
types in a single individual.  
 
2.1.4  Effect of SNP G-174C Genotype on IL6 RNA Expression in 
different Tissues 
In addition to the design of a preferential allelic transcription assay, the effect of SNP 
G-174C on IL6 mRNA expression in different tissues was also measured using real 
time PCR analysis. It was hoped that this would provide clues as to the interaction of 
genotype with tissue type. Expression of IL6 mRNA in adipose tissue, vein, muscle 
and leukocytes was measured and analysed according to G-174C genotype of the 
patient. This analysis consisted of an inter-individual comparison and was thus 
subject to potential confounding variables.  
Plasma levels of IL6 have been shown to vary with age. Smoking has also been 
shown to influence IL6 expression (140;272;273). The association of IL6 expression 
with age and smoking was therefore investigated in vein, adipose tissue, skeletal 
muscle and leukocytes. 
 
The following sections will provide a more detailed account of the methods used in 
this study. 
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2.2  Methods in Detail  
2.2.1  Ethics Consent 
Ethics approval was obtained from the Southampton & South West Hampshire 
Research Ethics Committees on the 01.03.2004 REC Reference: 040/04/w to collect 
samples of vein, skeletal muscle, subcutaneous adipose tissue as well as blood from 
anaesthetised patients undergoing varicose vein surgery at the Day Surgery Unit 
Southampton General Hospital/Royal South Hants Hospital (at this time the majority 
of varicose vein treatments were conventional surgery). Permission for genotyping 
and subsequent usage of samples in genetic studies was obtained. 
 
2.2.2  Patient Recruitment 
Patient recruitment was performed by the researcher. 108 patients were approached 
about the study and 95 agreed to take part. Of these 95 patients, 67 ultimately 
donated tissue samples which were used in the study (see Figure 2-2). Patients for 
recruitment were identified by review of the hospital waiting lists and theatre lists. 
Patients with ASA Grade 1 or 2 were included in the study (ASA=American Society of 
Anaesthesiologists: ASA I=no disease; ASA 2=mild systemic disease but no effect on 
daily activity; ASA 3= Symptomatic illness but minimal restriction on life; ASA 4= 
symptomatic illness causing severe restriction on life; ASA 5=moribund). Patients 
with ASA grade III or above or significant cardiovascular disease, acute 
inflammation/infection or untreated carcinoma were excluded from the study, as 
were patients currently taking steroids. Patient notes were reviewed and relevant 
data were collected on all patients who were recruited to the study. Ethnic origin, 
age, gender, type of operation, CEAP classification (Clinical, etiological, anatomical 
and pathological: 0=no visible venous disease, 1=telangiectasia or reticular veins, 
2=varicose veins, 3=oedema, 4=skin changes, 5=healed ulcer, 6= active ulcer), 
past medical history, current medication, smoking status and family history was 
recorded. Patients were recruited in the pre-assessment clinic after routine pre-
operative assessment. An information leaflet was given to the patient to read. The 
study was then explained to the patient in a private interview room. Possible side 
effects and complications were explained, including the potential risk of bleeding, 
bruising and pain. The patient was given the opportunity to ask questions before 
being given a copy of the consent form. In all cases it was made clear that signing 
the consent form would not preclude the patient from leaving the study at a later 
stage. A further copy of the consent form and the patient information sheet was   55 
given to the patient to take home. After one month it became clear that many 
patients currently on the waiting list for surgery had already been seen in the pre-
assessment clinic and that recruitment in the pre-assessment clinic was ineffective. 
Therefore ethics approval for a further method of recruitment was sought 
(Southampton & South West Hampshire Research Ethics Committee, Amendment 
Number 2 Ref. No: 040/04/w, approval granted 09
th February 2005). Patients 
recruited by this second method had already been allocated an operation date. They 
were sent a patient information sheet and a copy of the consent form in the post 
with an explanatory letter attached. This was followed up with a telephone call 
during which the study was explained and the patient was given the opportunity to 
ask questions. In these cases written consent was taken on the day of operation.  
Due  to  changes  in  the  provision  of  services  in  the Southampton  Region,  the  Day 
Surgery Unit at the Royal South Hants Hospital was due to be closed and very few 
varicose  vein  operations  were  carried  out  at  this  unit  in  the  later  part  of  patient 
recruitment.  It  was  therefore  decided  to  attempt  sample  collection  on  the  Isle  of 
Wight  where  the  through-put  of  varicose  vein  patients  had  remained  unaffected. 
Ethics consent was obtained to include the Day Surgery Unit at St. Mary’s Hospital, 
Newport,  Isle  of  Wight  in  this  study.  The  Isle  of  Wight  Healthcare  NHS  Trust 
Research and Development Committee granted approval on the 28
th July 2005.  
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Figure 2-2: Total number of patients asked to take part in the study (108): Patients who agreed to 
take part (95); patients who declined to take part (13). Of the 95 patients who agreed to take part in 
the study 68 donated tissue samples to the study. 25 did not donate samples due to logistic reasons 
and two did not donate samples for clinical reasons. One patient was found to have taken steroids 
prior to his varicose vein surgery and was therefore excluded from the study. 
 
Patients were not required to attend any additional appointments for the study. The 
patient’s GP was informed of their patient’s participation in this study by letter which 
also contained a copy of the patient information sheet. 
 
108 patients approached 
about the study  
2 patients did not 
donate samples due to 
clinical reasons 
25 patients did not 
donate samples for 
logistic reasons 
1 patients found to be 
unsuitable subsequent 
to tissue donation 
67 patients donated 
samples which could 
be used in the study  
13 patients declined 
to take part in the 
study 
68 patients donated 
tissue samples 
95 patients agreed to 
take part in the study   57 
2.2.3  Sample Collection 
Samples were collected by the researcher from anaesthetised patients. All samples 
were handled using universal precautions of infection control, including the wearing 
of gloves and avoiding contamination of any surfaces. A peripheral blood sample was 
collected by the researcher.  Blood was collected with a Safety-Lok
TM blood collection 
system and a standard BD Vacutainer
TM needle holder. The first sample for leukocyte 
DNA analysis for genotyping was collected into a nine millilitre EDTA plastic 
vacutainer tube. The second sample, for extraction of Leukocyte RNA, was collected 
using the PAXgene
TM Kit (PreAnalytiX). Tissue samples were collected during the 
operation (see Figure 2-3). 
 
 
Figure 2-3: Schematic representation of the sapheno-femoral junction during groin dissection for 
high long saphenous vein tie. A subcutaneous adipose tissue sample
1.) was taken from the edge of the 
wound, as convenient. Skeletal  muscle
2.) was taken as a biopsy from pectineus  muscle. The long 
saphenous vein
3.) was stripped as part of the varicose vein operation and a segment used for the 
study. (The diagram exaggerates the scale of the incision and in no patient was the incision enlarged 
to obtain the muscle specimen.) 
 
All tissue samples were harvested by the operating surgeon and handed to the 
researcher for further processing. Vein was harvested from the long saphenous vein 
which had been removed using a plastic stripper, except in two cases - in which   58 
short saphenous vein and 5 cases - in which vein material from avulsions was 
collected. Short saphenous vein was harvested by formal surgical dissection and 
excision of the proximal portion, as was standard clinical practice. Vein material from 
avulsion was obtained using a vein hook and mosquito forceps. Adipose tissue (1cm 
cube) was surgically excised from the subcutaneous tissue of the wound edges. 
Access to the pectineus muscle was gained through dissection of the medial part of 
the incision. The subcutaneous fat was dissected off the deep fascia overlying 
pectineus muscle. The pectineal fascia was opened and a 0.5cm length of superficial 
muscle fibres excised. Any resulting bleeding was treated with diathermy. Fat and 
muscle samples were collected in succession, either immediately before or after 
removal of the vein. Blood samples were collected during the same time period as 
the tissue samples.  
Tissue samples were placed on a single use sterile plastic container and immediately 
submersed in RNAlater
® (Sigma-Aldrich) to maintain the in vivo RNA profile (274). 
Sterile metal forceps and scalpel were used for processing. The section of vein was 
agitated in the RNAlater solution to remove adherent blood cells. It was then freed 
of adherent connective and adipose tissue with the help of a scalpel. The vein was 
dissected into sections of approximately 0.1 cm
 to allow easy penetration of the RNA 
stabilising solution into the tissue. The fat biopsy was dissected and inspected to 
ensure no lymphoid tissue was included before dissection into 0.3cm cubes. The 
muscle biopsy was equally dissected into 0.3cm cubes and any adipose tissue was 
removed. All tissue samples were transferred into 1.5ml microtubes containing 1.3ml 
of RNAlater
TM..   
EDTA  blood  collection  tubes  were  stored  at  -80°C  for  future  analysis.  PAXgene
TM 
tubes were incubated overnight at room temperature before being placed at -80°C 
for storage. All tissue samples were stored in the fridge at -4°C overnight before 
being transferred to -80°C until further analysis could take place.  
 
 
2.2.4  Patient Follow-Up 
The reason for follow up was initial concern about potential complications from 
added surgical procedures. The collection of vein tissue from patients did not 
represent an additional procedure for patients undergoing varicose vein surgery. 
Adipose tissue is often adherent to the stripped vein and thus the excision of fat 
from the area surrounding the sapheno-femoral junction was considered unlikely to   59 
put the patient at risk of additional complications. However it was unclear whether 
muscle biopsy could lead to additional complications, namely bleeding and prolonged 
recovery form operation due to pain. Patient follow up was therefore performed in 
the initial stages of the study. Further reason for follow up was to establish whether 
the change from personal recruitment to recruitment by post was acceptable to the 
patients. Patients were followed up with a telephone call and asked to answer a 
number of questions (for questionnaire see Appendix D:). They were asked about 
their satisfaction with the study recruitment process and whether they would 
consider taking part in clinical trials in the future. Any post-operative complications 
were noted, as was the time scale of return to normal daily activity following the 
surgery. Patients were asked to grade their pain in the first two postoperative days 
on a scale of one to ten, and finally whether they felt that they had suffered any ill 
effects from taking part in the study. 
This concluded the clinical part of the study. The following sections will describe the 
laboratory work carried out. 
 
 
2.2.5  DNA Extraction 
DNA was extracted from 9ml whole blood according to a method by Miller et al 
(275). Blood samples had all been stored at -80°C. Samples were defrosted on a 
roller mixer for at least 1 hour at 4°C. The blood was then transferred into 50ml 
conical tubes and 30ml of erythrocyte lysis buffer (ELB) was added. After repeated 
inversion the tubes were placed on ice and mixed gently on a rotating mixer for 15 
minutes. The tubes were centrifuged at 1500rpm for 10 minutes at 4°C and the 
supernatant poured off leaving a white cell pellet at the bottom of the tube. This ELB 
wash was repeated two more times. The white cell pellet was then washed into a 
15ml conical tube using 3ml nucleic lysis buffer (NLB). The white cell pellet was re-
suspended and 250ul 10% sodium dodecyl sulphate (SDS) and 150ul protease 
(40mg/ml) was added. The samples were placed in a shaker incubator overnight at 
37°C. Samples were allowed to cool to room temperature before adding 1ml 
saturated NaCl to each tube, which was shaken vigorously for 15 seconds.  The 
samples were centrifuged at 4000rpm for 20 minutes at room temperature. The 
supernatant was transferred to a fresh tube and exactly twice the volume of 
absolute cold alcohol was added. The tube was inverted until the DNA formed a 
pellet. The pellet was removed and washed in 1ml of 70% alcohol in a 1.5ml micro   60 
tube. The samples were pulse centrifuged and the ethanol poured off. The DNA was 
allowed to dry at room temperature before adding 500ul of TE buffer. Samples were 
left overnight to allow the DNA to dissolve prior to storage. Samples were 
transferred to screw top tubes and stored at -20°C. 
 
2.2.5.1 Quantification of Genomic DNA 
Quantification of DNA was kindly performed by Nikki Graham (Laboratory 
Technician). The method employed, used PicoGreen
®, an ultra-sensitive fluorescent 
nucleic acid stain which allows quantification of double-stranded DNA (dsDNA). 
Fluorescence of samples was measured against a standard curve created from 
standard DNA of known concentration.  
 
2.2.6  Genotyping for G-174C 
Genotyping was performed using white cell DNA from EDTA blood samples and an 
Odyssey LightTyper assay. 
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Figure 2-4: Principle of melt curves analysis: (A) A fluorescent labels probe[F] and a quencher 
probe[Q] bind to a nucleotide sequence, one wild type and one mutant containing the SNP. (B) As 
the temperature is raised, the complimentary strands are denatured, the fluorescent probe and the 
quencher probe are separated and fluorescence can be detected. This occurs at lower temperatures 
for the imprecisely bound probe. (C) Higher temperatures are required to separate the probe bound 
to the wild type. This leads to two separate peaks on the melt curve. 
 
 
This assay uses the principle of ‘melt curves’ (see  
 
 
Figure 2-4). A fluorescent labelled probe is designed to anneal to the precise 
sequence of one of the possible SNP alleles. A second quencher probe is designed to 
anneal to the adjacent sequence. Both probes are included in the PCR master mix as 
is a primer pair that will amplify the region surrounding the SNP. PCR amplification is 
then performed in the usual manner. Following PCR the samples are heated up to a   62 
set temperature. During the heating process the imprecisely bound probe (i.e. the 
probe bound to the alternative allele) melts off the DNA at a lower temperature than 
the precisely bound probe. As the fluorescent probe is separated from the quencher 
probe the detectable fluorescence (F) changes. The change in fluorescence [F(n+1)-
F(n)] is measured and plotted against temperature to produce a melt curve. This 
reveals individual peaks corresponding to each of the two alleles, allowing 
genotyping of template DNA (Figure 2-5).    63 
 
 
Figure 2-5 : Schematic representation of a LightTyper melt curves for the three different genotypes. 
The top graph shows detectable fluorescence according to ramp temperature. The bottom graph is 
a derivative of the top graph depicting increase in fluorescence at a given temperature. The 
prominenet peaks of the bottom graph allow allocation of genotype. Double peaks  correspond to 
heterozygote template. Single peaks correspond to homozygote templates, both wild type and 
mutant, differentiated by temperature. 
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An assay for genotyping of G-174C had previously been designed in the laboratory 
(Ryan Waters). The sequences for the forward and reverse primer, as well as the 
fluorescent and quencher probe for the LightTyper assay are shown below (see 
Sequences 1). 
 
 
 
Sequences 1: Sequence of forward and reverse primers annealing in areas of the gene adjacent to 
SNP G-174C . PCR using these primers will lead to amplification of the sequence surrounding the 
SNP G-174C. The sequence of the FITC probe and the quencher probe is also given. The FITC 
probe dimerises with the SNP itself (annealing base shown in red) and its neighbouring bases. The 
quencher probe anneals in close proximity to the FITC probe. Separation of the fluorescent probe 
from the quencher probe during the melt cycle occurs at different temperatures for the precisely 
bound and the imprecisely bound probe, allows detection of fluorescence peaks at different 
temperatures for different alleles (see text for a more detailed description of this assay). 
 
2ul of genomic DNA extracted from leukocytes was placed onto a 384 well plate and 
10ul of PCR master mix was added before placing the plate onto the thermal cycler. 
Below is a list of reagents for the PCR reaction for SNP G-174C genotyping using the 
Odyssey LightTyper:  
 
 
 
 
 
 
 
 
 
 
Genotyping assay primer sequences: 
G-174C    Forward  5’- cgctagcctcaatgacga  - 3’ 
        Reverse    5’– tctttgttggagggtgagg - 3’ 
 
Genotyping assay probe sequence: 
FITC Probe (fluorescent probe):    5’-ctttagcatCgcaagacac- 3’ 
DABCYL Probe (quencher):    5’-aaccttattaagattgtgcaatgtgacg- 3’   65 
 
PCR Reagents    10ul  Final Concentration 
10x PCR Buffer  1ul  (1xPCR Buffer) 
10mM dNTPs  0.2l  (200uM) 
25mM Mg
2+  0.6ul   (1.5mM) 
Primers(10pmol/ul) Forward  0.5ul  (500nM) 
                             Reverse  0.1ul  (100nM) 
FITC probe (10pmol/ul)  0.2ul  (200nM) 
DABCYL probe (10pmol/ul)  0.2ul  (200nM) 
Promega Taq (5U/ul)   0.04ul 
H2O  7.16ul 
   
Below are the timings for the PCR program for the SNP G-174C genotyping assay:
            
PCR cycling program:   
Initial denaturation step  94ºC for 2 minutes 
Denaturation step      94ºC for 20 seconds 
Primer annealing step  59ºC for 30 seconds 
Extension step  72ºC for 30 seconds 
  go to step 2 and repeat cycles 49 times 
Final extension step  72ºC for 2 minutes 
     
 
Following PCR the samples were covered with 5ul of Chill-Out
TM wax and melted from 
35˚C to 70˚in the 384 well Odyssey LightTyper. LightTyper software was used to 
analyse the change in fluorescence during melting and to assign genotypes to 
individual melt curves. Melt curves were visually inspected to ensure accurate 
assignment of genotype by the software.  
The Genotype assay was performed in triplicate on three separate PCR plates. All 
samples had at least 2 valid genotyping results. 
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2.2.7  Methods for RNA Extraction 
2.2.7.1 RNA extraction using TRI Reagent®   
Sample Preparation 
RNA extraction was carried out using TRI Reagent® according to the manufacturer’s 
instruction with some modifications to increased RNA yield. If possible RNase free 
disposable plastic ware was used. Glassware was washed with ethanol and 
diethylpyrocarbonate (DEPC)-treated water and baked overnight.  
Tissue samples were defrosted and weighed. Between 60-100mg of vein and muscle 
tissue and 150-200mg of fat tissue was taken and homogenised separately by 
repeated cutting with a disposable scalpel blade on a baked glass slide. The sample 
was then transferred to a 1.5ml micro tube. A 1.5ml micro tube holds a maximum of 
100mg of tissue; therefore fat samples were processed in two tubes. 
Homogenisation was continued using a disposable homogenisation pestle inserted 
into the micro tube while mixing the sample on a vortex. TRI Reagent® was 
gradually added during the homogenisation process. A total of 1.5ml of TRI 
Reagent® was added. Vein, muscle and fat tissue samples were then repeatedly 
aspirated with a needle and syringe. Samples were left to stand at room 
temperature for 5 minutes before centrifuging the homogenate at 13,000rpm in a 
refrigerated centrifuge for 10 minutes at 4°C. The clear supernatant was transferred 
to a fresh tube. The adipose samples developed a fatty layer on top of the 
supernatant at this stage. This layer was carefully removed by pipette aspiration 
before the supernatant was transferred to a fresh tube. Samples were allowed to 
stand for 5 minutes at room temperature before adding 0.3ml of chloroform. 
Samples were then covered and shaken vigorously for 15 seconds and were allow to 
stand for 5 minutes at room temperature, before centrifuging at 13,000rpm for 15 
minutes at 4°C. The colourless upper aqueous phase containing RNA was transferred 
to a fresh tube. 
 
RNA Isolation 
A total of 0.75ml of isopropanol was added to the aqueous phase and samples mixed 
thoroughly by repeated inversion. Samples were left to stand for at least 30 minutes 
at -20ºC before centrifuging at 13,000 x g for 18 minutes at 4°C.  
The supernatant was removed and the RNA pellet was washed by adding 1.5ml of 
75% ethanol and vortexing the sample. The RNA pellet was reformed by 
centrifugation at 13,000 x g for 18 minutes at 4°C. All ethanol was removed from   67 
the samples by decanting and pipette aspiration and the RNA pellet was then air 
dried for 10 minutes.  
Vein and muscle RNA was dissolved in 20-30µl of RNA storage solution. Fat RNA was 
dissolved in 10ul of RNA storage solution. To facilitate dissolution, samples were 
mixed by repeated pipetting at 55ºC for 10-15 minutes. The two fat RNA samples 
were merged. 
2.2.7.2 RNA Isolation using PAXgeneTM Kit 
 
All buffers, spin columns and proteinase K used in RNA isolation from blood were 
purchased as part of a kit from PreAnalytiX (Qiagen). Bloods were thawed in an open 
rack. The PAXgene
TM blood RNA tubes were centrifuged for 10 minutes at 3000-5000 
x g using a swing out rotor. The supernatant was removed by decanting. 5ml RNase 
free water was added to the pellet, a lid was applied and the sample was vortexed 
before centrifuging for 10 minutes at 3000-5000 x g. Again the supernatant was 
removed. 360ul of Buffer BR1 was added and the sample was vortexed until the 
pellet was visibly dissolved. Samples were pipetted into a microcentrifuge tube and 
300ul Buffer BR2 was added before adding 40ul Proteinase K. Samples were 
vortexed then incubated for 10 minutes at 55ºC using a shaker incubator. Samples 
were then centrifuged at a minimum of 10,000 x g for 3 minutes and the 
supernatant transfered to a fresh 1.5ml microcentrifuge tube. 350ul 99% ethanol 
was added and samples mixed by vortexing before centrifuging for 1-2 seconds at 
≤1000 x g. 700ul of the sample was added to the PAXgene
TM spin column place in a 
2ml processing tube and centrifuge for 1 minute at ≥8000 x g. The PAXgene
TM spin 
column was placed in a new 2ml processing tube. The remaining sample was added 
to the PAXgene
TM spin column and the spin column was centrifuged for 1 minute at 
≥8000 x g. The spin column was placed in a new 2ml processing tube. Then 700ul of 
Buffer BR3 was added to the PAXgene
TM spin column and centrifuged for 3 minutes 
at ≥ 8000 x g. The PAXgene
TM spin column was placed into a new processing tube 
before adding 500ul Buffer BR4 and centrifuging for 1 minute at ≥8000 x g. The 
Spin column was placed in a new 2ml processing tube and 500ul Buffer BR4 was 
added before centrifuging for 3 minutes at maximum speed to dry the spin column 
membrane. The PAXgene
TM spin column was placed in a new 2ml processing tube 
and again centrifuged for 1 minute at full speed. The spin column was placed in a 
1.5ml elution tube and 40ul Buffer BR5 was added before centrifuging for 1 minute 
at ≥8000 x g to elute the RNA. A further 40ul of Buffer BR5 was added and the spin 
column again centrifuged for 1 minutes at ≥8000 x g. The eluate containing RNA   68 
was incubated for 5 minutes at 65ºC in a heating block then chilled on ice 
immediately.  
 
2.2.7.3 RNA Quantification 
RNA was quantitated using spectrophotometry. A spectrophotometer measures light 
intensity as a function of wave length. In order to quantitate RNA concentration the 
absorbance of light with a wave length of 260nm is measured as it passes through 
the solution containing RNA.  
 
A=log10 (I0/I1)  
 
A=Absorbance; I0=Intensity of incident light; I1=Intensity of light after passing 
through material 
The concentration is then calculated according to the Beer-Lambert Law: 
 
A=αlc     or       c=A/αl         where:   α=4πk/λ 
 
α= absorption coefficient specific to absorbing material; l=path length; 
c=concentration of absorbing species in material; k=extinction coefficient; 
λ=wavelength 
 
For RNA the concentration is = Absorption at 260nm times 40ng/ul (assuming a path 
length of 1cm.) 
 
This way of measuring does not distinguish between DNA and RNA. 
To check the RNA concentration of the study samples using spectrophotometer, 4ul 
of RNA solution was added to 156ul of tris HCL buffer pH=8.0. 
 
All RNA was diluted to 50ng/ul for cDNA synthesis in all experiments. 
2.2.7.4 RNA Purity  
In order to check for RNA purity the relative absorption at 260nm and 280nm wave 
length was measured for all samples using spectrophotometry. Maximum absorption 
for RNA/DNA is at 260nm wave length. Protein is usually measured at 280nm. A   69 
ratio greater than 1.8 indicates little protein contamination. The ideal A260/A280 
ratio for RNA samples is regarded as 1.9-2.1.  
2.2.7.5 RNA Quality  
In order to ensure that the laboratory techniques and storage condition employed 
did not lead to degradation of RNA a few samples of control RNA (0.75ug) extracted 
from blood were checked for quality. A number of RNA samples which were known to 
be of good quality were analysed at the same time (kindly supplied by Jana 
Kralovicova).  
Ribosomal RNA (rRNA) makes up almost 80% of total RNA. The integrity of the 
major mammalian rRNA species (28S and 18S) can therefore be used to give an 
indication of RNA quality. The 28S and 18S bands should be clearly visible on an 
ethidium bromide gel for the RNA to be minimally degraded (276).  
Samples were mixed with gel loading buffer (50:50) and denatured by heating to 
65°C for 3-5 minutes. The samples were loaded onto the denaturing urea acrylamide 
gel run at 400V, 40mA, 9W for 1 hour. The gel was then stained in ethidium bromide 
for 10 minutes before imaging on Typhoon fluorimager. Clear 28S and 18S bands 
indicate minimal degradation of RNA. 
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2.2.8  Preferential Allelic Transcription  
The study plan was to design an assay to investigate the effect of promoter SNP G-
174C on primary transcription minimising inter-individual confounding variables by 
examining the allelic transcription ratio in heterozygous individuals.  
2.2.8.1  Allelic Transcription Assay - Theory 
Assuming SNP G-174C affects gene transcription, one would expect one of the 
alleles to be preferentially expressed in heterozygote individuals (preferential allelic 
transcription). Using RNA extracted from heterozygous tissue to make cDNA, yields 
cDNA with equal allelic ratio to the RNA template (Figure 2-6).  
 
 
Figure 2-6 : Preferential expression of one allele in a heterozygote individual. RNA extraction from 
heterozygous tissues and reverse transcription yields cDNA with equivalent allelic ratio to the 
extracted RNA . 
 
 
Preferential allelic transcription 
RNA 
Maternal and paternal allele 
of a gene 
RNA extraction & 
Reverse tanscription 
cDNA: copy 
numbers are 
equal to the 
allelic 
transcript   71 
When this cDNA is used as template in PCR amplification, copy number should 
increase while maintaining the original allelic ratio. Subsequent restriction digest of 
the PCR product with the appropriate enzyme results in the enzymatic digestion of 
only one of the two allelic amplicons. Subjecting the digest product to gel 
electrophoresis allows separation of undigested and digested PCR product (see 
Figure 2-7). Intensity of fluorescence of individual bands is proportionate to the 
amount of digest product present. The ratio between cut and uncut bands therefore 
represents the original allelic RNA ratio. 
                           
 
 
Figure 2-7: Schematic representation of the allelic transcription assay: Restriction digest of PCR 
amplicons and subsequent separation of digest products on a gel using electrophoresis. The intensity 
of fluorescence is proportional to the quantity of digest product present. This allows measurement of 
allelic transcription ratio through measurement of fluorescence intensity. 
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2.2.8.2 Identifying a Marker for SNP G-174C  
To assess allelic expression differences in heterozygotes with reference to a 
polymorphism, it is necessary to identify from which allele the RNA molecules were 
originally transcribed. This poses a problem in the case of promoter polymorphisms 
as the promoter sequence is not transcribed into RNA. To allow allocation of RNA 
molecules to the relevant allele, a marker has to be identified within the transcribed 
region of the gene that is co-inherited with the promoter polymorphism.  
SeattleSNPs Haplotype Data Phase Output Version 2.0 
http://pga.gs.washington.edu/data/il6/ilkn6.phase.out was used to identify possible 
markers. There were no markers within exon regions but three intron SNPs were 
identified, which were in linkage disequilibrium with SNP G-174C, one each in intron 
1, 2 and 3.  
Intron regions are not present in mRNA (Figure 2-8). It was therefore necessary to 
use primary transcript (hnRNA) as a template in this allelic expression experiment.  
To assess which of the intron SNPs was the best marker, linkage disequilibrium had 
to be assessed between individual SNPs by looking at haplotypes present in the 
population. This data was gained from SeattleSNPs Haplotype Data Phase Output 
Version 2.0 http://pga.gs.washington.edu/data/il6/ilkn6.phase.out. 
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Figure 2-8: IL6 Transcription: Schematic representation of IL6 gene with promoter SNP G-174C 
and intron SNPs in light blue. Note that promoter region are not transcribed into hnRNA and intron 
regions are not transcribed into mRNA. 
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Table 2.2-1: Haplotypes for IL6 promoter SNP and intron SNPs. 
 
SNP G-174C is in perfect linkage disequilibrium (LD) with SNP T2529G i.e. there are 
only two possible haplotypes GT and CC. SNP G3572T is in perfect LD with SNP 
A5014G.  SNP G-174C is in complete LD with SNP G3572T and A5014G i.e. only 
three possible haplotypes exist: GGA, CTG and GTG. The ideal marker for the 
promoter SNP would therefore be T2529G. Markers G3572T and A5014G would also 
be useful, as the rarer haplotype GTTG could be identified and excluded.  
2.2.8.3 DNA Extraction – Allelic Transcription Assay Design 
Leukocyte DNA was extracted from blood from volunteers in the laboratory 
according to method previously described (see section 2.2.5) and used as control 
DNA, to allow design of the allelic transcription assay. 
2.2.8.4 Genotyping SNP G-174C –Allelic Transcription Assay Design 
Control DNA from volunteers was genotyped using LightTyper assay (see section 
2.2.6) 
2.2.8.5 RNA Extraction – Allelic Transcription Assay Design 
Control RNA was extracted from the blood of volunteers in the laboratory, found to 
be heterozygous for SNP G-174C, according to the method previously described (see 
section 2.2.7.2).  For all optimization steps, control RNA from leukocytes was used. 
To optimise DNase treatment one sample of vein cDNA (study sample) and placenta 
cDNA (RNA was extracted from placenta tissue samples available in the laboratory) 
was also used. 
 
SNP  G-174C  T2529G  G3572T  A5014G 
Haplotype 1  G  T  G  A 
Haplotype 2  C  C  T  G 
Haplotype 3  G  T  T  G   75 
2.2.8.6 Assay Design for Intron SNPs 
2.2.8.6.1 Primer Design 
PCR primers were designed to amplify the region surrounding the intron SNP using 
Primer3 software http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi (see 
Sequences 2). To avoid cross homology with other regions of the genome, primers 
were ‘BLASTed’ using software provided by the national centre for biotechnology 
information (NCBI) http://www.ncbi.nlm.nih.gov/BLAST/ . Amplification products 
were 163bp, 249bp and 262bp in length for SNP 2529, 3572 and 5014 respectively.  
 
 
Sequences 2: Sequence of primers used in amplification of intron regions surrounding SNPs. The 
forward and reverse primers in the right hand column anneal in areas adjacent to the SNP given in 
the left hand column, thus leading to amplification of the sequence surrounding the SNP.   
 
The sequence required for this experiment was downloaded from GenBank, 
accession number: AF 372214. It became apparent during optimisation that 
restriction digest of the amplification product of the region surrounding SNP G3572T 
lead to restriction fragments of similar length (118 and 131 bp), thus difficult to 
distinguish on gel electrophoresis. New primers were designed for SNP G3572T to 
give an amplification product of 418bp (restriction fragment length 119 and 299 bp) 
Primer for SNP:    Sequence of forward (F) and reverse (R) primers: 
 
T2529C      F  5’ - ctgaaaggcatgttcagcttc -3’ 
                       R  5’ – atctccccactttcaatgca – 3’ 
 
G3572T      F  5’ - ggcagtttattcttggacagg – 3’ 
R  5’ – ataaaaggaggttccagccc -3’ 
 
 
G3572T new          F  5’ – ggcagtttattcttggacagg – 3’ 
        R  5’ –caatgtcccaaaacatgctg – 3’ 
 
A5014G      F   5’ – ggtgggtctatggaaaggtg - 3 
R  5’ – caaacaaataagatagtgatgctgg – 3’   76 
2.2.8.6.2 Restriction Enzymes 
Restriction enzymes for the three intron SNPs were chosen using NEBcutter 
software. 
Restriction enzymes were Mae I, Dde I, Msp I for SNP 2529, 3572, 5014 
respectively. Optimum enzyme concentration was determined using 1.0, 2.0, 3.0, 
4.0ul of enzyme in a 20ul reaction.  
2.2.8.6.3 PCR Amplification and Restriction Digest of Intron Regions 
PCR Amplification and Restriction Digest for SNP T2529C 
2ul of genomic control DNA (concentration: 7-10ng/ul) was taken as a template for 
PCR and dried at 80ºC for 10 minutes on a 96 well plate before loading the PCR 
mixture.  For  the  final  experiment  3ul  cDNA  was  used  which  was  un-dried. 
Optimisation  of  the  reaction  had  previously  been  performed  using  magnesium 
concentrations of 1.5, 2.0 and 2.5mM and a range of temperatures form 55ºC to 
67ºC. The optimum conditions were 1.5mM magnesium and 57ºC for the annealing 
temperature. The concentration of the reagents used in the PCR reaction to amplify 
the intron regions are given in the box below: 
 
PCR Reagents    Amount  
10x PCR Buffer   2ul   
5M Betaine         5.2ul   
5mM dNTPs   0.5ul 
25mM Mg
2+   1.2ul     
Primers Forward   0.2ul 
Reverse   0.2ul 
Promega Taq   0.2ul 
H2O  10.5ul 
Total PCR mix  20ul 
 
The timing of the PCR program used for amplification of the intron regions are set 
out below:   
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PCR cycling program:   
Initial denaturation step  92ºC for 2 minutes 
Denaturation step  92ºC for 30 seconds 
Primer annealing step  57ºC for 30 seconds 
Extension step  70ºC for 30 seconds 
  go to step 2 and repeat cycles 29 times 
Final extension step  70ºC for 2 minutes 
         
10ul of PCR product was loaded onto a 96 well plate and 1unit of restriction enzyme 
MaeI was added. Samples were subjected to digestion at 45ºC for 16 hours. 
 
3ul of PCR product was mixed with loading dye and loaded onto a 5% 
polyacrylamide MADGE (microplate array diagonal gel electrophoresis) gel, which 
had been pre-stained with ethidium bromide. Electrophoresis was performed at 150 
volts(V), 2 amps for 14 minutes in a dry box.  
PCR Amplification and Restriction Digest for SNP G3572T 
Apart from the primers used in the PCR reaction (see Sequences 2), a magnesium 
concentration of 2.5mM and 62.2ºC annealing temperature, the PCR reaction for the 
amplification of the intron region surrounding SNP G3572T was performed as for SNP 
T2529C. The restriction digest for genotyping was performed as for SNP T2529C 
except for the use of restriction enzyme DdeI and a digest temperature of 37ºC.  
PCR Amplification and Restriction Digest for SNP A5014G 
Apart from the primers used in the PCR reaction (see Sequences 2), a magnesium 
concentration of 2.0mM and 62.2ºC annealing temperature, the PCR reaction for the 
amplification of the intron region surrounding SNP A5014G was performed as for 
SNP T2529C. The restriction digest for genotyping was performed as for SNP T2529C 
except for the use of restriction enzyme MspI and a digest temperature of 37ºC. 
2.2.8.7 cDNA Synthesis 
cDNA synthesis was performed by reverse transcription of RNA. The majority of IL6 
RNA is mRNA, with hnRNA representing only a fraction of the total. The majority of 
cDNA therefore does not contain intron regions (see Figure 2-9). This can be used to 
confirm the presence of cDNA as a ‘short product’ following PCR, using primers 
spanning intron regions. The length of the product allows differentiation from   78 
amplification of gDNA contamination, often present in RNA samples (see Figure 
2-10). cDNA from hnRNA can not be differentiated from gDNA contamination in this 
way as both contain intron regions. 
 
 
 
Figure 2-9: Transcription of gDNA into hnRNA, the splicing of hnRNA into mRNA and reverse 
transcription of mRNA into cDNA: The 5’ end of the intron is autolytically cleaved to form a lariat. 
The lariat is an intermediate circular structure which is formed by connecting the 5’ terminus (UG) 
to a base (A) within the intron. Subsequent cleavage of the 3’ site releases the intron in lariat form. 
Concurrently the right exon is ligated (spliced) to the left exon resulting in mRNA. mRNA does not 
contain intron regions. cDNA transcribed from mRNA in turn does not contain intron regions. 
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Figure 2-10: PCR products of a gDNA template (A) and cDNA template (B). The presence of intron 
regions (containing splice sites and SNP – in this case G/T) allows differentiation between the two 
products by length in gel electrophoresis. 
 
In the optimisation phase oligo(dT) primer was used to synthesis cDNA. IL6 cDNA 
could be demonstrated on a gel, by showing a short product amplified using primers 
spanning intron 3 (Ex3/In3/Ex4 Primer see Sequences 3 & Sequences 4). However 
bands were faint and thus not useful for gel based quantitation. hnRNA exists before 
polyadenylation and it is not entirely clear, whether polyadenylation is complete 
before the splicing process begins, thus oligo(dT) primer may not be useful in 
amplifying hnRNA, therefore specific primers were used to improve signal strength 
(see Sequences 3 & Sequences 4).  
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Sequences 3:  Ex3/In3/Ex4 Primer used to detect presents of cDNA and Primers used for reverse 
transcription of RNA. 
 
 
Sequences 4: Sequence of exon 3 and 4 (highlighted in pink) and intron 3 containing SNP G3572T 
(green writing on green highlight): The primer for reverse transcription from exon 4 (grey) and the 
primer pair for amplification of short and long cDNA (light green - Ex3/In3/Ex4 Primer) 
transcription product can be seen.  
 
For cDNA synthesis RNA was diluted in RNase free water to a concentration of 
50ng/ul. 10ul of this dilution i.e. 500ng of RNA was used in the reverse transcription 
reaction. 500ng of primer was added to the RNA and both were heated in a 
microcentrifuge tube to 70˚C for 5 minutes before cooling on ice.  
 
agtggtgtttgttttagggacacttaggtgataacaattctggtattctttcccagacat 
gtaacaagagtaacatgtgtgaaagcagcaaagaggcactggcagaaaacaacctgaacc 
ttccaaagatggctgaaaaagatggatgcttccaatctggattcaatgaggtaccaactt 
gtcgcactcacttttcactattccttaggcaaaacttctccctcttgcatgcagtgcctg 
tatacatatagatccaggcagcaacaaaaagtgggtaaatgtaaagaatgttatgtaaat 
ttcatgaggaggccaacttcaagcttttttaaaggcagtttattcttggacaggtatggc 
cagagatggtgccactgtggtgagattttaacaactgtcaaatgtttaaaactcccacag 
gtttaattagttcatcctgggaaaggtactcgcagggccttttccctctctggctgcccc 
tggcagggtccaggtctgccctccctccctgcccagctcattctccacagtgagataacc 
tgcactgtcttctgattattttataaaaggaggttccagcccagcattaacaagggcaag 
agtgcaggaagaacatcaagggggacaatcagagaaggatccccattgccacattctagc 
atctgttgggctttggataaaactaattacatggggcctctgattgtccagttatttaaa 
atggtgctgtccaatgtcccaaaacatgctgcctaagaggtacttgaagttctctagagg 
agcagagggaaaagatgtcgaactgtggcaattttaacttttcaaattgattctatctcc 
tggcgataaccaattttcccaccatctttcctcttaggagacttgcctggtgaaaatcat 
cactggtcttttggagtttgaggtatacctagagtacctccagaacagatttgagagtag 
tgaggaacaagccagagctgtgcagatgagtacaaaagtcctgatccagttcctgcagaa 
aaaggtgggtgtgtcctcattccctcaacttggtgtgggggaagacaggctcaaagacag 
 
Primer pair spanning intron 3: 
 
Ex3/In3/Ex4      F        5’- gaaagcagcaaagaggcact – 3’ 
           R       5’ – agctctggcttgttcctcac -3’ 
 
Reverse primer for reverse transcription annealing in exon 4:  
 
RevPrRtEx 4                                        5’ – tttctgcaggaactggatca – 3’ 
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The following was added in this order: 
 
Mastermix for cDNA synthesis   
M-MLV RT 5x Reaction Buffer       5ul 
dNTP 10nm  1.25ul 
Moloney murine leukaemia virus reverse 
transcriptase RNase H-  (M-MLV RT H-) 
1ul (200 units) 
Nuclease free water  6.75ul 
 
The reaction was incubated at 53°C for 60 minutes and then inactivated for 15 
minutes at 70°C. 
 
2.2.8.8 Dealing with Genomic DNA contamination 
 
RNA samples which have been extracted from tissue often contain a significant 
amount of genomic DNA contamination. Assays measuring mRNA expression can 
differentiate between cDNA and gDNA because the mRNA sequence differs from that 
of gDNA due to the loss of introns during the splicing process. However hnRNA, used 
as template in this experiment, is an exact copy of the genomic DNA i.e. it still 
contains the intron regions. Contaminating gDNA would therefore be co-amplified 
with hnRNA in any PCR, thus influencing the results of hnRNA quantification. gDNA 
content of the RNA samples therefore had to be kept to a minimum. In order to 
check for genomic DNA (gDNA) contamination an assay was used that amplified the 
promoter region of an unrelated gene low density lipoprotein receptor (LDLR). 
Promoter regions are not transcribed into hnRNA and therefore allow differentiation 
between gDNA contamination and hnRNA. The LDLR assay was performed on cDNA 
from untreated RNA, RNA which had received one standard DNase treatment and 
from RNA treated twice with DNase (rigorous DNase treatment). Genomic DNA of 
known concentration was also subject to the same protocol to assess how much DNA 
the DNase process was able to digest. 
 
2.2.8.8.1 Standard DNase Treatment 
This treatment will remove up to 2ug of genomic DNA from total RNA in a 50ul 
reaction according to the manufacturer manual. This treatment was used on 20ul of 
RNA and 30ul of gDNA (7-10ng/ul). In the first step 1/10 of the total volume of 10x   82 
DNase I buffer and 1ul of rDNase was added to the sample which was then 
incubated for 30 minutes at 37ºC. The rDNase was inactivated by adding 0.1 x 
volume of DNase inactivation reagent to the sample before incubation at room 
temperature for 2 minutes. The sample was centrifuged at 10,000 x g for 1.5 
minutes and the supernatant (RNA) was carefully transfered to a fresh tube. 
 
2.2.8.8.2 Rigorous DNase Treatment 
This was used to treat 20ul of RNA and 30ul of gDNA (7-10ng/ul). In the first step 
1ul of rDNase was added to the sample which was then incubated for 30 minutes at 
37ºC. A further 1ul of rDNase was added and the sample incubated for a further 30 
minutes at 37ºC. The rDNase was inactivated by adding 0.1 x volume of DNase 
Inactivation Reagent and incubating at room temperature for 2 minutes. The sample 
was then centrifuged at 10,000 x g for 1.5 minutes and the supernatant (RNA) was 
carefully transfer to a fresh tube. A second cycle of DNase treatment followed using 
2ul of rDNase added to the reaction mix before incubation for 30 minutes at 37ºC. 
Inactivation of rDNase was carried out as before. 
In the allelic transcription assay for vein, leukocytes and adipose tissue rigorous 
DNase treatment with DNA-free
TM was performed on all samples prior to 
quantification by spectrophotometry. 
 
 
2.2.8.8.3 LDLR Promoter Assay 
Primers previously designed in the laboratory (by Xiao-he Chen) were used for 
amplification of the promoter region of the low density lipoprotein receptor gene 
(LDLR) (see Sequences 5). PCR conditions had previously been optimised.  
 
 
Sequences 5: Sequence of the forward (F) and reverse (R) primers used in amplification of the 
promoter region of the LDLR gene. 
 
Primers for amplification of promoter region of LDLR 
 
LDLR-Promoter    F     5’-aggactggagtgggaatcagagc-3' 
        R     5'- tgctgtgtcctagctggaaaccc -3 
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A 96 well plate was used. 3ul of cDNA was added to the well (not dried). Below are 
the reagents used in the PCR reaction amplifying the promoter region of the LDLR 
gene: 
 
PCR Reagents  20ul Reaction 
PCR Buffer  2ul 
dNTP (25mM)   0.16ul 
MgCl2 (25mM) 2ul  2.5mM 
Oligos (100pM/ul)  0.08ul + 0.08ul 
Taq DNA Polymerase        0.04ul 
H2O  15.64ul 
         
20ul of the PCR mixture was added to each well, the plate was sealed with a rubber 
mat and placed on a thermal cycler. The timings of the PCR program used are set 
out below:  
 
PCR cycling program:   
Initial denaturation step  95ºC for 3 minutes 
Denaturation step  94ºC for 1 minutes 
Primer annealing step  68ºC for 40 seconds 
Extension step  72ºC for 1 minutes 
  go to step 2 and repeat cycles 35 times 
Final extension step  72ºC for 10 minutes 
 
3ul of PCR product was mixed with loading dye and loaded onto a 5% 
polyacrylamide MADGE gel. Electrophoresis was performed at 150V for 12 minutes in 
a dry box and the gel stained with vistra green. Imaging was performed using 
Fluorimager: Model 595, Molecular Dynamics, Amersham Pharmacia Biotech, Little 
Chalfont, Bucks, UK and TyphoonTRIO+: variable Mode Imager, Amersham 
Biosciences UK Ltd. 
 
2.2.8.9 Detection of Heteronuclear RNA using Gel based Method 
2.2.8.9.1 Amplification of Intron Region 
In order for the experiment to proceed the presence of IL6 hnRNA in the RNA 
samples had to be demonstrated. Concentration of hnRNA needed to be sufficient for   84 
its PCR product to be visible on a gel. The control leukocyte RNA samples used, had 
been demonstrated to be free of gDNA contamination. Two types of cDNA were 
synthesised using specific primers, one annealing in intron 2 and one annealing in 
intron 3 (see Sequences 6).  
 
Sequences 6: Specific primers for reverse transcription, annealing in intron regions. 
 
Primers annealing in introns were used in order to ensure cDNA was transcribed 
from hnRNA only and not from mRNA. cDNA was used as a template for PCR for the 
region surrounding SNP T2529G in intron 2 and G3572T in intron 3 (see section 
2.2.8.6, Sequences 7 and Sequences 8).  
 
 
Specific Primers for cDNA synthesis annealing in intron regions: 
 
Reverse Primer for RT Intron2    5’ - agtgtgggctcccaatctc - 3’ 
 
Reverse Primer for RT Intron3    5’- cttgcccttgttaatgct – 3’ 
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cagcagcagaggcaggctcccagctgtgctgtcagctcacccctgcgctcgctcccctcc 
ggcacaggcgccttcggtccagttgccttctccctggggctgctcctggtgttgcctgct 
gccttccctgccccagtacccccaggagaagattccaaagatgtagccgccccacacaga 
cagccactcacctcttcagaacgaattgacaaacaaattcggtacatcctcgacggcatc 
tcagccctgagaaaggaggtgggtaggcttggcgatggggttgaagggcccggtgcgcat 
gcgttccccttgcccctgcgtgtggccgggggctgcctgcattaggaggtctttgctggg 
ttctagagcactgtagatttgaggccaacggggccgactagactgacttctgtatttatc 
ctttgctggtgtcaggaggttcctttcctttctggaaaatgcagaatgggtctgaaatcc 
atgcccacctttggcatgagctgagggttattgcttctcagggcttccttttccctttcc 
aaaaaattaggtctgtgaagctcctttttgtcccccgggctttggaaggactagaaaagt 
gccacctgaaaggcatgttcagcttctcagagcagttgcagtactttttggttatgtaaa 
ctcaatggttaggattcctcaaagccattccagctaagattcatacctcagagcccacca 
aagtggcaaatcataaataggttaaagcatctccccactttcaatgcaaggtattttggt 
cctgtttggtagaaagaaaagaacacaggaggggagattgggagcccacactcgaattct 
ggttctgccaaaccagccttgtgatcttgggtaaattccctaccacctctggactccatc 
agtaaaattgggggtggactaggtgatctcatagatccttcctgctggaacattctatgg 
cttgaattatattctcctaattattgtcaaaattgctgttattaagtatctactgtgtgc 
caggcactttaaataaatattgtgtctaatcttcaaaacaaatttgcaaggaaggttttt 
ggagataaggaaactgagactcaggattaagtaacacacctaaagtcaaaggtgagcttg 
gaactgaacccaagtgtgcccccactccactggaatttgcttgccaggatgccaatgagt 
tgtagcttcatttttcttagagactttcctggctgtggttgaacaatgaaaaggccctct 
agtggtgtttgttttagggacacttaggtgataacaattctggtattctttcccagacat 
gtaacaagagtaacatgtgtgaaagcagcaaagaggcactggcagaaaacaacctgaacc 
ttccaaagatggctgaaaaagatggatgcttccaatctggattcaatgaggtaccaactt 
 
agtggtgtttgttttagggacacttaggtgataacaattctggtattctttcccagacat 
gtaacaagagtaacatgtgtgaaagcagcaaagaggcactggcagaaaacaacctgaacc 
ttccaaagatggctgaaaaagatggatgcttccaatctggattcaatgaggtaccaactt 
gtcgcactcacttttcactattccttaggcaaaacttctccctcttgcatgcagtgcctg 
tatacatatagatccaggcagcaacaaaaagtgggtaaatgtaaagaatgttatgtaaat 
ttcatgaggaggccaacttcaagcttttttaaaggcagtttattcttggacaggtatggc 
cagagatggtgccactgtggtgagattttaacaactgtcaaatgtttaaaactcccacag 
gtttaattagttcatcctgggaaaggtactcgcagggccttttccctctctggctgcccc 
tggcagggtccaggtctgccctccctccctgcccagctcattctccacagtgagataacc 
tgcactgtcttctgattattttataaaaggaggttccagcccagcattaacaagggcaag 
agtgcaggaagaacatcaagggggacaatcagagaaggatccccattgccacattctagc 
atctgttgggctttggataaaactaattacatggggcctctgattgtccagttatttaaa 
atggtgctgtccaatgtcccaaaacatgctgcctaagaggtacttgaagttctctagagg 
agcagagggaaaagatgtcgaactgtggcaattttaacttttcaaattgattctatctcc 
tggcgataaccaattttcccaccatctttcctcttaggagacttgcctggtgaaaatcat 
cactggtcttttggagtttgaggtatacctagagtacctccagaacagatttgagagtag 
 
Sequences 8: Sequence for intron 3 of IL6: Exons - pink, SNP G3572T used as marker for 
promoter SNP G-174C - green, forward and reverse primer for PCR – yellow, reverse primer for 
cDNA synthesis – grey. 
 
Sequences 7: Sequence for intron 2 of IL6: Exons - pink, SNP T2529G used as marker for 
promoter SNP G-174C – red on green, forward and reverse primer for PCR – yellow, reverse 
primer for cDNA synthesis - grey 
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2.2.8.10  Excluding Amplification from Un-degraded Splice Products 
Intron splicing is followed by de-branching and degradation of the lariat (see above). 
It is unclear how quickly the splice product is degraded. It is therefore possible for 
un-degraded splice products to contaminate the reaction. To ensure PCR 
amplification arose from intact hnRNA and not from an un-degraded splice fragment, 
continuity of the amplified intron 3 region with adjacent exon regions had to be 
demonstrated. A further set of primers was therefore designed (see Sequences 9 & 
Sequences 10).  
 
 
Sequences 9: Sequence of a primer pair spanning the intron 3/exon 3 boundary. A PCR using this 
primer pair only amplifies templates  with intact intron 3/exon 3 boundaries i.e.  genomic DNA or 
hnRNA but not un-degraded splice products.  
 
 
The forward primer was placed in exon 3 and the reverse primer just downstream of 
SNP G3572T i.e. amplicon spanned exon 3/intron 3 boundary. Optimisation of the 
 
Primer for assay checking continuity of amplified intron template with 
adjacent exon:  
 
Intron3/Exon3 continuity     Forward  5’ – gaaagcagcaaagaggcact - 3’ 
         Reverse       5’ – gcagccagagagggaaaag – 3’ 
 
agtggtgtttgttttagggacacttaggtgataacaattctggtattctttcccagacat 
gtaacaagagtaacatgtgtgaaagcagcaaagaggcactggcagaaaacaacctgaacc 
ttccaaagatggctgaaaaagatggatgcttccaatctggattcaatgaggtaccaactt 
gtcgcactcacttttcactattccttaggcaaaacttctccctcttgcatgcagtgcctg 
tatacatatagatccaggcagcaacaaaaagtgggtaaatgtaaagaatgttatgtaaat 
ttcatgaggaggccaacttcaagcttttttaaaggcagtttattcttggacaggtatggc 
cagagatggtgccactgtggtgagattttaacaactgtcaaatgtttaaaactcccacag 
gtttaattagttcatcctgggaaaggtactcgcagggccttttccctctctggctgcccc 
tggcagggtccaggtctgccctccctccctgcccagctcattctccacagtgagataacc 
tgcactgtcttctgattattttataaaaggaggttccagcccagcattaacaagggcaag 
agtgcaggaagaacatcaagggggacaatcagagaaggatccccattgccacattctagc 
atctgttgggctttggataaaactaattacatggggcctctgattgtccagttatttaaa 
atggtgctgtccaatgtcccaaaacatgctgcctaagaggtacttgaagttctctagagg 
agcagagggaaaagatgtcgaactgtggcaattttaacttttcaaattgattctatctcc 
tggcgataaccaattttcccaccatctttcctcttaggagacttgcctggtgaaaatcat 
cactggtcttttggagtttgaggtatacctagagtacctccagaacagatttgagagtag 
Sequences 10: Sequence for intron 3 of IL6: Exons - pink, SNP G3572T used as marker for promoter 
SNP G-174C - green, primer for reverse transcribtion reaction - grey, forward and reverse primer for 
PCR - yellow   87 
PCR reaction was performed using magnesium concentrations of 1.5, 2.0 and 2.5mM 
and a range of temperatures form 53ºC to 63ºC. Control DNA was used as a 
template in the optimisation. 
 
3ul Leukocyte cDNA was used for PCR amplification. Apart from the primers 
Magnesium concentration of 2.0mM, 56ºC annealing temperature the PCR reaction 
conditions were as for T2529C. 
 
2.2.8.11  Ensuring Amplification from Intact hnRNA 
Findings of the above experiment (chapter 3) suggested, amplification could occur 
from un-degraded splice products. Design of the assay was therefore changed to 
ensure amplification occurred only from intact hnRNA. cDNA was synthesised using a 
reverse primer annealing in exon 4. A long PCR assay was designed for amplification 
of intron region three using a forward and  a reverse primers placed in the adjacent 
exons 3 and 4 (spanning intron 3; product size=899bp - Ex3/In3/Ex4 primers) 
(Sequences 11). 
 
 
 
Primers annealing in adjacent exons ensured amplification occurred from an intact 
sequence and not from an un-degraded splice product (see Sequences 12). This 
experiment allowed the demonstration of presence of mRNA derived cDNA as the 
amplification of this cDNA would result in a short product, distinguishable from the 
long amplicon of hnRNA. The former consists of transcript from the exon sequence 
only, whereas the later is transcribed from exon and intron regions. 
Sequences 11: Sequence of the reverse primer used in the cDNA synthesis from RNA. This 
reverse primer anneals in exon 4. Using the synthesised cDNA as a template in a subsequent PCR  
with the forward and reverse primer shown, allowed amplifying intron region 3.   
 
Reverse Primer for cDNA synthesis 
Reverse Primer for RT Exon4    5’ - tttctgcaggaactggatca - 3’ 
 
Primer pair for long PCR amplifying region spanning intron 3 
Ex3/In3/Ex4      Forward        5’- gaaagcagcaaagaggcact – 3’ 
           Reverse        5’ – agctctggcttgttcctcac -3’ 
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This experiment was optimised using magnesium concentrations of 1.5mM, 2.0mM 
and 2.5mM and a range of temperatures form 54ºC to 64ºC. 
 
 
Sequences 12: Sequence for intron 3 of IL6: Exons - pink, reverse primer for RT - grey, forward and 
reverse primer for amplification of intro 3 region -light green (Ex3/In3/Ex4 Primers). Amplification 
of intact hnRNA using the light green primers will result in an 899bp amplicon that can only arise 
from intact hnRNA or gDNA. 
 
Primer optimisation for long PCR was performed using control DNA as the template. 
Amplification with long PCR was performed using 3ul cDNA un-dried on a 96 well 
plate to which 20ul of PCR master mix was added. Below are the reagents used in 
the PCR reaction: 
 
 
 
 
 
 
 
 
 
 
  
agtggtgtttgttttagggacacttaggtgataacaattctggtattctttcccagacat 
gtaacaagagtaacatgtgtgaaagcagcaaagaggcactggcagaaaacaacctgaacc 
ttccaaagatggctgaaaaagatggatgcttccaatctggattcaatgaggtaccaactt 
gtcgcactcacttttcactattccttaggcaaaacttctccctcttgcatgcagtgcctg 
tatacatatagatccaggcagcaacaaaaagtgggtaaatgtaaagaatgttatgtaaat 
ttcatgaggaggccaacttcaagcttttttaaaggcagtttattcttggacaggtatggc 
cagagatggtgccactgtggtgagattttaacaactgtcaaatgtttaaaactcccacag 
gtttaattagttcatcctgggaaaggtactcgcagggccttttccctctctggctgcccc 
tggcagggtccaggtctgccctccctccctgcccagctcattctccacagtgagataacc 
tgcactgtcttctgattattttataaaaggaggttccagcccagcattaacaagggcaag 
agtgcaggaagaacatcaagggggacaatcagagaaggatccccattgccacattctagc 
atctgttgggctttggataaaactaattacatggggcctctgattgtccagttatttaaa 
atggtgctgtccaatgtcccaaaacatgctgcctaagaggtacttgaagttctctagagg 
agcagagggaaaagatgtcgaactgtggcaattttaacttttcaaattgattctatctcc 
tggcgataaccaattttcccaccatctttcctcttaggagacttgcctggtgaaaatcat 
cactggtcttttggagtttgaggtatacctagagtacctccagaacagatttgagagtag 
tgaggaacaagccagagctgtgcagatgagtacaaaagtcctgatccagttcctgcagaa 
aaaggtgggtgtgtcctcattccctcaacttggtgtgggggaagacaggctcaaagacag 
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PCR Reagents    20ul Reaction  Final Concentration 
Long PCR Buffer  2ul  (1xPCR Buffer) 
5M Betaine  5.2ul  (1.3M) 
10mM dNTPs  0.5ul   
25mM Mg
2+    1.6ul  (2mM) 
100pmol/ul Primers     
                          Forward  0.08ul   
                          Reverse  0.08ul   
Promega Taq  0.2ul   
1/250 PWO  0.4ul   
H2O    9.94ul   
                   
The timings of the PCR program used are set out below:  
      
PCR cycling program: 
 
 
Initial denaturation step  94ºC for 2 minutes 
Denaturation step  94ºC for 30 seconds 
Primer annealing step    60ºC  for  30  seconds  for  Ex3/In3/Ex4 
primers 
Extension step  68ºC for 1 minute 
  go to step 2 and repeat cycles 35 times 
Final extension step    68ºC for 20 minutes 
 
The PCR product was loaded onto a 1% agarose gel which had been pre-stained with 
vistra green and run at 120 Volts in 1% 1xTBE buffer, with a vistra green 
concentration of 1:20000, for 30 minutes. Imaging was performed using 
Fluorimager: Model 595, Molecular Dynamics, Amersham Pharmacia Biotech, Little 
Chalfont, Bucks, UK and TyphoonTRIO+: variable Mode Imager, Amersham 
Biosciences UK Ltd. 
2.2.8.12  Nested PCR and Restriction Digest 
Results from the previous experiment showed that hnRNA concentration was to low 
to give adequate bands for gel based quantification. PCR yield had to be improved 
and therefore a nested PCR was designed. Cycle numbers were optimised to ensure 
adequate band intensity. The first PCR used primer pair spanning intron 3, with the   90 
forward primer annealing in exon 3 and the reverse primer annealing in exon 4 
(Ex3/In3/Ex4 Primer pair Sequences 13 & Sequences 14). 
 
Sequences 13: Sequences of primer pair spanning intron 3.  
 
 
 
Sequences 14: Sequence for intron 3 of IL6: Exons - pink, forward and reverse primer for 
amplification of intro 3 region -light green (Ex3/In3/Ex4 Primer pair). Amplification of intact 
hnRNA using the light green primers will result in an 899bp amplicon that can only arise from intact 
hnRNA or gDNA.  
 
Amplification with long PCR was performed using 3ul cDNA un-dried on a 96well 
plate to which 20ul of PCR master mix was added. Below are the reagents used in 
the PCR reaction: 
 
 
 
 
 
 
agtggtgtttgttttagggacacttaggtgataacaattctggtattctttcccagacat 
gtaacaagagtaacatgtgtgaaagcagcaaagaggcactggcagaaaacaacctgaacc 
ttccaaagatggctgaaaaagatggatgcttccaatctggattcaatgaggtaccaactt 
gtcgcactcacttttcactattccttaggcaaaacttctccctcttgcatgcagtgcctg 
tatacatatagatccaggcagcaacaaaaagtgggtaaatgtaaagaatgttatgtaaat 
ttcatgaggaggccaacttcaagcttttttaaaggcagtttattcttggacaggtatggc 
cagagatggtgccactgtggtgagattttaacaactgtcaaatgtttaaaactcccacag 
gtttaattagttcatcctgggaaaggtactcgcagggccttttccctctctggctgcccc 
tggcagggtccaggtctgccctccctccctgcccagctcattctccacagtgagataacc 
tgcactgtcttctgattattttataaaaggaggttccagcccagcattaacaagggcaag 
agtgcaggaagaacatcaagggggacaatcagagaaggatccccattgccacattctagc 
atctgttgggctttggataaaactaattacatggggcctctgattgtccagttatttaaa 
atggtgctgtccaatgtcccaaaacatgctgcctaagaggtacttgaagttctctagagg 
agcagagggaaaagatgtcgaactgtggcaattttaacttttcaaattgattctatctcc 
tggcgataaccaattttcccaccatctttcctcttaggagacttgcctggtgaaaatcat 
cactggtcttttggagtttgaggtatacctagagtacctccagaacagatttgagagtag 
tgaggaacaagccagagctgtgcagatgagtacaaaagtcctgatccagttcctgcagaa 
aaaggtgggtgtgtcctcattccctcaacttggtgtgggggaagacaggctcaaagacag 
 
Primer pair for long PCR amplifying region spanning intron 3 
Ex3/In3/Ex4      F        5’- gaaagcagcaaagaggcact – 3’ 
           R       5’ – agctctggcttgttcctcac -3’ 
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PCR Reagents    20ul Reaction 
Long PCR Buffer  2ul   
5M Betaine  5.2ul   
10mM dNTPs  0.5ul 
25mM Mg
2+  1.6ul     
100pmol/ul Primers   
                   Forward  0.08ul 
                   Reverse  0.08ul 
Promega Taq    0.2ul 
1/250 PWO  0.4ul 
H2O  9.94ul 
           
 The timings of the PCR program used are set out below:  
PCR cycling program:   
Initial denaturation step  94ºC for 2 minutes 
Denaturation step  94ºC for 30 seconds 
Primer annealing step  60ºC  for  30  seconds  for  Ex3/In3/Ex4 
primer 
Extension step  68ºC for 1 minute 
  go to step 2 and repeat 30 cycles  
Final extension step  68ºC for 20 minutes 
 
The PCR product from this reaction was diluted 1 in 1000 (dilution was optimised 
using dilutions 1:100; 1:1000; 1:10.000; 1:100.000 and 1:1.000.000) and 2ul used 
as a template in the second PCR reaction in which the region surrounding SNP 
G3572T in intron 3 was amplified (Sequences 15 & Sequences 16).  
 
 
Sequences 15: Sequence of primer pair used in PCR reaction amplifying the region surrounding 
intron SNP G3572T. 
 
Amplification of intron 3 region: Sequence of primers: 
G3572T new          Forward  5’ – ggcagtttattcttggacagg – 3’ 
        Reverse  5’ –caatgtcccaaaacatgctg – 3’ 
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Sequences 16: Sequence for intron 3 of IL6: Exons - pink, forward and reverse primer for 
amplification of intro 3 region -light green (Ex3/In3/Ex4 Primer pair). Amplification of intact 
hnRNA using the Ex3/In3/Ex4 primers will result in an 899bp amplicon that can only arise from 
intact hnRNA or gDNA. This is then amplified in a second PCR reaction using primer s annealing in 
intron 3 – red. 
 
The  template  was  loaded  onto  a  96well  plate  and  20ul  of  PCR  master  mix  was 
added. The basic formula for the PCR mixture was: 
 
PCR Reagents     
10x PCR Buffer  2.0ul 
5M Betaine  5.2ul   
5mM dNTPs  0.5ul 
25mM Mg
2+  2.0ul    
Primers   
           Forward  0.2ul 
           Reverse  0.2ul 
Promega Taq  0.2ul 
H2O  10.5ul 
 
 
   
   
 
             
agtggtgtttgttttagggacacttaggtgataacaattctggtattctttcccagacat 
gtaacaagagtaacatgtgtgaaagcagcaaagaggcactggcagaaaacaacctgaacc 
ttccaaagatggctgaaaaagatggatgcttccaatctggattcaatgaggtaccaactt 
gtcgcactcacttttcactattccttaggcaaaacttctccctcttgcatgcagtgcctg 
tatacatatagatccaggcagcaacaaaaagtgggtaaatgtaaagaatgttatgtaaat 
ttcatgaggaggccaacttcaagcttttttaaaggcagtttattcttggacaggtatggc 
cagagatggtgccactgtggtgagattttaacaactgtcaaatgtttaaaactcccacag 
gtttaattagttcatcctgggaaaggtactcgcagggccttttccctctctggctgcccc 
tggcagggtccaggtctgccctccctccctgcccagctcattctccacagtgagataacc 
tgcactgtcttctgattattttataaaaggaggttccagcccagcattaacaagggcaag 
agtgcaggaagaacatcaagggggacaatcagagaaggatccccattgccacattctagc 
atctgttgggctttggataaaactaattacatggggcctctgattgtccagttatttaaa 
atggtgctgtccaatgtcccaaaacatgctgcctaagaggtacttgaagttctctagagg 
agcagagggaaaagatgtcgaactgtggcaattttaacttttcaaattgattctatctcc 
tggcgataaccaattttcccaccatctttcctcttaggagacttgcctggtgaaaatcat 
cactggtcttttggagtttgaggtatacctagagtacctccagaacagatttgagagtag 
tgaggaacaagccagagctgtgcagatgagtacaaaagtcctgatccagttcctgcagaa 
aaaggtgggtgtgtcctcattccctcaacttggtgtgggggaagacaggctcaaagacag 
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 The timings of the PCR program used are set out below:              
Initial denaturation step  92ºC for 2 minutes 
Denaturation step  92ºC for 30 seconds 
Primer annealing step  63ºC for 30 seconds 
Extension step  70ºC for 30 seconds 
  go to step 2 and repeat cycles 29 times 
Final extension step  70ºC for 2 minutes 
Final heating cycle  95ºC  for  45  seconds  followed  by 
immediate cooling on ice 
     
The rapid heating and cooling cycle at the end of the PCR ensured that heteroduplex 
formation  occurred  randomly  without  any  new  strand  synthesis  taking  place  that 
may have interfered with this process. Heteroduplexs can not be cut by the chosen 
restriction enzymes. 
 
4ul of PCR product was loaded onto a 96 well plate and digested with 2 units of DdeI 
restriction enzyme for 16 hours at 37ºC in a 10ul reaction. (Restriction digest was 
optimised using known homozygous and heterozygous gDNA as a template in the 
nested PCR and using 3ul, 4ul and 5ul of nested PCR product and 1 unit, 2 units and 
3 units of enzyme in a 10ul digest reaction.) Below are the reagents used in the 
restriction digest: 
 
The timing of the restriction digest is set out below: 
 
16hours at 37ºC 
 
2.5ul of digest product was mixed with 4ul diluted loading dye and loaded onto a 5% 
polyacrylamide MADGE gel, which had been pre-stained with Ethidium bromide. 
Electrophoresis was performed at 150V for 14 minutes in a dry box. Imaging was 
Restriction Digest Reagents  10ul reaction 
PCR product  4.0ul 
DdeI enzyme  0.2ul (2Unit) 
DdeI Buffer  1.0ul 
DD H2O  4.8ul   94 
performed using TyphoonTRIO+: variable Mode Imager, Amersham Biosciences UK 
Ltd. 
 
2.2.8.13  Standard Curve 
Ratiometric analysis of the restriction digest product of the nested PCR required a 
standard curve. Control gDNA available in the laboratory, was genotyped for SNP G-
174C using the Odyssey LightTyper assay and for SNP G3572T using restriction 
digest assay. One SNP G-174C homozygous CC and one homozygous GG DNA 
sample were selected. Concentration of control DNA stock solution was checked by 
two people at two separate time points using spectrophotometry. The stock solutions 
were diluted to a concentration of 10ng/ul by a laboratory technician. The two DNA 
samples at 10ng/ul each were diluted according to the ratios below (Table 2.2-3). 
 
Table 2.2-3: Dilution ratios for standard curve for ratiometric analysis of allelic transcription assay  
Standard  1  2  3  4  5  6  7  8  9  10  11 
GG  1  0.9  0.8  0.7  0.6  0.5  0.4  0.3  0.2  0.1  0 
CC  0  0.1  0.2  0.3  0.4  0.5  0.6  0.7  0.8  0.9  1.0 
 
 
A total of 30ng of each standard as well as two heterozygous gDNA samples were 
used as a template for a nested PCR (see section 2.2.8.12). Heterozygous gDNA 
samples were amplified on the same plate as the standard curve as quality control. 
The ratio of alleles in gDNA is 50:50. Thus heterozygous gDNA acts as a control for 
the accuracy of the standard curve.  
The final digest product was diluted 1 in 50 before loading onto two ethidium 
bromide acrylamide gels to ensure the fluorescent signal from the digest product fell 
within the range of detection of the imager. Digest products were loaded twice onto 
the same gel and once onto a second gel. Gels were then de-stained twice. (Initially 
the gels were re-stained with vistra green following the de-staining step, however it 
became clear that the fluorescence measurement with vistra green gel produced 
inaccurate results due to the impurities within the gel. Therefore fluorescence 
measurements were taken as the average of the first measurement of the ethidium 
bromide gel and the subsequent two measurements of the de-stained gel.)   95 
Gels were scanned using the TyphoonTRIO+ variable Mode Imager after each step of 
staining and de-staining. This experiment was repeated 3 times to demonstrate 
extent of inter assay variance. A total of 36 gel images of the standard curve were 
analysed. 
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Figure 2-11: Gel appearances of digest products of PCR of different standard templates: Standard 
template containing only gDNA of genotype SNP-174 CC gives rise to a cut product (band B and 
band C visible on gel) following nested PCR and restriction digest; Standard template containing 
gDNA of both SNP-174 genotype GG and CC give rise to cut (band B and C) and uncut (band A) 
product; Standard template containing only gDNA of SNP-174 genotype GG gives rise to a single 
band A on the gel. Comparison of the fluorescence intensity of band A and band B allows calculation 
of the ratio of GG and CC template present in original PCR.  Band C is not used in the calculation.  
C/C only  C/C & G/G 
     50:50 
G/G only 
Standards 
Gel Appearance 
        = Restriction Digest 
Band A 
Band B 
Band C 
Nested PCR  
Restriction Digest   97 
The gel pictures were analysed using Image Quant 6.0 software. Intensity of 
fluorescence of the uncut band A (see Figure 2-11), containing amplification product 
of the GG gDNA, was compared to intensity of the larger fragment B (see Figure 
2-11) of the cut band (containing amplification product of the CC gDNA). The base 
pair difference between uncut product A (418bp) and fragment B (299bp) was 
119bp. Therefore given a situation where exactly half the DNA strands are cut i.e. 
products of  transcription of the G and  the C allele were present  in equal amounts, 
the measured fluorescence would not be equal between the two band. In order to 
account for this error, intensity of fluorescence for band A was multiplied by 299/418 
(299/418xA=A*). To compare fluorescence between the bands, B was divided by the 
sum of A* and B (B/A*+B). These measurements were plotted on the Y-axis against 
the known concentrations of the standards measured on the X-axis.  
Heteroduplex formation leads to non linearity of the curve. The highest number of 
heteroduplexes are formed when transcript from G and C allele are present in equal 
amounts. The number of heteroduplexes formed decreases as the concentration of 
the transcript product from one allele increases compared to the other. This would 
leads to a “sag” in the curve. To adjust for heteroduplex formation the known 
concentration of the standard q was squared i.e. x=q
2. Using Excel software a linear 
trend line was fitted. The resulting trend line equation was used to calculate the 
concentration ratio from the measured band intensity ratio of the heterozygous 
samples. 
2.2.8.13.1  Statistical Analysis 
The relationship between the known concentration ratio squared and the measured 
band intensity was investigated using linear regression analysis in SPSS for the three 
PCRs of the standards. The variance of the measured band intensity ratio was 
measured for each standard concentration, to assess the reproducibility of the assay. 
 
2.2.8.14  Allelic Transcription Assay for Vein Samples cDNA 
2.2.8.14.1  RNA Extraction from Vein 
Using Odyssey LightTyper assay as described above 17 study patients were found to 
be heterozygous for SNP G-174C. RNA was extracted from their vein samples 
according to the method described above.   98 
2.2.8.14.2  cDNA Synthesis - Vein 
Heterozygous vein RNA samples were subjected to rigorous DNase treatment as 
described above. This RNA was used for cDNA synthesis using a specific primer 
complimentary to a sequence in exon 4. The cDNA was used in a PCR amplification 
of the LDLR promoter region to assess if samples were free of genomic DNA 
contamination. This was performed in duplicate. The PCR product was loaded onto 
an acrylamide gel, run on the electrophoresis and stained with vistra green. 
2.2.8.14.3  Allelic Transcription Assay - Vein 
Nested PCR amplification was performed as previously described using 3ul vein 
cDNA, 2ul of each of the 11 standards (see section 2.2.8.12) and two heterozygous 
gDNA samples as templates. Each sample was loaded three times on a 96 well PCR 
plate and nested PCR was performed as previously described (see section 2.2.8.12). 
The nested PCR product was then digested using restriction enzyme Dde I. (see 
Figure 2-12). In order to achieve equivalent intensity of fluorescence in the standard 
curve and the samples, sample digest products were diluted 1:2 and standard digest 
products were diluted 1:10. Each digest product was loaded onto a gel stained with 
ethidium bromide before electrophoresis at 150V for 14 minutes in a dry box. Band 
fluorescence intensity was measured using Typhoon Image Quant TL software. The 
gel was then de-stained twice and the band fluorescence intensity measured after 
each de-staining process. 
Figure 2-12: Work flow for individual cDNA sample during ratiometric analysis. 
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A standard curve was plotted and used to calculate the allelic transcription ratio 
(square root of calculated x-value) for the heterozygous gDNA samples and the 
individual vein samples. For the purpose of this study the allelic transcription ratio 
describes the ratio of RNA transcribed from the C-allele compared to total IL6 RNA 
transcribed. 
Samples with at least one repeat measurement were included in the analysis. The 
data was not normally distributed. Therefore the Mann-Whitney test was used to test 
for difference between the results for gDNA and cDNA. 
 
2.2.8.15  Allelic Transcription Assay for Control Leukocyte cDNA 
 
The above experiment (see section 2.2.8.14) was repeated using control leukocyte 
RNA. It was hoped that leukocytes might express more IL6 than vein tissue, thus 
improving the accuracy of the assay. 
 
2.2.8.15.1  RNA Extraction – Leukocytes 
Eight blood samples were taken from a healthy heterozygous volunteer for RNA 
extraction according to the method described above (section 2.2.7.2).  
2.2.8.15.2  cDNA Synthesis – Leukocytes 
The eight heterozygous controls RNA samples were treated with rigorous DNase 
treatment.  cDNA was synthesises using specific primers annealing in exon 4 as well 
as intron 4 (Sequences 17).  
 
Sequences 17: Sequences for two reverse primers used in cDNA synthesis from leukocyte RNA. 
Different reverse primers were used in an attempt to increase cDNA yield. 
 
The intron 4 reverse primer was chosen to test if the yield of cDNA derived from 
hnRNA could be improved by placing the reverse primer in the intron region ensuring 
cDNA synthesis occurred only from hnRNA. Genomic DNA contamination was 
Reverse Primer for cDNA synthesis 
Reverse Primer for RT Exon4    5’ - tttctgcaggaactggatca - 3’ 
 
Reverse Primer for RT Intron4  5’ – gaatgaggacacacccacct – 3’ 
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checked by PCR amplification of the LDLR promoter region in triplicate, loading of 
the PCR product onto a vistra green acrylamide gel, electrophoresis and image 
fluorescence detection as previously described. 
 
2.2.8.15.3  Allelic Transcription Assay - Leukocytes 
Nested PCR was performed for leukocyte control cDNA samples in triplicate using 3ul 
of leukocyte cDNA and 2ul of heterozygous gDNA and standards as a template as 
previously described. Each PCR product was digested by Dde I restriction digest. In 
order to achieve equivalent intensity of fluorescence in the standard curve and the 
samples, sample digest products were diluted 1:2 and standard digest products were 
diluted 1:10, before loading onto an ethidium bromide gel and electrophoresis at 
150V for 14 minutes in a dry box. Band intensity on the gel was measured using 
Typhoon ImageQuant TL software. The gel was then de-stained twice and the band 
fluorescence intensity measured after each de-staining process. 
 
A standard curve was plotted and used to calculate the allelic transcription ratio for 
two heterozygous gDNA samples and the individual leukocyte cDNA samples (square 
root of calculated x-value).  
The Mann Whitney test was used to look for a difference between the mean allelic 
transcription ration for vein cDNA and heterozygous gDNA.  
 
The original study plan had been to examine allelic transcription in all tissue types. 
Because of results obtained in the vein and leukocyte assay, muscle and adipose 
tissue were not examined at this stage. The study proceeded to examine relative IL6 
mRNA expression in different tissues in individuals. 
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2.2.9   Ex Vivo IL6 Expression in Different Tissues 
Raised circulating levels of IL6 have been linked to aspects of vascular disease (see 
section 1.5 & 1.6 ). IL6 is expressed in a variety of cells including 
monocytes/macrophages, adipocytes, endothelial cells, fibroblasts and myocytes. 
The circulating levels of IL6 are therefore the result of its secretion from all these 
tissues types. However the relative contribution individual tissues make to the 
plasma IL6 level is not known.  
This study aimed to gain further insight into the relative RNA expression of IL6 in 
different tissues by comparing relative IL6 transcription in a variety of tissue types in 
a single individual. Real Time PCR analysis (RT-PCR) was used to measure relative 
IL6 expression in different tissues. Results could provide clues to the likely in vivo 
contribution of individual tissues to circulating IL6 in healthy individuals.  
2.2.9.1 Subjects 
33 patients were selected from the patients recruited to the study. Selection criteria 
were: donation of all four tissue samples (vein, adipose tissue, muscle and 
blood=complete complement of tissues). All were healthy patients free of 
cardiovascular disease (ASA grades I or II). None of the patients suffered with 
diabetes. One patient was found to be asthmatic, with acute symptoms on the day of 
operation subsequent to tissue collection. He had taken inhaled steroids prior to 
sample collection and was therefore excluded from the study leaving 32 subjects. 
2.2.9.2 RNA Extraction 
RNA was extracted from vein, blood, muscle and peripheral adipose tissue of all 
selected 32 patients.  RNA was extracted from vein, muscle and adipose tissue using 
the modified TRI Reagent® (Sigma-Aldrich) method as described in section 2.2.7.1. 
Leukocyte RNA was extracted using the PAXgene
TM Kit as described in section 
2.2.7.2. RNA was quantified using spectrophotometry.  
 
2.2.9.3 cDNA Synthesis 
In order to establish which cDNA synthesis method had the best result in terms of 
best cDNA yield, random hexamer primers as well as oligo (dT) primers were used. 
There was no obvious difference between primers used. For reverse transcription 
500ng of RNA was transcribed into cDNA using random hexamer primers 
(PrimerDesign Ltd) and M-MLV reverse transcriptase (PrimerDesign Ltd). 
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Annealing Step: 
For each RNA sample the following was added to a 500µl tube: 
RNA    10.0 ul 
Hexomer primer/ dNTP mix    2.5 ul 
Final volume  12.5ul 
           
A lid was applied and the sample heated at 65°C for 5 minutes on a heated block 
before transferring onto ice.  
 
Extension step 
Mastermix was made up according to the protocol: 
MMLV 5Xbuffer      5.0 ul 
RNA/DNase-free water   6.5 ul 
MMLV enzyme   1.0 ul 
Final volume  12.5 ul 
 
12.5ul of this Mastermix was added to each of the samples on ice. Samples were 
mixed and incubated on a heated Block according to the protocol below: 
 
The synthesised cDNA was used in real-time PCR analysis. 
 
2.2.9.4 Real-Time PCR Analysis 
2.2.9.4.1 Real-Time PCR Principle 
Real time PCR uses a fluorescent reporter probe method. This experiment used a 
sequence specific probe with a fluorescent reporter at one end and a quencher at the 
opposite end. During PCR amplification the annealed probe is broken down by the 5’ 
to 3’ exonuclease activity of the Taq (thermus aquaticus) polymerase leading to 
separation of the reporter and the quencher and thus to a detectable increase in 
fluorescence. The increase in fluorescence is proportional to the increase in target of 
the reporter probe during each PCR cycle.  
According to the basic PCR equation: 
 
37ºC  for 15 minutes 
42ºC  for 45 minutes   103 
 
N=N0 x E
Cp        
 
where:  N=generated copy number at a certain cycle 
  N0= initial copy number 
  E=PCR efficiency 
Cp=Cycle number at which PCR amplification begins its exponential phase 
 
Cp is considered the point most reliably proportional to the initial concentration. 
Where different primers or probes are used the efficiency of the PCR may vary. The 
LightCycler
® 480 Real Time PCR System allows the use of standard curves in the 
experiment. These are used to perform an efficiency correction calculation to 
increase the accuracy of the result. 
 
Relative quantification compares the ratio of a target sequence to a reference 
sequence in an unknown sample. Reference genes are housekeeping genes. The 
principle of relative quantification is based on the assumption that the reference 
gene is equally expressed across all samples. 
 
The LightCycler
® 480 Real Time PCR System uses a calibrator sample to normalise 
samples within one run and provides a constant calibration point between several 
LightCycler system runs. The result is expressed as a normalised ratio: 
 
 
 
2.2.9.4.2 Real-Time PCR: Optimization 
All four tissue types showed IL6 expression in the optimisation phase. Cp values 
were 29.2 to 36.3 depending on cDNA concentration and tissue type. In order to 
Normalised ratio = 
(concentration.target/concentration.ref)sample 
(concentration.target/concentration.ref)calibrator   104 
achieve the lowest Cp values, but taking into account limited amount of RNA 
available, it was decided to use 1.5ul of cDNA in the RT-PCR reaction.  
 
2.2.9.4.3 Real-Time PCR: Experimental Set-Up 
 
Real Time PCR analysis was performed to measure levels of IL6 mRNA expression in 
128 samples using the LightCycler
® 480 Real Time PCR System.  
The IL6 assay (AppliedBiosystems) consisted of pre-designed primers and a 
hydrolysis probe labelled with fluorescein and a quencher. Different concentrations 
of cDNA (0.5ul; 1.0ul; 2.0ul) in a 20ul RT PCR reaction were used for all different 
tissue types, to establish expression in these tissues and the optimum level of cDNA 
template. Two patients’ samples (vein, leukocytes, muscle and adipose tissue) were 
used for optimisation. Reaction volume was optimised to 10 ul and IL6 assay 
concentration was optimised to the minimum level required in order to save costs.  
A variety of housekeeping genes were used in the optimisation phase. The first 
assay used was already available in the laboratory. It consisted of a multiplex 
reaction for ubiquitin C (UBC) and glyceraldehyde 3-phosphate dehydrogenase 
GAPDH. The UBC assay worked consistently for control samples; however the 
GAPDH assay failed repeatedly. It was assumed that this failure was either the result 
of a problem with the multiplex reaction or a problem relating to the GAPDH cDNA in 
the study samples. After discussion with the company it became clear that this 
particular assay had been withdrawn from the market, as other researchers had had 
similar problems. The likely explanation for the GAPDH failure was the competitive 
nature of multiplex PCR reaction leading to preferential amplification of a more 
abundant transcript, not a degradation of GAPDH cDNA. To test this, a simplex RT 
PCR reaction for GAPDH was performed. This showed consistent expression of 
GAPDH in the study samples. It was therefore decided to use a GAPDH simplex 
reaction in all future reactions. This was cost effective as the assay had been 
supplied free of charge as part of a promotional offer.  
Final analysis was performed as relative quantification with reference to the 
housekeeping gene GAPDH. The assay for GAPDH used pre-designed primers and a 
probe labelled with fluorescein (FAM) at the 5’ end and with a dark quencher dye 
near the 3’-end. Both target and housekeeping assay were cDNA specific. Assays 
were run on the ROCHE LC480
® using a FAM filter. Relative quantification data was 
analysed using ROCHE LC480
® Relative Quantification Software.    105 
RT-PCR for each tissue type was performed on one plate which contained a standard 
curve and a calibrator sample as well as negative template controls. The assay was 
performed as a simplex reaction. All reactions were performed in duplicate. Failed 
samples were re-run in duplicate. 
 
IL6 assay:  
The reagents for the mastermix for the IL6 RT PCR are listed below: 
 
Universal mastermix x 2  5ul 
IL6 20x TaqMan expression assay  0.25ul 
RNase free H2O  3.25ul 
total  8.5ul 
 
 
GAPDH Assay: 
The GAPDH Primer Probe Mix (x10) for the GAPDH RT PCR assay was made up 
according to the following formula: 
 
 
 
       
The primer probe mix was heated to 95˚C for 1 minute. 
 
The mastermix for the GAPDH RT PCR assay was made up according to the following 
formula: 
Universal Mastermix x 2  5ul 
GAPDH Primer Probe Mix x 10  1.0ul 
RNase free Water  2.5ul 
Total  8.5ul 
 
Primer R (100pmol/ul)  0.05ul 
Primer F (100pmol/ul)  0.05ul 
Probe No. 60 (10pmol/ul)  0.1 ul 
Water (PCR grade)        0.8 ul 
total  1.0 ul   106 
The cDNA template (1.5ul) and the Mastermix (8.5ul) were loaded onto a plate 
which was sealed with an optical adhesive cover, before centrifugation to prevent 
bubble formation. The plate was placed into the ROCHE LC480
®. Thermal cycler 
conditions were: 
 
Taq activation:  95˚C  10 minutes 
Amplification:  95˚C  15 seconds 
  60˚C  1 minute – one acquisition 
per cycle 
 
The average cycle number was 45. Samples were designated as zero expression if 
both duplicates of the reference amplification were positive and both IL6 
amplifications were negative. Samples which gave a zero result were repeated to 
ensure the result was not due to a technical error. Results were included in the 
analysis as zero expression if both the initial result and the repeat analysis gave a 
value of zero. Values for samples included in the analysis were normalised to the 
calibrator sample to allow comparison between individual PCR runs. 
 
2.2.9.4.4 Standard Curves 
Standard curves were used to calculate efficiency of the RT PCR reaction. cDNA was 
synthesised from control RNA extracted from leukocytes (see section 2.2.7.2). This 
cDNA was used to obtain standard cDNA concentrations. The cDNA was diluted 
according to the dilution factors: 
 
x1.0  x1.25  x1.5  x1.75  x2.0  x4.0  x8.0  x16.0 
 
Thus the relative concentration of the standard samples was known and could be 
used to calculate the efficiency of the RT-PCR reaction, which in turn was used in the 
relative quantification. 
 
2.2.9.4.5 Statistical Analysis  
Statistical analysis was performed using SPSS software. The normalised 
concentration ratios were grouped together according to tissue type. The normalised 
concentration ratio was not normally distributed in any of the tissues. Therefore to 
test if there was a significant difference in expression between tissue types, the   107 
Mann-Whitney U test was applied. To ensure any significant difference shown by the 
Mann-Whitney U test was not related to different variance between the groups, the 
data was then Log transformed and reanalysed using the independent t-test with 
equal variance not assumed.  
To ensure that the analysis was not affected by extreme outliers, normalised 
concentration values in the four tissues were paired for each subject. Variation of IL6 
expression between tissues was then assessed for the individual patient by Wilcox 
signed rank test. 
Data for adipose tissue were analysed for correlation between body mass index and 
IL6 RNA expression, using the Spearman correlation. 
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2.2.10  Relative Expression of IL6 in Different Tissues with 
Regards to SNP G-174C Genotype  
Expression of IL6 may be influenced by tissue type as well as G-174C genotype or 
by the interaction of genotype with tissue type. To try and assess the effects of SNP 
G-174C in a variety of tissues, levels of IL6 RNA in adipose tissue, vein, muscle and 
leukocytes were measured and analysed according to G-174C genotype.  
As this analysis consisted of an inter-individual comparison, potential confounding 
variables were also examined. It has previously been found that plasma levels of IL6 
vary with age; and smoking has previously been found to affect IL6 expression 
(140;272). The association of IL6 expression with age and smoking was therefore 
also investigated in the individual tissues.  
 
2.2.10.1  Subjects and Samples 
Of the 68 patients taking part in the study, 43 patients were included in the analysis 
of tissue specific IL6 expression according to SNP G-174C genotype. 25 patients 
were not included as they could not be genotyped due to loss of access to the 
Odyssey LightTyper. All included 43 patients donated blood for genotype analysis, 
vein and adipose tissue for RNA extraction to the study. Of these 40 patients also 
agreed to a muscle biopsy and 34 also had blood taken for RNA extraction (Table 
2.2-4).  
Table 2.2-4: Numbers of samples processed for each tissue type 
 
2.2.10.2  DNA Extraction and Genotyping 
Leukocyte DNA was extracted from whole blood for genotype analysis as previously 
described. Samples were genotyped using the LightTyper assay described in section 
2.2.8.4.  
Tissue type  Number of samples 
Adipose tissue   43 
Leukocytes   34 
Vein tissue   43 
Muscle tissue   40 
Total number of samples  160   109 
2.2.10.3  RNA Extraction and cDNA Synthesis 
RNA was extracted from all the collected tissues including leukocytes according to 
the methods previously described. 500ng of RNA was used for reverse transcription 
with random hexamer primers into cDNA.  
2.2.10.4  Real-Time PCR Analysis 
Real Time PCR analysis was performed to measure levels of IL6 RNA expression in 
160 samples using ROCHE LC480 as described in section 2.2.9.4. Analysis was 
performed as relative quantification with reference to the housekeeping gene 
GAPDH. Relative quantification was performed using ROCHE relative quantification 
software. RT-PCR analysis for each tissue type was performed on one plate which 
also contained a standard curve and a calibrator sample. All samples were performed 
in duplicate. Only samples with valid duplicate results were included in the analysis. 
Samples were designated as zero expression if both duplicates of the reference 
amplification were positive and both IL6 amplifications were negative. Samples were 
called invalid if either one of the reference or one of the IL6 amplifications was 
negative. Samples with zero expression for IL6 and high Cp-values for GAPDH 
outside the range of the standard curve, indicating very low overall RNA levels 
leading to poor amplification, were designated as invalid. Samples which gave a zero 
result or an invalid result were repeated to ensure the result was not due to a 
technical error or low initial RNA content. Values for samples included in the analysis 
were normalised to the calibrator sample to allow comparison between individual 
PCR runs. 
 
2.2.10.5  Statistical Analysis  
Statistical analysis was performed using SPSS software except for the Fisher Exact 
test which used a web based resource http://www.matforsk.no/ola/fisher.htm . To 
look for difference in IL6 expression depending on genotype all valid results were 
included. Tissues were analysed individually using the Kruskal Wallis test (see 
6Appendix C:c:). 
One-way ANOVA was employed to test if there was a significant difference in age 
distribution in the different genotype groups. 
To test for an association between age and IL6 expression, tissues were analysed for 
all genotype groups together. A linear regression model was applied. As the data 
was non-normally distributed the Spearman correlation coefficient was used to test 
for a linear relationship.    110 
To test if the genotype groups differed significantly with regards to smoking status 
the Fisher exact test was applied.  The Mann Whitney U test was applied to test if 
there was a significant difference between smokers and non smokers with regards to 
IL6 expression.  
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2.2.11  Allelic Transcription Assay for Adipose Tissue Samples 
cDNA 
Results from the allelic transcription experiments for vein and leukocytes and the ex 
vivo expression of IL6 mRNA in different tissues experiment, suggested investigating 
allelic transcription in adipose tissue might provide further insight into the effect of 
promoter SNP G-174C and allow refinement of the allelic transcription assay (see 
section 3.8 & 3.9). The allelic transcription experiment was therefore performed 
using adipose tissue RNA. 
2.2.11.1  Subjects and Samples 
Seventeen adipose tissue samples from SNP G-174C heterozygous patients were 
used in this experiment. 
2.2.11.2  RNA Extraction and cDNA Synthesis  
RNA was extracted from the adipose tissue samples according to the method 
described above. All RNA samples were subjected to rigorous DNase treatment prior 
to quantitation using spectrophotometry. This RNA was used in cDNA synthesis, 
using specific primers complimentary to a sequence in exon 4 (cDNA Ex4) and intron 
4 (cDNA In4) (see Sequences 18). The reverse primer annealing in an intron region 
was chosen in order to investigate whether the yield from hnRNA could be improved. 
Reverse transcription can only occur from hnRNA not mRNA when the primer 
anneals in an intron. This eliminates competitive transcription from mRNAs. 
 
 
 
 
 
 
 
 
The final experiment used cDNA In4 as template.  The cDNA was used in a PCR 
amplification of the LDLR promoter region to investigate gDNA contamination 
according to the method described in section 2.2.8.8.3. This was performed in 
triplicate. The PCR product was loaded onto an acrylamide gel, run on the 
electrophoresis and stained with vistra green. 
Reverse primers for cDNA synthesis from adipose tissue hnRNA 
 
Reverse Primer for RT Exon4        5’ - tttctgcaggaactggatca - 3’ 
Reverse Primer for RT Intron4      5’ – gaatgaggacacacccacct -3’ 
 
Sequences 18: Sequences of reverse primers used in cDNA synthesis from adipose tissue RNA.   112 
cDNA Ex4 was used as template for PCR for amplification of intron 3 and adjacent 
exon/intron boundaries in order to confirm the presence of IL6 mRNA in the 
samples. The PCR amplification product was loaded onto an acrylamide gel and 
stained with vistra green. As the PCR primers (Ex3/In3/Ex4) spanned intron 3, the 
presents of IL6 mRNA in the tissue samples could be confirmed by demonstrating a 
short product on the gel. A long product represented either gDNA contamination or 
amplification from hnRNA. 
 
 
2.2.11.3  Allelic Transcription Assay – Adipose Tissue 
Nested PCR amplification was performed as previously described (see section 
2.2.8.12), using adipose tissue cDNA, 11 standards and three heterozygous gDNA 
samples as template. 3ul of template was loaded onto the PCR plate before adding 
the PCR Mix. Each sample was loaded three times on a 96 well PCR plate.  
The nested PCR product was then digested using restriction enzyme Dde I. In order 
to achieve equivalent intensity of fluorescence in the standard curve and the 
samples, sample digest products were diluted 1:2 and standard digest products were 
diluted 1:10. 
Each digest product was loaded on a gel stained with ethidium bromide and band 
fluorescence intensity measured using Image Quant TL. The gel was then de-stained 
twice and the band fluorescence intensity measured after each de-staining process. 
 
A standard curve was plotted and this curve used to calculate the allelic transcription 
ratio for the heterozygous gDNA samples and the individual adipose tissue samples. 
The mean of the results from the three PCRs was taken for each individual sample to 
calculate the allelic transcription ratio. The Mann Whitney test was used to test if the 
mean allelic transcription ratio for vein cDNA differed significantly from the ratio 
measured for gDNA. 
Genotyping for SNP G3572T was performed on all 17 heterozygous samples, using 
the restriction digest method previously described in section 2.2.8.6.3 to identify 
rare haplotype SNP G-174C/SNP G3572T: GC/TT, i.e. homozygous in the intron SNP 
despite being heterozygous in the promoter SNP 
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3  Results  
3.1  Patient Recruitment/Sample Collection 
3.1.1  Patient Recruitment 
108 patients were approached about the study in the pre-assessment unit or by post 
asking them to take part in the study. Recruitment was ineffective when patients 
were recruited from the pre-assessment unit because for many of the patients the 
operating date had not been set and it was unclear which surgeon would be 
operating on these patients. Not all surgeons took part in the sample collecting 
process so a number of patients who had agreed to take part were lost to the study. 
The method of recruitment was therefore changed to recruiting only patients who 
had been allocated an operating date and these patients were recruited by letter and 
telephone. This improved the numbers successfully recruited; however some 
patients were still lost, as operating dates were frequently changed for patients at 
the last minute. Of the 108 patients approached about the study 95 agreed to take 
part. Thirteen of the patients approached about the study declined to take part i.e. 
uptake was 88%. 68 patients donated tissue samples to the study; of these one 
patient was subsequently found to have taken steroids on the day of surgery and 
was thus excluded from the study (see Table 3.1-1 for demographic data of study 
participants). 25 patients had agreed to take part but did not donate samples. These 
patients were lost because they were operated on by a surgeon not taking part in 
the study or because the investigator was not available to process the tissue 
samples. Two patients were found not to be suitable for the study on the day of the 
operation. One suffered from bleeding tendency and one did not require a groin 
dissection (see Figure 2-2).  
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Table 3.1-1: Demographic data of the study participants. 
  Number of Patients 
Total  67 
Gender 
male  24 
female  43 
Risk Factors for atherosclerosis 
hypertension  8 
hypercholesterolaemia  1 
diabetes mellitus  0 
history of MI or Stroke  0 
Smoking 
non-smokers  47 
smokers  14 
gave up smoking within 2-4 weeks  2 
no smoking history available  3 
Age  Mean age (age range) 
  48 years (22-70 years) 
 
 
Of the 67 study patients recruited 32 were un-medicated and 35 were medicated 
(for medication details see Table 3.1-2).    115 
 
Table 3.1-2: Number of subjects taking a particular drug. Note that out of 67 patients 32 were un-
medicated. The total in the table is more than the medicated 35 patients as some patients were taking 
more that one drug. 
 
 
 
 
3.1.2  Sample Collection 
Although the majority of patients agreed to donate all four tissue types to the study, 
one patient had concerns regarding the muscle biopsy and only donated fat, vein 
and blood. In three cases collection of muscle sample was technically impossible 
because access to the muscle could not be gained without extending the field of 
dissection, as these patients had short saphenous vein surgery only.  
In the initial stages of patient recruitment there was no system available that would 
allow extraction of RNA from blood. Therefore the first seven patients did not have 
blood taken for RNA extraction.  
 
3.2  Patient Follow-Up 
19 patients were contacted for follow up, four of which had been recruited in the 
pre-assessment unit and 15 had been recruited by letter ± telephone call. 12 were 
‘very satisfied’ with the way in which they were recruited and seven were ‘satisfied’. 
All four patients recruited in the pre-assessment clinic were ‘very satisfied’. All 19 
patients would consider taking part in a clinical trial again. None reported 
Medical Therapy  Number  of  Patients 
taking medication 
Antihypertensive  8 
Anti-depressant  6 
Diuretic  4 
Contraceptive 
agent/HRT/Raloxifene 
8 
Aspirin  2 
Adcal/ Alendronic acid  1 
Omeprazole  1 
Simvastatin  1 
Allopurinol  1   116 
complications associated with bleeding such as active bleeding, groin haematoma or 
excessive bruising. However two patients had groin infections. One was a minor 
infection which responded to oral antibiotics the other required surgical drainage of 
abscess. There was no haematoma associated with the abscess. The average time 
scale for return to normal daily activity was 1-2 weeks. Average pain scores (scale: 
1-10) on the first and second postoperative day were 3.9 and 3.6 respectively. None 
of the patients felt that they had suffered any ill effect through taking part in the 
study.  
 
3.3  DNA Extraction from Leukocytes 
DNA yield from 9ml of whole blood varied between 44.5ug and 391.0ug. 
 
3.4  Genotyping for G-174C 
The Odyssey LightTyper assay was used for genotyping. Below are examples of the 
Odyssey LightTyper output curves (Figure 3-1, Figure 3-2 & Figure 3-3). Single melt 
curve peaks are seen for homozygous samples. Peaks occur at lower temperatures 
for the imprecisely bound probe. Homozygous samples show a double melt curve 
peak indicating presence of both alleles. A total of 42 out of 68 patients were 
genotyped for SNP G-174C. The remaining 26 could not be genotyped as access to 
the Odyssey LightTyper was lost due to changes within the laboratory staffing 
structure. Of the 42 DNA samples genotyped for G-174C, 7 were homozygous CC, 
18 were homozygous GG and 17 were heterozygous GC. (see Table 3.4-1; for 
individual results of genotyping see Table_Apx C-33).  
 
Table 3.4-1: Genotype of subjects 
Genotype  Number of subjects 
GG  18 
GC  17 
CC   7 
Total  42 
 
The genotype distribution was in Hardy Weinberg Equilibrium (CHI-squared value = 
0.72, not significant with one degree of freedom) 
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Figure 3-1: Example of output from Odyssey LightTyper showing a melt curve for a homozygote 
(common  allele)  individual.  Y-axis  represents  detected  fluorescence  and  x-axis  represents  ramp 
temperature. This curve was obtained by PCR amplification of genomic DNA. Post PCR the product 
was  subjected  to  thermal  ramping  leading  to  separation  of  a  fluorescent  probe  from  the  PCR 
amplicon and quencher probe. The resulting increase in fluorescence was detected by the Odyssey 
LightTyper and is represented by the peak of the melt curve. The temperature at which separation 
of the probe occurs is higher when the probe is precisely bound to the G-allele than when it is 
imprecisely  bound  to  the  C-allele.  A  single  peak  at  a  relatively  high  temperature  (57  degree 
centigrade in this instance) indicates that only G-alleles are present. 
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Figure 3-2: Odyssey LightTyper output for heterozygote individual. There are two peaks in the melt 
curve  one for the common allele G (high temperature 57 degree centigrade) and one for the rare 
allele C (low temperature 44.5 degree centigrade). 
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Figure 3-3: Odyssey LightTyper output for a homozygote (rare C allele) individual. There is one 
peak in the melt curve at a low temperature (44.5 degree centigrade). 
 
 
3.5  RNA Extraction and Quantification 
RNA was extracted from 45 vein samples, 42 muscle samples, 45 fat samples and 40 
blood samples. Vein and muscle tissue are high in fibrous content making 
homogenisation difficult. An automatic homogeniser of adequate size was not 
available in the laboratory and tissues was therefore homogenised by hand. The 
laborious nature of this process allowed a maximum of six samples to be processed 
per day. RNA yield was poor and repeat RNA extraction from tissue samples was 
necessary for individual experiments. Initially 100mg of tissue per sample was used 
on average for homogenisation in 1ml TRI Reagent® for vein, muscle and adipose 
tissue as per manufacturer’s protocol. RNA yield using this method was low, in 
particular for adipose tissue. The method was therefore modified (see section 
2.2.7.1) to using smaller amounts of tissue in a greater volume of TRI Reagent®. 
Leukocyte RNA was extracted from 2mls of blood with an average RNA yield of 
10.54ug (see Table 3.5-1). 
Single 
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Table 3.5-1: Average RNA yield in different tissues 
  mean  vein  RNA 
yield in ug 
mean  muscle 
RNA yield in ug 
mean  adipose 
tissue  RNA 
yield in ug 
mean  leukocyte 
RNA yield in ug 
initial method  2.89  1.92  1.63   
final method  8.41  10.89  3.18  10.54 
 
 
3.6  RNA Purity 
Purity of RNA as assessed by A260:A280 ratio varied between tissue samples (see 
Table 3.6-1). Leukocyte RNA had the lowest protein contamination. Protein 
contamination in RNA from tissue samples was high. In particular fat samples had 
substantial protein contamination.  
 
Table 3.6-1: Average A260/A280 values for different tissues 
Average 
A260:A280 ratio 
 vein  muscle  fat  Leukocytes 
In tris HCL Buffer  1.73  1.74  1.33  1.91 
 
 
3.7  RNA Quality 
RNA samples are easily degraded by RNases, nucleases that act as catalysts in the 
hydrolytic cleavage of RNA into smaller components. RNases are common in the 
environment. Thus it was necessary to ensure collection and storage conditions of 
the study samples did not lead to degradation of RNA. The results of electrophoresis 
of RNA samples on a denaturing urea acrylamide gel, suggest that RNA extracted in 
this experiment was of equal quality to RNA, used successfully in previous 
experiments. The gel showed clear 28s and 18s bands with little or no degradation 
(see Figure 3-4).  
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Figure 3-4: A denaturing urea acrylamide gel showing 28s and 18s RNA bands: Comparison of RNA 
of known quality with control RNA extracted and stored for the purpose of this study. Clear 28S and 
18S bands indicate little or no degradation of RNA. 
 
3.8  Preferential Allelic Transcription Assay 
3.8.1  gDNA Contamination 
PCR using genomic DNA from leukocytes, treated with the standard DNase 
treatment, as a template was able to amplify the LDLR promoter region in all three 
samples, indicating incomplete digestion (see Figure 3-5). PCR from genomic DNA 
treated with rigorous DNase treatment showed no amplification indicating complete 
digestion. cDNA samples from standard DNased RNA from vein, placenta and 
leukocytes showed promoter amplification; however the same RNA treated with 
rigorous DNase treatment showed no amplification from cDNA indication complete 
digestion of genomic DNA contamination. 
 
28s 
18s 
RNA samples of known quality  RNA samples extracted for study   122 
 
Figure 3-5: Acrylamide gel 5% stained with vistra green: Result of PCR amplification of promoter 
region of LDL-R (35 PCR cycles). All samples treated with rigorous DNase protocol failed to show 
amplification indicating complete digestion of genomic DNA/contamination. Samples treated with 
standard DNase protocol show residual amplification, indicating some residual gDNA/contamination 
is present (arrows).  
 
Rigorous DNase treatment was enough to digest at least 300ng of gDNA and 
appeared to be sufficient to rid control RNA samples of gDNA contamination. 
Therefore all samples for the experiment were treated with rigorous DNase 
treatment.  
 
3.8.2  Detection of hnRNA Using Gel Based Method 
3.8.2.1 Amplification of Intron Region 
Using cDNA synthesised from RNA free of gDNA contamination, intron region 2 and 
intron region 3 were amplified using PCR. The correct sized product could be 
Pos Control 
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Standard DNase 
Genomic DNA 
Genomic DNA 
cDNA 
cDNA 
Vein      Placenta    Leukocyte 
Vein     Placenta    Leukocyte   123 
demonstrated following PCR for intron 3 but not for intron 2. Despite designing 
another primer pair for intron 2, this region failed to amplify.  
 
 
Figure 3-6: Acrylamide gel 5% with vistra green stain: PCR amplification of intron 2 region of IL6 
from cDNA-In2 and cDNA-In3 templates. Amplification could not be demonstrated. 
 
Figure 3-6 shows PCR amplification of the region surrounding SNP T2529C in intron 
two. Different cDNAs had been used as template. Some had been synthesised using 
a reverse primer annealing in intron 2 (cDNA in2) other using a primer annealing in 
intro 3 (cDNA in3). No obvious bands were seen. 
 
 
Figure 3-7: Acrylamide gel 5% with vistra green stain: PCR amplification of intron 3 region of IL6 
from cDNA-In3 templates. Bands are visible for all samples demonstrating amplification. 
 
Figure 3-7 shows PCR amplification of the region surrounding SNP G3572T in intron 
three. The cDNA used as template had been synthesised using a reverse primer 
annealing in intron 3 (cDNA in3). Bands of the correct size were demonstrated 
suggesting possible presence of hnRNA. 
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3.8.3  Excluding Amplification from Un-degraded Splice Product 
Results of section 3.8.2.1 suggested that hnRNA was present, as intron regions 
could be amplified. To test if amplification may have occurred from an un-degraded 
splice product (spliced but un-degraded intron sequence) amplification was 
attempted of the exon 3/intron 3 boundary. It was not possible to demonstrate a 
PCR product for this reaction, suggesting amplification could have occurred from 
splice product (see Figure 3-8). 
 
Figure 3-8: Agarose Gel 1.5% EB stain: PCR amplification of control leukocyte cDNA template of 
Exon/Intron 3 boundary - no product was visible for cDNA. Positive gDNA controls both showed 
bands of the correct size.  Repeat staining of the gel with Vistra Green also failed to demonstrate 
bands for cDNA. 
 
3.8.4  Ensuring Amplification from Intact hnRNA  
To ensure amplification of intron3 could not occur from a splice product, intron 3 was 
amplified including the adjacent exon/intron boundaries. Both a short product 
(mRNA derived) and a long product (hnRNA or gDNA) could be demonstrated. LDLR 
promoter amplification was unsuccessful indicating freedom from genomic DNA 
contamination Figure 3-9. Assuming freedom of gDNA contamination, this 
experiment showed the presence of IL6 mRNA in control leukocyte RNA (short 
product) and hnRNA (long product). Therefore hnRNA cDNA PCR product was 
concluded to be a suitable candidate for nested PCR template. 
   125 
 
Figure 3-9: Agarose Gel 1.5% stained with vistra green loaded with PCR amplification product of 
control  leukocyte  cDNA  (samples  1,  2  &  3)  and  negative  water  control  (neg):  There  is  no 
amplification in the LDLR promoter assay, indicating lack of gDNA contamination. Amplification of 
intron 3 from control leukocyte cDNA template using primer Ex3/In3/Ex4, shows a faint band for 
sample  1,  2  and  3  of  about  899  bp  (potential  amplification  product  from  hnRNA)  and  a  short 
product from cDNA template.  
 
3.8.5  Nested PCR and Restriction Digest 
Using the nested PCR allelic transcription assay the region surrounding SNP G3572T 
in intron 3 could be amplified sufficiently to produce clearly visible bands on an 
ethidium bromide gel (Figure 3-10). Following digestion the bands were of sufficient 
fluorescence intensity to allow fluorescence quantification. In a nested PCR the first 
product is diluted to reduce potential contaminants. Different dilution factors were 
tested to determine optimal signal strength. In the final experiment a dilution factor 
1:1000 was used. 
Ex3/In3/Ex4 PCR 
spanning Intron 3 
 1       2        3 
LDLR Promoter PCR 
 
     1        2      3   126 
 
Figure 3-10: Acrylamide gel 5% with ethidium bromide stain: Product of the nested PCR of control 
leukocyte cDNA for amplification of intron region 3 and restriction digest Dde I.  The amplification 
product of the first PCR was diluted. A dilution of 1:1000 results in clearly visible bands following 
second PCR and restriction digest. Bands are not clearly visible at a dilution of 1:10 000. 
3.8.6  Standard Curve  
Nested PCR was performed using a mixture of two types of homozygous gDNA at 
known ratios (standards) (see section 2.2.8.13) as a template. The PCR product was 
digested and loaded onto a gel allowing measurement of ratio between alleles as 
previously described. Below are examples of the gel appearances of the standard 
samples (see Figure 3-11 & Figure 3-12).  
 
 
Figure 3-11: Acrylamide gel 5% with ethidium bromide stain: Amplification product of the nested 
PCR and restriction digest using gDNA standards (gDNA of varying ratio between two samples, 
each homozygous for SNP G-174C; one GG the other CC) as a template,    127 
 
Figure 3-12: Acrylamide gel 5% with ethidium bromide stain: Nested PCR and restriction digest 
product of standards (ratios 0-1.0), heterozygous gDNA samples (het) and negative water control 
(neg) as well as an uncut nested PCR product (uncut) loaded twice onto the gel. 
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Below are the standard curves achieved by plotting the measured fluorescence 
intensity ratios against the known concentration ratios of the standard samples 
(squared) and fitting a trendline (see Figure 3-13) as previously described (see 
section 2.2.8.13; for data see Table_Apx C-38, Table_Apx C-39, Table_Apx C-40). 
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Figure 3-13: Standard curves: Standard samples (varying ratios of two gDNA samples homozygous 
for SNP G-174C; one GG the other CC) were used as templates for the nested PCR reaction and 
restriction digest. Fluorescence measurement ratios of the two larger bands were plotted on a graph 
against the known ratios of the standard samples squared. This was performed in triplicate using the 
same standards as a template. To create the standard curve a trendline was fitted. Note that the 
trendline from PCR 1 and PCR 3 are super-imposed indicating good reproducibility of the assay for 
the standard samples.  
  
Linear regression analysis indicated a very strong linear relationship between the 
variables. R-squared for PCR 1, 2, 3 was 0.98, 0.90, 0.97 respectively with a 
significance value p<0.001. (for SPSS linear regression analyses see Table_Apx 
C-16, Table_Apx C-17, Table_Apx C-18). 
 
The variance in measured band intensity for each standard concentration was close 
to zero (Table 3.8-1)   129 
 
Table 3.8-1: Variance of measured  band intensity ratio for each standard concentration. 
Standard 
concentration 
ratio 
10:0  9:1  8:2  7:3  6:4  5:5  4:6  3:7  2:8  1:9  0:10 
Variance   0.003  0.004  0.024  0.002  0.001  0.001  0.003  0.003  0.001  0.000  0.000 
 
 
Each nested PCR contained two samples of heterozygous gDNA as a control. The 
measured band intensity ratios for the two samples of heterozygous gDNA were 
plotted on the standard curves (see Figure 3-14). Calculated allelic concentration 
ratio was 0.51 (expected=0.50) 
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Figure 3-14: Standard curve from PCR 1 using heterozygous gDNA (control gDNA 26 and 28 = C26 
and C28) as well as standard samples as a template. The measured band fluorescence intensity ratio 
of the heterozygous gDNA samples is plotted on the standard curve. The values for heterozygous 
gDNA are marked in yellow and pink. The calculated concentration ratio squared for heterozygous 
gDNA was 0.26 i.e. allelic ratio was 0.51  (expected=0.50)   130 
3.8.7  Allelic Transcription Assay for Vein Sample cDNA 
Following design and validation of the allelic transcription assay, study vein sample 
cDNA were examined for gDNA contamination. Despite rigorous DNase treatment 4 
samples out of 17 showed gDNA contamination in one of the PCRs (see Figure 3-15).   131 
 
Figure  3-15:  Acrylamide  Gel  5%  stained  with  vistra  green:  Results  from  PCR  amplification  of 
LDLR  promoter  region  for  vein  samples  (numbered  samples);  negative  water  (neg  control) and 
positive gDNA (pos control) controls are included. Bands indicating gDNA contamination are seen in 
samples 2, 8, 11 and 43. 
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Nested PCR and restriction digest was performed in triplicate on all samples 
including those contaminated with gDNA. Out of 17 vein samples 13 samples had 
measurements for all three PCRs, for 3 vein samples only two out of three PCRs 
showed amplification. Samples with at least one duplicate measurement were 
included in the analysis i.e. one samples was excluded from the analysis (see Figure 
3-16:).  
 
 
Figure 3-16: Acrylamide gel 5% with ethidium bromide stain: Example of one of the repeat nested 
PCR/restriction digest products for vein cDNA. Negative (neg) controls and heterozygous (hetero) 
gDNA samples are also included. Numbers 1.0-0 represent the standard homozygous ratio. 
 
All values for the standard curve samples were plotted on a graph and a linear trend 
line was fitted using Excel software. The average values of band fluorescence 
intensity for the two genomic DNA samples were then plotted on the graph using the 
calculated trend line equation. The mean calculated allelic ratio for the gDNA   133 
samples was 0.53 (see Figure 3-17). (Data see Table_Apx C-43 and Table_Apx 
C-44)  
 
 
 
Figure 3-17: Graph showing standard curve and mean result for two heterozygous gDNA samples as 
well as the mean value for vein samples. The mean of the vein samples falls to the right of the mean 
for gDNA indicating that the C-allele was preferentially transcribed. 
 
The mean allelic transcription ratio for all the vein samples was 0.54 (SEM+0.05). 
This was not significantly different from the calculated allelic ratio for the genomic 
DNA samples 0.53 (Mann Whitney U test p=0.78) (for statistical analysis see 
Table_Apx C-1).  
When individual tissue samples are plotted on this curve, the results were widely 
spread (see Figure 3-18). 
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Figure 3-18: Graph showing standard curve and result for the mean of two heterozygous gDNA 
samples as well as individual values for the vein samples. The vein samples cluster to the right of the 
value  for  gDNA  indicating  that  in  the  majority  of  samples  the  C-allele  was  preferentially 
transcribed. 
 
 
To assess the reproducibility of the measurements for the individual samples, the 
mean of the 3 PCRs was plotted and the 95% confidence intervals were calculated 
(see Figure 3-19). 
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Figure 3-19: Mean allelic transcription ratio for individual vein samples (TIG sample numbers) and 
results for two heterozygous gDNA samples. The error bars indicate the 95% confidence interval 
(CI). CIs for gDNA are narrow indicating good reproducibility with minimal variation. CIs in the 
majority of cDNA samples are wide indicating poor reproducibility of results. 
 
CI for gDNA were narrow consistent with the reproducibly results observed for 
gDNA. Though some showed good reproducibility CI for the majority of cDNA 
samples were wide, demonstrating the poor reproducibility of individual 
measurements. The mean variance for individual samples was 0.07. 
3.8.8  Allelic Transcription Assay - Leukocytes 
All eight RNA samples appeared clear of cDNA contamination, with no visible 
amplification in LDLR promoter PCR (see Figure 3-20).   136 
 
Figure 3-20: Result of LDL-R promoter PCR amplification on an acrylamide Gel (5%) stained with 
vistra green stain: 0=negative control, 1-8 = leukocyte, 1-8 = leukocyte, 26 and 33 = genomic DNA 
(positive control). A 50bp marker is included on the gel.  Bands are seen only in the positive control 
(arrows) indicating cDNA samples are free of gDNA contamination. 
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The result of the nested PCR and digest are shown on the gel below (see Figure 
3-21). (Results of ratiometric analysis see Table_Apx C-42) 
 
 
Figure 3-21: Result of leukocyte cDNA amplification with nested PCR and digest described in section 
2.2.8.12: Samples (1-8) = cDNA Ex4, samples (1*-8*) = cDNA In4, heterozygous genomic DNA 
samples 26 and 33 as well as standards (1.0-0.0) and negative control=0 are included on the gel. Two 
different types of cDNA were used as template to see if the reproducibility of the assay could be 
improved. 
   138 
Out of the 16 samples all three PCRs gave a valid result in 10 cases, two PCRs 
worked for two samples and four samples only showed amplification in one PCR.  
The mean allelic transcription value of all cDNA samples was 0.65 (SEM+0.08). The 
mean calculated allelic ratio for gDNA was 0.56 (see Figure 3-22). This suggests that 
the C-allele was preferentially transcribed. 
 
 
Figure 3-22:Graph showing standard curve and mean result for the heterozygous gDNA samples as 
well as the mean value for the leukocyte cDNA samples. 
 
 
When plotted independently on the standard curve, mean values of the three PCRs 
predominantly fell to the right of the values for gDNA i.e. indicating greater 
transcription from the C-allele compared to the G-allele in the majority of cases (see 
Figure 3-23:). 
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Figure  3-23:Graph  showing  standard  curve  and  mean  result  for  heterozygous  gDNA  as  well  as 
individual values for the leukocyte cDNA samples. 
 
 
The Mann Whitney test showed that the mean calculated allelic transcription ratio for 
the cDNA samples did not differed significantly form the value obtained for genomic 
DNA p<0.47 (see Table_Apx C-2). 
 
To assess variation between the three PCRs carried out for one cDNA sample, the 
95% CI was calculated for individual cDNA samples, and plotted on a graph (Only 
samples with at least two valid PCRs included) (see Figure 3-24). 
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Figure 3-24: Graph showing the allelic transcription ratio for individual leukocyte samples as well as 
results for heterozygous gDNA samples. The bars indicate the 95% confidence interval 
 
 
Low inter-assay variability was demonstrated for gDNA samples, with narrow 95% 
CI. The CI for leukocyte cDNA samples remained wide, indicating high inter-assay 
variability. Mean variance for cDNA Ex4 and cDNA In4 were 0.04 and 0.08 
respectively, i.e. assay reproducibility was not improved by annealing the reverse 
primer in an intron region for cDNA synthesis. The between sample variance was 
0.08.  
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3.9  Ex Vivo IL6 Expression in Different Tissues  
3.9.1  Subjects 
All patients were of white British origin. In 11 out of the 32 patients (128 tissue 
samples) at least one of the tissues failed to give real time quantification data, 
despite repeated attempts. Normalised concentration ratios were available for all 
four tissues (complete tissue complement) in 21 patients. In order to avoid inter-
individual confounding variables distorting the final result, only patients with relative 
real time quantification data for all four tissue types were include in the analysis. The 
mean age of included patients was 48 years (range 26-69 years) and the mean body 
mass index was 26.7kg/m
2 (range 22-33kg/m
2). Demographic data of included 
patients is listed in Table 3.9-1.  
 
Table 3.9-1: Demographic data for the 21 subjects with complete tissue complements. 
   Number 
Subjects  21 
Smoking Status    
non-Smoker  14 
smoker  7 
Gender    
male  9 
Female  12 
Medication    
nil  10 
Oral 
Contraceptive  2 
Amitriptyline  2 
Ca Channel 
Blocker  1 
Diuretics  1 
Aspirin  1 
Ventolin  1 
Omeprazole  1 
Celest  1 
Allopurinol  1 
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3.9.2  Standard Curves 
Standard curves for GAPDH showed good replicates for all dilutions (see Figure 
3-25).  
 
 
Figure 3-25: GAPDH standard curve for Leukocyte cDNA shows good reproducibility of the assay 
with replicate measurement for different dilutions showing minimal variability. 
 
The IL6 standard curves showed greater variability in the repeats than the GAPDH. 
Efficiency of the IL6 assay also tended to be less then the efficiency of the GAPDH 
assay, as shown by the steeper gradient of the GAPDH standard curve (see Figure 
3-26).  
 
 
Figure 3-26: IL6 standard curve from Leukocyte cDNA. 
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3.9.3  RT-PCR Amplification Curves 
 
The RT-PCR amplification curves of individual tissues are shown below (see Figure 
3-27, Figure 3-28, Figure 3-29 & Figure 3-30). These graphs show the change in 
fluorescence i.e. product amplified per PCR cycle. In the figures the top graph shows 
the IL6 assay amplification curves. The bottom graph shows the reference 
amplification curve for the same samples. The majority of reactions in the IL6 assay 
enter the exponential phase of amplification around cycle 32 - 34 (Cp-value); 
however several samples have Cp values as low as 26 in the adipose tissue assay. 
The GPDH assay shows mean Cpvalues of 28 with values as low as 19 for some 
samples.  
Both GAPDH and IL6 assay appeared to work reliably for the majority of samples. 
Cp-values for GAPDH tended to be lower than for IL6, indicating lower expression of 
IL6 compared to the housekeeping gene. 
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Figure 3-27: These graphs show the change in fluorescence i.e. product amplified per PCR cycle. The 
top figure shows the IL6 assay amplification curves of adipose tissue. The bottom figure shows the 
reference amplification curve for the same samples. The majority of reactions in the IL6 assay enter 
the exponential phase of amplification around cycle 32 (Cp-value), however several sample have Cp 
values as low as 26. The GPDH assay shows mean Cpvalues of 28 with values as low as 19 for some 
samples.    145 
 
Figure 3-28: RT PCR curves for GAPDH (reference gene) and IL6 (target gene) for vein samples: 
The graphs show the change in fluorescence i.e. product amplified per PCR cycle. The top figure 
shows the IL6 assay amplification curves. The bottom figure shows the reference amplification 
curve.   146 
 
Figure 3-29: RT PCR curves for GAPDH (reference gene) and IL6 (target gene) for leukocyte 
samples. The graphs show the change in fluorescence i.e. product amplified per PCR cycle. The top 
figure shows the IL6 assay amplification curves. The bottom figure shows the reference amplification 
curve.   147 
 
Figure 3-30: RT PCR curves for GAPDH (reference gene) and IL6 (target gene) for skeletal muscle 
samples. The graphs show the change in fluorescence i.e. product amplified per PCR cycle. The top 
figure shows the IL6 assay amplification curves. The bottom figure shows the reference amplification 
curve.   148 
3.9.4  Relative Quantification of IL6 mRNA Expression 
The measured relative IL6 mRNA expression in adipose tissue, leukocytes, vein 
tissue and muscle tissue is given below (see Table 3.9-2). Values were normalised to 
a calibrator sample which was included in each LightCycler system run. Individual 
runs may vary in efficiency leading to erroneous results. The calibrator sample 
provides a constant calibration point between individual LightCycler system runs 
thereby reducing this error. 
 
Table 3.9-2: Normalised concentration ratio of IL6 mRNA in four different tissues in 21 patients 
(TIG X). 
    normalised concentration ratio by tissue type 
Patient 
identification 
number  adipose tissue  leukocytes  vein  muscle 
TIG 010  14.9  1.49  0.4  0.01 
TIG 014  2.49  0.76  0.24  1.42E-04 
TIG 015  1.08E+02  1.81  7.56  0.03 
TIG 017  98.16  0.72  0.82  0.02 
TIG 018  3.03E+02  6.11  15.52  0.72 
TIG 019  13.23  0.4  5.21  0.09 
TIG 021  2.77E+02  10.35  3.66  0.72 
TIG 024  38.42  0.47  0.38  0.04 
TIG 025  6.17  1.37  1.63  0.04 
TIG 028  1.74E+02  0.46  0.66  0.02 
TIG 029  27.61  0.83  0.24  0.04 
TIG 030  21.85  1.52  4.34  0.08 
TIG 031  2.38  0.6  1.28  0.02 
TIG 034  11.16  1.53  0.22  0 
TIG 035  5.8  0.9  1.65  4.84E-03 
TIG 036  16.63  0.66  0.64  0.04 
TIG 037  4.6  0.64  0.16  7.89E-03 
TIG 038  57.38  0.24  0  0.04 
TIG 041  15.07  0.35  0.23  0.03 
TIG 043  2.48  0.85  0.41  0.05 
TIG 046  0  0.43  0.9  0.04 
 
 
Mean normalised concentration ratio of IL6 mRNA compared to the housekeeping 
gene GAPDH was 57.2 (SEM + 19.4) [median=15.1] for adipose tissue; 1.6 (SEM + 
0.5) [median=0.8] for leukocytes; 2.2 (SEM + 0.8) [median=0.7] for vein and 0.1 
(SEM + 0.05) [median=0.04] for muscle.    149 
Median and mean relative expression of IL6 mRNA was significantly higher in 
adipose tissue than in all other tissues (Mann Whitney U: (two-tailed) p< 0.001; 
independent t-Test: (two-tailed) p≤ 0.001) (see Figure 3-31). Expression in vein and 
leukocytes was also significantly higher than in muscle tissue (Mann Whitney U: 
(two-tailed) p< 0.001; independent t-Test: (two-tailed) p≤ 0.001). There was no 
significant difference between vein tissue and leukocytes (Mann Whitney U: (two-
tailed) p=0.55; independent t-Test: (two-tailed) p=0.93). (For statistically analysis 
please see Table_Apx C-20 to Table_Apx C-31.) 
 
 
 
Figure  3-31:  Individual  values  for  logarithm  of  normalised  concentration  ratio  of  IL6  RNA 
expression in different tissues. There are 21 samples represented in each tissue type. IL6 expression 
data were logarithmically transformed for this graphic representation to allow better visualisation of 
individual values. 
    150 
These findings were the result of comparing the mean IL6 RNA expression between 
tissues in a small sample number.  Such a comparison is susceptible to skew from 
outlying values in some patients in one or more tissue types. An intra-individual 
comparison between tissue types is less likely to be skewed by outlying values (see 
Figure 3-32). The relative expression in different tissues in one individual was 
therefore examined using the Wilcox signed rank test. Figure 3-2 shows that in all 
individuals adipose tissue has the highest IL6 RNA expression of all four tissue types. 
Fat expression was on average 55.5 [median=25.2]; 47.5 [median=22.8] and 
2178.3 [median=542.7] times higher than IL6 expression in leukocytes, vein and 
muscle respectively in individuals. Leukocytes and vein expressed 304.6 
[median=19.9] and 136.5 [median=27.8] times more IL6 mRNA than muscle in 
individuals. 
The difference in IL6 mRNA expression was statistically significant in fat when 
compared to all other tissues examined in that subject. (Wilcox signed rank test 
p<0.001). Vein and leukocytes also expressed significantly more IL6 mRNA than 
muscle (Wilcox signed rank test p<0.001). There was no significant difference 
between the expression in vein and leukocytes (Wilcox signed rank test p=0.72) 
Table_Apx C-32.  
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Figure 3-32: Logarithm of normalised concentration ratio of IL6 mRNA for individual patients in all 
four tissue types. Data were logarithmically transformed for this graphic representation to allow 
better visualisation.  
 
3.9.4.1 Correlation between BMI and relative IL6 RNA Expression in 
Adipose Tissue 
There was no significant correlation between patients BMI and IL6 mRNA expression 
(p=0.12) in adipose tissue (see Figure 3-33). 
 
 
 
 
 
 
 
Patient 
identification 
number (TIG)   152 
 
 
Figure 3-33: This graph shows the correlation between measured relative IL6 mRNA expression in 
adipose tissue (normalised concentration ratio) and BMI of the patient. No significant correlation is 
shown. 
 
 
 
Correlation of relative IL6 RNA expression in adipose 
tissue and body mass index (BMI)   153 
3.10 Relative Expression of IL6 in Different Tissues with Regards to 
SNP G-174C Genotype 
 
3.10.1  Results for Adipose Tissue 
Of the 42 samples examined 10 gave an invalid result, i.e. 32 samples were 
analysed. The genotype distribution of the 32 samples is given in Table 3.10-1. 
   
Table 3.10-1: genotype distribution in the adipose tissue samples 
Adipose tissue: 
Genotype  Frequency  Percent 
C/C  6  18.8 
G/C  11  34.4 
G/G  15  46.9 
Total  32  100.0 
 
The mean expression of IL6 mRNA was highest in the CC genotype group and lowest 
in the GG group (see Table 3.10-2). The mean normalised relative IL6 mRNA 
concentration ratio was 173.71 (SEM±109.92) for the CC genotype, 43.39 
(SEM±18.37) for the GC genotype and 28.40 (SEM±35.44) for the GG group. Large 
inter-individual variation was seen in the expression of IL6 mRNA, relative 
expression ranging between 3.91 and 671.00 for the CC genotype, zero to 174.00 
for the GC genotype and 1.12 to 108.00 for the GG genotype (see Figure 3-34). 
The CC group expressed on average 4.0 times as much IL6 mRNA as the GC 
genotype and 6.1 times as much as the GG genotype (see Table 3.10-2).  
 
Table 3.10-2: IL6 mRNA normalised concentration ratio in different genotypes in adipose tissue. 
 
6  173.7117  269.24805  109.92006  -108.8468  456.2702  3.91  671.00 
11  43.3864  60.95622  18.37899  2.4354  84.3373  .00  174.00 
15  28.3993  35.43978  9.15051  8.7734  48.0252  1.12  108.00 
32  60.7972  128.61417  22.73599  14.4268  107.1675  .00  671.00 
CC 
GC 
GG 
Total 
N  Mean  Std. Deviation  Std. Error  Lower Bound  Upper Bound 
95% Confidence Interval for 
Mean 
Minimum  Maximum 
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The normalised concentration ratio was non-normally distributed (Kolmogorov 
Smirnov Z=1.81, asympt. sign. Two tailed 0.003), therefore non-parametric tests 
were employed to assess differences in expression. 
 
 
 
Figure  3-34:  The  graph  shows  the  distribution  of  normalised  concentration  ratio  of  IL6  RNA 
expression  for  the  three  different  genotypes  in  adipose  tissue.  The  individual  coloured  circles 
represent one individual with the patient identification number given in the legend. 
 
The Kruskal Wallis test showed that the differences in IL6 expression between 
genotype groups in adipose tissue were not significant (p=0.375) (Table_Apx C-3). 
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3.10.2  Results for Leukocytes 
Of the 34 samples included in the study all gave valid results following RT-PCR. See 
Table 3.10-3 for genotype distribution. 
   
 
Table 3.10-3: Genotype distribution in Leukocytes. 
Leukocytes: 
Genotype  Frequency  Percent 
C/C  5  14.7 
G/C  14  41.2 
G/G  15  44.1 
Total  34  100.0 
 
The normalised relative IL6 mRNA expression ratio was 2.38 (SEM±0.95) for the CC 
genotype, 1.29 (SEM±0.58) for the GC genotype and 0.77 (SEM±0.12) for the GG 
genotype. The range of the IL6 mRNA expression ratio was 0.83 to 6.11 for the CC 
group, 0.35 to 8.78 for the GC group and 0.24 to 1.81 for the GG group (Table 
3.10-4).  
 
Table 3.10-4: IL6 mRNA normalised concentration ratio in different genotypes in leukocytes. 
   
 
Normalised concentration ratio was non-normally distributed (Kolmogorov Smirnov 
Z=1.80, asympt. sign. Two tailed 0.003), and non-parametric tests were employed 
to assess differences in expression. 
5  2.3800  2.12321  .94953  -.2563  5.0163  .83  6.11 
14  1.2936  2.17053  .58010  .0403  2.5468  .35  8.78 
15  .7653  .48077  .12413  .4991  1.0316  .24  1.81 
34  1.2203  1.67349  .28700  .6364  1.8042  .24  8.78 
CC 
GC 
GG 
Total 
N  Mean  Std. Deviation  Std. Error  Lower Bound  Upper Bound 
95% Confidence Interval for 
Mean 
Minimum  Maximum 
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Figure  3-35:  Distribution  of  normalised  concentration  ratio  for  the  three  different  genotypes  in 
leukocytes. The individually coloured circle represent one individual of a certain genotype and the 
patient identification number is given in the legend. 
 
Again mean expression was highest in the CC genotype group and lowest in the GG 
group (Figure 3-35). The CC genotype expressed 1.8 times more than the GC 
genotype and 3.1 times more than the GG genotype. The GC genotype group 
expressed on average 1.7 times more IL6 mRNA than the GG group. The difference 
between genotype groups was statistically significant (p=0.028) (see Table_Apx 
C-4).    157 
3.10.3  Results for Vein Tissue 
42 samples underwent RT PCR. Four of these had invalid results, leaving 38 samples 
to be included in the analysis. The genotype distribution in this group is listed in 
Table 3.10-5. 
 
Table 3.10-5: Genotype distribution in vein samples. 
Vein Tissue: 
Genotype  Frequency  Percent 
C/C  7  18.4 
G/C  16  42.1 
G/G  15  39.5 
Total  38  100.0 
 
 
The mean normalised relative IL6 mRNA expression ratio was 4.06 (SEM±2.04) for 
the CC genotype, 0.65 (SEM±0.27) for the GC genotype and 1.53 (SEM±0.54) for 
the GG genotype. The range of relative IL6 mRNA expression ratio was 0.24 to 
15.52 for the CC genotype, zero to 4.54 for the GC genotype and zero to 7.56 for 
the GG genotype (Table 3.10-6). 
 
Table 3.10-6: IL6 normalised concentration ratio in different genotypes in vein samples. 
 
 
The IL6 expression ratio was non-normally distributed (Kolmogorov Smirnov 
Z=1.93, asympt. sign. Two tailed 0.001). Non-parametric tests were therefore used 
to test for significant difference. 
 
 
7  4.0614  5.39343  2.03852  -.9267  9.0495  .24  15.52 
16  .6463  1.07651  .26913  .0726  1.2199  .00  4.54 
15  1.5300  2.08484  .53830  .3755  2.6845  .00  7.56 
38  1.6242  2.89354  .46939  .6731  2.5753  .00  15.52 
CC 
GC 
GG 
Total 
N  Mean  Std. Deviation  Std. Error  Lower Bound  Upper Bound 
95% Confidence Interval for 
Mean 
Minimum  Maximum 
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Figure 3-36: Distribution of IL6 normalised concentration ratio in vein tissue in different genotypes. 
The  individual  coloured  circle  represent  one  individual  of  a  certain  genotype  with  the  patient 
identification number given in the legend. 
 
Relative IL6 RNA expression was highest in the CC genotype group. The expression 
in the CC genotype was 6.3 times higher than in the GC genotype. Expression in the 
CC group was also 2.7 times higher than in the GG genotype. The GG genotype 
expressed 2.4 times more IL6 than the GC genotype (Figure 3-36). Differences in 
expression were borderline significant (p= 0.041) Table_Apx C-5. 
 
3.10.4  Results for Muscle Tissue 
   
40 muscle RNA cDNA samples were used as template in RT-PCR. Of these three did 
not have genotype information. Three returned an invalid result i.e. six muscle   159 
samples could not be included in the analysis. 34 samples were included in the final 
analysis. The genotype distribution of the 34 samples is shown in Table 3.10-7. 
 
Table 3.10-7: Genotype distribution for muscle tissue 
 
Muscle Tissue: 
Genotype  Frequency  Percent 
C/C  6  17.6 
G/C  14  41.2 
G/G  14  41.2 
Total  34  100.0 
 
The mean normalised relative IL6 mRNA expression ratio was 0.16 (SEM±0.11) for 
the CC genotype, 0.038 (SEM±0.01) for the GC genotype and 0.03 (SEM±0.01) for 
the CC genotype. The range was 0.01 to 0.72 for the CC group, 0.01 to 0.16 for the 
GC group and zero to 0.72 for the GG group (Table 3.10-8). The data was non-
normally distributed (Kolmogorov Smirnov Z=2.33, asympt. sign. Two tailed 
<0.001).  
 
 
6  .1550  .27776  .11339  -.1365  .4465  .01  .72 
14  .0375  .03856  .01030  .0152  .0598  .01  .16 
14  .0296  .02390  .00639  .0158  .0434  .00  .09 
34  .0550  .12133  .02081  .0127  .0973  .00  .72 
CC 
GC 
GG 
Total 
N  Mean  Std. Deviation  Std. Error  Lower Bound  Upper Bound 
95% Confidence Interval for 
Mean 
Minimum  Maximum 
 
Table 3.10-8: IL6 normalised concentration ratio in different genotypes in muscle.   160 
 
Figure  3-37:  Distribution  of  IL6  normalised  concentration  ratio  in  muscle  tissue  in  different 
genotypes. The individual coloured circles represent one individual of a certain genotype and the 
patient identification number is given in the legend.  
 
Similar to the findings in the other tissues, the CC genotype expressed on average 
4.1 times more IL6 than the GC genotype and 5.2 times more than the GG 
genotype. The lowest expresser overall was the GG genotype (Figure 3-37). None of 
these differences were statistically significant (p=0.28) (Table_Apx C-6). 
 
3.10.5  Age Dependence  
 
The distribution of age between genotype groups was tested as not all patients had 
donated all four tissues and therefore differences in age distribution between 
genotype groups could have affected the result (Table 3.10-9). There was no   161 
significant difference in age distribution between the genotype groups for any of the 
tissues. For statistical analysis please see Table_Apx C-7, Table_Apx C-8, Table_Apx 
C-9, Table_Apx C-10). 
 
Table 3.10-9: Mean age in different genotype groups in different tissues 
  CC genotype 
Mean age (range) 
n=numbers 
GC genotype 
Mean age (range)  
n=numbers 
GG genotype 
Mean age (range) 
n=numbers 
Fat tissue  49.5 (30-65) 
n=6 
43.6 (23-66) 
n=11 
45.9 (25-66) 
n=15 
Leukocytes  50.0 (30-61) 
n=5 
46.7 (23-69) 
n=14 
45.7 (27-66) 
n=15 
Vein tissue  50.9 (30-65) 
n=7 
46.1 (23-69) 
n=16 
47.1 (27-66) 
n=15 
Muscle tissue  48.5 (30-61) 
n=6 
48.2 (24-69) 
n=14 
44.6 (25-66) 
n=14 
 
 
The Spearman correlation coefficient was used to test for a significant linear 
relationship between age and IL6 mRNA expression, as the data was not normally 
distributed. No significant linear correlation was seen between age and IL6 
expression in leukocytes and in muscle (Spearman correlation coefficient=-0.17 and 
0.30 and  p-value 0.35 and 0.08 respectively) (see Figure 3-39 and Figure 3-41). 
Fat and vein showed significant linear correlation (see Figure 3-38 and Figure 3-40). 
For fat there was a moderate linear correlation between age and IL6 mRNA 
expression (Spearman correlation coefficient=0.45, p-value=0.010). For vein a 
moderate linear relationship was also demonstrates (Spearman correlation 
coefficient =0.42, p-value =0.008) (for statistical analysis see Table_Apx C-11, 
Table_Apx C-12, Table_Apx C-13, Table_Apx C-14). 
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Figure  3-38:  Linear  regression  for  age/IL6  expression  in  adipose  tissue.    The  coloured  circles 
represent individual patients and the patient identification number is given in the legend. The ‘fit 
line’ shows the linear relationship between age and IL6 mRNA expression ratio.  The graph shows a 
moderate linear relationship which is significant. 
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Figure 3-39: Linear regression for age/IL6 expression in leukocytes. The coloured circles represent 
individual patients and the patient identification number is given in the legend. The ‘fit line’ shows 
the relationship between age and IL6 mRNA expression ratio.  The graph shows no significant linear 
relationship between age and IL6 mRNA expression ratio in leukocytes. 
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Figure 3-40: Linear regression for age/IL6 expression in vein tissue. The coloured circles represent 
individual patients and the patient identification number is given in the legend. The ‘fit line’ shows 
the linear relationship between age and IL6 mRNA expression ratio.  The graph shows a moderate 
linear relationship which is significant. 
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Figure  3-41:  Linear  regression  for  age/IL6  expression  in  muscle  tissue.  The  coloured  circles 
represent individual patients and the patient identification number is given in the legend. The ‘fit 
line’ shows the relationship between age and IL6 mRNA expression ratio.  The graph shows no 
significant linear relationship between age and IL6 mRNA expression ratio in muscle tissue. 
 
3.10.6  Association with Smoking Status  
There was a difference in the distribution of smokers and non-smokers between the 
genotype groups (see Table 3.10-10). This was of borderline statistical significance 
(p-value=0.05) (for statistical analysis see Table_Apx C-15). In all tissues smokers 
expressed more IL6 than non-smokers; however the result did not reach statistical 
significance in any of the tissues (see Table 3.10-11). 
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Table 3.10-10: Number of smokers and non smokers in each genotype group. 
 
 
Table 3.10-11: Median expression ratio in different tissues. 
Tissue type  Median IL6 
expression ratio in 
non smokers 
Median IL6 expression 
ratio in smokers 
Mann Whitney U test 
P value (asympt. two 
tailed) 
Adipose tissue  12.5    n=22  33.4    n=7  0.067 
Leukocytes   0.64   n=25   0.82   n=7  0.210 
Vein   0.42   n=26   0.82   n=9  0.059 
Muscle   0.03   n=24   0.05   n=8  0.079 
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3.11 Allelic Transcription Assay for Adipose Tissue Samples  
The previously designed allelic transcription assay showed good reproducibility for 
genomic DNA but proved unreliable when vein or leukocyte hnRNA was measured 
(see section 3.8). It was felt that the most likely cause was low copy numbers in the 
primary template.  Adipose tissue had been shown to expresses 40 times as much 
IL6 mRNA as leukocytes; therefore it was thought that using adipose tissue hnRNA 
as a template in the allelic transcription assay may lead to improved accuracy of the 
assay. Thus the allelic transcription assay was performed using adipose tissue RNA 
as a template  
 
3.11.1  gDNA Contamination 
cDNA samples were checked for gDNA contamination. Despite rigorous DNA 
treatment, 11 adipose tissue samples out of 17, showed gDNA contamination (see 
Figure 3-42). In the majority of cases contamination was only shown in one out of 
three PCRs suggesting low levels of contamination, however in two cases 
contamination was seen in all three PCRs. In particular sample number 44 showed 
strong bands in all three PCRs suggesting significant gDNA contamination. 
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Figure  3-42:  Results  for  LDLR  promoter  assay  for  adipose  tissue  samples  (numbered  samples): 
Acrylamide  Gel  5%  stained  with  vistra  green:  NTC=negative  template  control;  PTC=positive 
template control (template=gDNA). Bands indicating gDNA contamination are seen in samples 2, 3, 
8, 9, 12, 13, 17, 22, 28, 43, 44 and 46 (red arrows). 
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When cDNA Ex4 was used in a PCR for amplification of intron 3 and adjacent intron 
exon boundaries, the following results were seen:  
 
Figure 3-43: This gel shows the result of the PCR amplifying IL6 intron 3 region and adjacent 
intron/exon boundaries. Samples 2, 11, 13, 17, 20, 41, 43 and 46 failed to amplify. Samples 3, 8, 9, 12, 
22, 26, 28 and 37 show a short (green arrows) and a long (red arrows) product indicating presence of  
cDNA (green arrows) and hnRNA/gDNA (red arrows), sample 44 only shows a long product i.e. 
there gDNA contamination but no cDNA and therefore no hnRNA. 
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Figure 3-43 shows the result of the PCR amplifying IL6 intron 3 region and adjacent 
intron/exon boundaries. Eight samples failed to amplify. Eight samples showed a 
short and a long product indicating presence of cDNA and hnRNA/gDNA, sample 44  
showed a long product only i.e. there is gDNA contamination but no cDNA and 
therefore most probably no hnRNA. Sample 44 was therefore excluded form the final 
analysis. 
 
3.11.2  Genotyping for Intron SNP G3572T 
Sample number (TIG) 12 showed amplification from the C-allele only in repeat runs 
of the adipose tissue allelic transcription assay. The lack of variability in the results 
appeared different form the rest of the samples. This raised the possibility the 
Subject 12 was a rare haplotype SNP G-174C/SNP G3572T: GC/TT. Genotyping for 
SNP G3572T was therefore performed on study gDNA samples. Results are shown in 
Figure 3-44.  
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Figure 3-44: Genotyping for intron SNP G3572T in heterozygotes for promoter SNP G-174C using 
restriction digest: Acrylamide Gel 5% stained with ethidium bromide. NTC=negative control; TT or 
GG=positive gDNA control homozygous for SNP G3572T; GT=positive gDNA control heterozygous 
for SNP G3572T. Samples are numbered with patient identification number. Majority of samples 
are heterozygous with both uncut and cut band visible (blue arrows). Exception is sample No. 12 
which only shows the cut band (red arrows) identical to the pattern seen in the known homozygous 
TT gDNA control (pink arrow) 
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All samples, except one, were heterozygous with both uncut and cut band visible 
(blue arrows) Figure 3-44. The exception was sample number (TIG) 12 which only 
showed the cut band (red arrows) identical to the pattern seen in the known 
homozygous TT gDNA control (pink arrow). Sample number 12 was therefore 
concluded to be rare haplotype GC/TT. This explained the apparent consistent 
amplification from only the C-allele in the allelic transcription assay. Sample number 
12 was therefore excluded from the analysis.  
 
3.11.3  Results of Allelic Transcription Assay in adipose tissue 
In repeat experiments template cDNA In4 showed better reproducibility of results 
(mean variance for individual samples = 0.007) than cDNA Ex4 (mean variance for 
individual samples = 0.1). The final experiment was therefore performed using cDNA 
In4 as a template. The results for the allelic transcription assay for adipose tissues 
are displayed in Figure 3-45. Samples with at least one duplicate measurement were 
included in the analysis. The acrylamide gel shows nested PCR/restriction digest 
products for tissue samples as well as negative template control, heterozygous gDNA 
samples and standard curve samples.   173 
 
Figure 3-45: Acrylamide gel 5% stained with ethidium bromide: Result of the allelic transcription 
assay  for  adipose  tissue.  NTC=negative  template  control,  C26,  C28,  C33  =  heterozygous  gDNA 
samples, 0-1.0 = standards, samples labelled: 2,3,8,9,11,12,13,17,20,22,26,28,37,41,43,44,46 = patient 
samples (TIG number). 
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Following fluorescence intensity measurement, values for the standard curve 
samples were plotted on a graph and a linear trend line was fitted using Excel 
software. The average values of band fluorescence intensity for the two genomic 
DNA samples were then plotted on the graph using the calculated trend line 
equation. The mean calculated allelic ratio for the gDNA samples was 0.56. The 
mean values of all measurements for the adipose tissue samples were also plotted 
(see Figure 3-46:). (Data see Table_Apx C-45) 
 
Figure 3-46: Graph showing results for the allelic transcription assay for adipose tissue, using cDNA 
In4: The standard curve and mean result for two heterozygous gDNA samples, as well as values for 
adipose  tissue    samples  are  shown.  Note  the  proximity  of  sample  44  (known  to  have  gDNA 
contamination present but no cDNA) to the value for gDNA. 
 
In line with previous results in this thesis the C-allele appeared to express more IL6 
hnRNA than the G-allele.  The mean allelic transcription ratio for all the adipose 
tissue samples was 0.76 (SEM+0.08) indicating that on average 76% of IL6 hnRNA 
was transcribed form the C-allele. Statistically this was not significantly different 
from the calculated allelic ratio for the genomic DNA samples 0.56 (Mann Whitney 
test p=0.38) (for statistical analysis see Table_Apx C-19) 
 
As in the previous allelic transcription assay for vein there was wide inter-individual 
variation in the allelic transcription ratio.  
Allelic Transcription of IL6 in Adipose Tissue 
 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
0  0.2  0.4  0.6  0.8  1  1.2 
allelelic transcription ratio 
m
e
a
s
u
r
e
d
 
b
a
n
d
 
i
n
t
e
n
s
i
t
y
 
r
a
t
i
o
 
 
 
 
 
 
 
standard curve 
3 
8 
9 
13 
22 
26 
28 
44 
Mean of heterozyg.  
 gDNA 
Linear 
(standard 
curve)   175 
To assess the reproducibility of the measurements for the individual samples, the 
mean of the 3 PCRs was plotted and the 95% confidence intervals were calculated 
(see Figure 3-47). 
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Figure 3-47: Graph showing the allelic transcription ratio for individual samples and results for two 
heterozygous gDNA samples. The error bars indicate the 95% confidence interval.  Compared to the 
previous allelic transcription assay for vein and leukocytes the 95% CI are narrower indicating 
improved reproducibility of the results. 
 
Confidence intervals were narrow compared to previous allelic transcription assays in 
vein and leukocytes suggesting improvement in the reproducibility of the results. 
Mean variance of the allelic transcription ratio for the individual adipose tissue 
samples was 0.008 compared to a variance of 0.05 and 0.06 for vein and leukocyte 
respective. 
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4  Discussion 
4.1  Patient Recruitment  
Participation in the study required patients to donate tissue in addition to samples 
routinely removed during varicose vein surgery. This represented an invasive 
procedure. Despite this, the majority a patients agreed to take part in the study, 
with an uptake of 88%. The fact that samples were collected during anaesthesia and 
no extra hospital attendances were required could have contributed to the high 
uptake. Of the 95 patients who agreed to take part in the study, 25 did not donate 
tissue samples. This was due to the difficulty encountered in sample collection in 
remote hospitals, frequent cancellation of operations and the generic booking system 
in which patients were not assigned to a named consultant. This resulted in recruited 
patients being operated on by consultants not taking part in the study or on an 
operating list which could not be attended by the researcher collecting samples. 
These difficulties contributed to fewer patients donating tissue samples than 
anticipated in the conception of this study. However, sample numbers achieved, 
were sufficient to attempt allelic assay design/validation and study expression in 
different tissues.  
The patient follow-up was designed as a safety control to ensure there was no 
increase in bleeding complications from the additional muscle biopsy and to assess 
the level of patient satisfaction with the study process. No detailed conclusions can 
be drawn from the follow-up, as no control group was questioned. However, there 
were no bleeding complications reported in the follow up. Two patients developed 
groin infections. This rate is higher than some rates reported in the literature, but 
the infection rate following ‘clean surgery’ is often grossly underestimated 
(277;278). In studies with a surveillance period of greater than 30 days, suitable 
definitions and wound infection scores such as the ASEPSIS scoring system 
(279;280), the reported infection rate is 15% or more (278). Thus the infection rate 
of 10.5% in this study appears to be within normal limits and it seems that muscle 
biopsy was safe in this unit. The average return to normal daily activity was 1-2 
weeks. This compares favourably with a study showing a median time period of  
return to work following varicose vein surgery at 2 weeks for self employed subjects 
and 4 weeks for employees (281). Pain scores recorded on the first and second post-
operative day are lower than scores previously reported (282). The additional   177 
procedures necessary to perform this study did not therefore appear to have had 
adverse effects on the patients. 
The method of recruitment both in the pre-assessment and by letter+/-telephone 
call was entirely acceptable to patients and all patients were satisfied with the study 
process. However, the results on patient satisfaction and acceptability of the 
recruitment process may have been biased by the lack of anonymity, as these were 
assessed by telephone interview. Lack of anonymity has previously been shown to 
skew results from questionnaires regarding patient satisfaction (283). 
 
The original aim was to recruit healthy individuals, free from significant 
cardiovascular disease and un-medicated to the study. As recruitment occurred in 
the Day Surgery Unit, patients with significant cardiovascular disease were 
automatically excluded from the study. It soon became apparent that restricting the 
subjects to un-medicated patients would be impractical, as it would significantly 
reduce the number able to join the study. Thus patients of ASA grade I and II 
(I=normal healthy individual, II=mild systemic disease that does not limit activity) 
were included even if medicated. Patients currently taking steroids or suffering from 
acute inflammation/infection or untreated carcinoma were excluded from the 
analysis. Of the 69 recruited patients 32 were un-medicated. The most common 
medications taken by participants were antihypertensive therapy and hormone 
therapy. Previous studies have shown that treating heart failure patients with beta 
blockers lowers IL6 levels (284). Calcium channel blockers also appear to exercise 
an effect on IL6 expression, however both positive and negative effects have been 
reported in the literature (285-287). The effects of angiotensin-converting enzyme 
inhibitors and angiotensin II receptor antagonists are likely to be one of IL6 
suppression, more specifically the effect of these agents may depend on G-174C 
genotype (288). 
Hormone treatment may also decrease IL6 levels as estradiol inhibits IL6 expression. 
It is thought that lack of 17 beta-oestradiol following the menopause is partly 
responsible for the increase in circulating IL6 and it has been shown that HRT can 
decrease IL6 expression (289). Antidepressants have been found to suppress pro-
inflammatory cytokine production (290). Though interest has mainly focused on INF-
gamma/IL10 ratio as well as IL2, TNFα and IL1β, it is likely that antidepressant 
agents also affect IL6 as both IL1 β and TNFα up regulate expression of IL6.    
Diuretics such as frusemide have been found to inhibit the production and release of 
IL6 from peripheral mononuclear cells and there is a suggestion that thiazide   178 
diuretics may decrease circulating IL6 levels (291;292). Aspirin is thought to 
decrease IL6 expression through NF-kappa B antagonism and cyclo-oxygenase 
inhibition (293).  
Therefore it seems likely that participant’s medication may have affected IL6 RNA 
expression in individuals, but its precise effect is difficult to define. The effect of 
medication appears to be largely one of IL6 suppression; however this effect may be 
counterbalanced by the IL6 induction resulting from the treated condition, e.g. 
hypertension. This study was designed to eliminate the influence of confounding 
variables, such as medication, on the result, by performing intra-individual 
comparisons in the allelic transcription assay and by investigating different tissues in 
the same individual. Thus the results of the intra-individual comparisons should be 
largely unaffected by participant’s medication. 
 
4.2  RNA Extraction 
RNA extraction from fibrous tissue (skeletal muscle and vein tissue) and lipid rich 
tissue such as peripheral adipose tissue, required optimisation of the technique. RNA 
extraction was a laborious process, preventing a high throughput of samples. The 
quality of the RNA extracted for our study appeared satisfactory for the control 
samples tested with minimal or no degradation. Quality was not assessed for the 
study samples as there was only a limited amount of RNA available. However as 
handling and storage for the study samples was the same as for the control samples, 
equal quality was assumed for the study samples as for the control samples.  
For vein and muscle A260:A280 ratios were below the ideal target of 1.9 and 2.1 
indicating that some protein contamination was present in the samples. The purity of 
adipose RNA remained particularly low with mean A260:A280 ratios of 1.3. 
A260:A280 ratios were above 1.9 for leukocytes. Protein contamination can affect 
downstream enzymatic reactions e.g. may interfere with cDNA synthesis (276). This 
may in part account for the lack of amplification in RT PCR analysis of 9% of vein, 
8% of muscle and 23% of adipose tissue samples. In comparison, all leukocyte 
samples amplified in the real time PCR assay.  
 
 
4.3  Genotyping 
The CC genotype was rarer than all other genotypes in the study population. The 
reported allele frequency varies widely in different ethnic groups. Even within   179 
European populations the reported allele frequency varies considerably, so there is 
no consensus as to which allele is the more common. However the finding of this 
study that the C-allele is the less common allele has been replicated in other studies 
conducted in European populations (240). The fact that genotypes were in Hardy-
Weinberg equilibrium also validates the genotyping in this study. 
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4.4  Preferential Allelic Transcription Assay Design 
4.4.1  Experimental design 
4.4.1.1 Amplification of Heteronuclear RNA 
 
The lack of suitable markers for the promoter SNP G-174C in exon regions of the 
gene led to a variety of difficulties. The design of the new allelic IL6 transcription 
assay relied on the amplification of RNA intron transcripts containing markers in LD 
with SNP G-174C. These were only present in hnRNA. A previous experiment in 
murine cell culture showed that IL6 hnRNA levels correlate well with IL6 mRNA levels 
suggesting that hnRNA can be used to assess gene expression (294;295) and 
therefore hnRNA was used as a template in this study. Beside the practical need to 
use hnRNA as a template there is an advantage in measuring primary transcript. The 
promoter SNP G-174C most likely regulates primary transcription and thus level of 
the primary transcription product (hnRNA). Therefore measuring hnRNA rather than 
mRNA may reflect the effect of a promoter SNP more accurately than conventional 
mRNA assays.  
 However, one disadvantages of using hnRNA as a template rather than mRNA lies in 
the inability to differentiate between hnRNA and gDNA contamination. The usual way 
of differentiating between cDNA and genomic DNA in quantification assays is for one 
of the primers or the amplicon itself to span an intron exon boundary. As both 
hnRNA and genomic DNA have the same sequence this method could not be used. It 
was therefore important to ensure minimum contamination with genomic DNA and to 
find a different way of checking for genomic DNA contaminations in the study 
samples. Promoter regions are not transcribed into RNA and can therefore be used 
to assess gDNA contamination. Amplification of the promoter region of an unrelated 
gene (LDLR) was used. This method was able to provide information about the 
presence of gDNA contamination in the study samples. However, it did not eliminate 
the effect of gDNA contamination on the study results. 
IL6 expression is low in un-stimulated tissues and some authors claim that IL6 is not 
constitutively expressed (24). This study demonstrated that IL6 expression does 
occur in un-stimulated ex vivo tissues (short product in amplification of region 
spanning intron 3). However it showed that IL6 RNA is not abundant in un-
stimulated tissue, as shown by the high Cp values in the RT PCR experiments (see 
section 4.5 & 4.6). Because hnRNA make up only a fraction of total IL6 RNA, the 
study was relying on amplification of a fraction of an already low abundance   181 
template. It therefore had to be demonstrated, that intron regions of hnRNA could 
be amplified and visualised on a gel. Therefore amplification of intron region 2 and 
intron region 3 was attempted. Only intron region 3 could be amplified. This could be 
explained by a difference in efficiency between the assays for intron 2 and 3. High 
reaction efficiency may be required when dealing with very low template numbers. 
Another possible reason for the lack of intron 2 amplification is a more efficient 
splice process affecting intron 2. Intron 2 may be removed earlier in the splicing 
process than intron 3 leading to a less abundant template.  A further possible 
explanation for the successful amplification of intron 3 but not intron 2 would be the 
presence of alternative splice products in which intron retention had occurred. No 
alternative splice product retaining intron 3 has been described to date. However, 
intron retention in general has been less well studied than other forms of alternative 
splicing. This is due to the difficulty that arises from differentiating between true 
alternative splice forms and un-spliced or partially spliced pre-mRNAs (29). It is 
therefore possible such an alternative splice product could be found in the future, 
however at present no such evidence exists.  
 
Amplification of intron 3 from hnRNA seemed possible and further experiments were 
therefore focused on intron region 3 rather than intron region 2. During the splice 
process the intron is released as a free lariat and degraded in the nucleus. However 
it is unclear how long intron fragments exist before degradation. Therefore a splice 
fragment which had not yet been degraded was a further possible template for 
intron 3 amplification. To investigate this, attempts were made to amplify 
exon3/intron3 boundary from cDNA. This was unsuccessful. Failure to amplify 
exon/intron 3 boundary may have been due to inefficiency of the reaction. However 
an alternative explanation would be that the previously demonstrated amplicon of 
intron region 3 was the product of a free floating fragment of spliced intron 3 and 
not hnRNA. Therefore the assay design had to be changed to ensure amplification 
would occur from intact hnRNA only. This was achieved by basing the assay on 
amplification of a region spanning intron 3 and the adjacent intron/exon boundaries. 
This experimental set up raised further problems as it used specific primer annealing 
in exon 4 for reverse transcription. Therefore, there was no preferential reverse 
transcription of hnRNA and the majority of cDNA arose from mRNA (as indicated by 
the relatively stronger band in Figure 3-9), resulting in minimal amplification of the 
long product arising from hnRNA, with a correspondingly weak band on the gel (see 
Figure 3-9). The planned gel based analysis of allelic transcription involved   182 
measurement of fluorescence intensity of this band. The signal from this band would 
have been too weak to perform reliable measurements therefore a nested PCR was 
designed. The nested PCR demonstrated adequate PCR product from intron 3 
amplification, to perform analysis of preferential allelic transcription. This was the 
first time the feasibility of a gel based allelic transcription assay for IL6 using hnRNA 
as a template had been demonstrated.  
4.4.1.2 Standard Curve  
In order for the experiment to proceed a standard curve had to be designed and 
validated. There was a strong linear relationship between the known concentration 
ratios and the measured band intensity ratio for the standard gDNA samples. 
Variance of the measured band intensity ratios for the individual standard 
concentrations was close to zero. Standard curves produced by three separate 
experiments were very similar, showing good reproducibility of the results.  
When band fluorescence intensity ratios for heterozygote gDNA samples were 
plotted on the standard curve the estimated concentration ratio was marginally 
higher than expected at 0.51 (expected ratio: 0.50 or q
2=0.25). This may be due to 
inaccuracy in the preparation of the standards. This should not have affected the 
results as heterozygous gDNA samples were included in each experimental run. 
Point of equal expression from both alleles could therefore be accurately determined.  
It was concluded that the standards prepared and the assay design gave a reliable, 
linear standard curve, which could be used in the ratiometric measurement of allelic 
transcription. 
 
4.4.2  Allelic Transcription Assay for Vein Samples  
Genomic DNA contamination was still visibly present in four vein samples following 
rigorous DNase treatment. This is not surprising as the nucleic acid content of RNA 
samples from tissues may  vary widely, ranging from nearly pure RNA to containing 
mostly DNA (296). Genomic DNA contamination is most likely the result of 
insufficient homogenisation during RNA extraction. Collagen rich tissues, such as 
vein are difficult to homogenise fully and often give rise to low yield and poor quality 
RNA (297).  
The LDLR promoter assay which was used to check for gDNA contamination provided 
a rough guide only as to the degree of contamination. Because different assays were 
used to amplify the LDLR promoter region and IL6 hnRNA, no direct comparison 
could be made as to the ratio of gDNA and hnRNA in the samples. It is therefore   183 
unclear to what degree gDNA contamination affected the results for the preferential 
allelic transcription assay. One can assume that gDNA contamination skewed the 
results for hnRNA towards the ratio found for gDNA samples in the experiment. Thus 
any effect of promoter SNP G-174C on preferential transcription would be 
underestimated by the assay. 
The results of the allelic transcription assay for vein samples did showed slightly 
more expression from the SNP G-174C C-allele then from the G-allele though this 
was not significant. The mean results for individuals were widely spread on the 
standard curve. Potentially this was the result of true inter-individual variation in 
allelic expression or alternatively the result of poor reproducibility of the assay.  
The later may be more likely as reproducibility of the individual results in different 
PCR reactions was poor. Variance in repeat PCR of individual samples was more than 
ten times the variance seen for standard curve. It is likely that this variance 
rendered the result inaccurate. This type of assay, using gel based analysis, has 
been successfully used previously for allelic transcription analysis of the angiotensin 
II type 1 receptor gene (AGTR 1) in placenta RNA (298). However that study 
investigated a non-coding SNP in the 3’ UTR and an encoding SNP, thus was able to 
use mRNA as a template. This study however used hnRNA; therefore the initial copy 
number would have been substantially lower than in the AGTR 1 study. In an ideal 
situation every cDNA molecule present will be amplified during each cycle of the 
exponential phase of the PCR. However in reality this is rarely the case. With an 
abundant template this does not lead to significant alteration of the ratio of different 
alleles. However if the copy number is very low the lack of amplification of just one 
molecule in the early phases of PCR could significantly affect the final allele ratio due 
to the exponential nature of PCR amplification, thus leading to variation in repeat 
PCRs. It could be argued that amplification of individual molecules occurs at random, 
therefore if enough repeat measurements are taken the average should tend 
towards the correct ratio. However, tissues such as those examined in this study 
have a low RNA yield making a substantial number of repeat experiments obsolete. 
4.4.3  Allelic Transcription Assay for Leukocytes  
Unlike the RNA samples extracted form tissues, which demonstrated gDNA 
contamination in some samples, gDNA contamination was not demonstrated in the 
leukocyte RNA samples. This is likely to relate to sample type. Tissues are more 
difficult to homogenize than cell suspensions for mechanical reasons. gDNA   184 
contamination increases with reduced homogenization, therefore RNA extracted form 
tissue is more likely to contain gDNA contamination than cell suspensions (299;300).  
This experiment differed from the vein assay in as much as all RNA samples were 
taken from one individual. Therefore the results of the samples were expected to be 
similar. However, results varied widely between individual samples (between sample 
variance of 0.08).  
This could be related to poor reproducibility of the assay or variation in RNA and 
cDNA preparation. Variation in RNA or cDNA preparation is unlikely to influence 
allelic transcription ratio as both alleles were subject to the same preparation and 
should be equally affected. Therefore the most likely explanation for the spread of 
the results is poor reproducibility of the assay. Variation between the three repeat 
PCRs for individual sample was also substantial as indicated by the wide confidence 
intervals and the measured variance (> x10 the variance seen for standard curve), 
which was similar to the variance seen in vein samples. The experimental setup 
allows good reproducibility for gDNA amplification as indicated by the narrow 
confidence intervals for the two genomic DNA samples. Therefore it is likely that the 
wide spread of the results is related to a problem with the template, most likely low 
copy numbers, leading to stochastic amplification in the initial PCR. An attempt to 
increase yield of cDNA synthesised from hnRNA by using a reverse primer annealing 
in intron 4 did not improved variability. Mean variance for individual samples was 
0.04 and 0.08 for cDNA Ex4 and cDNA In4 respectively.  
If one argues that stochastic amplification in low copy number samples can be over 
come by increasing repeat measurements (see section 4.4.2), this experiment may 
provide a true reflection of the allelic transcription pattern. This experiment showed 
a not statistically significant trend towards higher expression of the C-allele 
compared to the G-allele. However it would be difficult to argue that such a result 
could be relied upon. 
 
The designed allelic assay is unlikely to be useful in assessing allelic transcription in 
tissues with low IL6 expression. It may be more successfully employed for samples 
with a higher baseline expression or in stimulated tissues or cells. It may also be 
useful in cell culture experiments with a higher RNA yield.    185 
4.5  Ex Vivo IL6 Expression in Different Tissues  
 
IL6 was expressed in adipose, vein and muscle tissue as well as leukocytes. Overall 
expression was low, as indicated by the relatively high Cp-values measured when 
compared to Cp values of the reference gene. These findings are not surprising, as it 
has previously been stated that IL6 is not constitutively expressed (24) and that 
adult vascular endothelial cells incubated without stimulus released scant IL6 activity 
(301), thus low expression values had been expected.  
 
To date, comparative data on IL6 expression has been available in the form of the 
gene expression atlas (302). The gene expression atlas has generated gene 
expression data from a set of human and mouse tissue samples using high 
throughput gene expression profiling techniques. The tissue samples and cell lines 
were analysed. The tissue samples were predominantly from a normal physiological 
state. The gene expression atlas data was based on commercially obtained tissues 
which originated from different individuals. There is large variation in IL6 expression 
in individuals, partially related to variables such as smoking, medication and age. 
Such confounding variables are likely to have affected the results of the gene 
expression atlas experiment (140;272;288). In contrast, this study uses paired 
tissue samples from one individual, taken at the same time point thereby reducing 
the effect of confounding variables, giving a more accurate insight into the effect of 
tissue type on IL6 gene expression.  In addition vein, adipose and muscle tissue, are 
not represented in the atlas, though all have been shown to express IL6. IL6 RNA 
expression in adipose tissue is of particular interest, as obesity is a known risk factor 
for arterial disease. For a long time adipose tissue was regarded as a passive organ 
designed for energy storage. However it has recently become apparent that adipose 
tissue has an important endocrine function and is able to release a variety of active 
mediators into the circulation including IL6 (159). Obesity has seen a rapid increase 
in prevalence in recent years (303) and is likely to result in a further rise in the 
occurrence of atherosclerosis (158). Therefore the above results provide important 
additional data to the gene expression atlas data. Another advantage of this study 
was the ex vivo nature of the samples, which are likely to reflect the in vivo 
expression better than cell culture experiments.  
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The presented data showed that adipose tissue expressed significantly more IL6 
mRNA than the other tissues examined, suggesting that increased adiposity might 
influence circulating IL6 levels and thus potentially vascular risk and treatment 
outcome. These data are consistent with a 23% fall in plasma IL6 levels associated 
with 33% weight loss in the very obese (304). Indeed, arterio-venous differences in 
plasma IL6 levels across an abdominal subcutaneous tissue bed suggest that up to  
30% of plasma IL6 may be derived form adipose tissue depending on BMI (305).  
Adipose tissue thus appears to be an important source of circulating IL6. Increase in 
adiposity will therefore lead to an increase in IL6 due to a volume increase in the 
production site of IL6. This study tested for a correlation between the BMI of the 
study subject and adipose IL6 mRNA expression in this subject. This may appear to 
be the wrong approach because an equal amount of total RNA was used in each 
examined sample. Differences in adipose tissue volume between individual should 
therefore not be able to influence the results. However, one may still expect to see a 
correlation, as increased adiposity may lead to a change in the cell composition of 
adipose tissue with a relative increase in those cells that are mainly responsible for 
the expression of IL6. Only 10% of IL6 derived from  adipose tissue cell culture 
arises from adipocytes (167). Other sources of IL6 in adipose tissue are stromal-
vascular cells and macrophages, with macrophages thought to be the main 
contributors (306;307). Adipose tissue macrophage infiltration is increased in obese 
subjects (308) and decreases during weight loss (309). Therefore the relative IL6 
expression in adipose tissue may increase with adiposity beyond a pure volume 
effect. This study does not support this view, as there was no significant correlation 
between BMI and IL6 expression in adipose tissue. It is possible that variables such 
as age, smoking or medication masked any effect of cell composition on adipose IL6 
expression. Further studies may provide better insight.  
It is not possible to deduce the exact percentage adipose tissue contributes to the 
circulating IL6 from relative IL6 mRNA levels measured in this study. Various steps 
exist that exert post transcriptional control, i.e. not all mRNA will be translated into 
protein, and these post-transcriptional changes may vary between tissue types. In 
addition, protein production within the cell may not translate into equivalent 
secretion of the protein, as an intracellular signalling pathway for IL6 is thought to 
exist (21). It is therefore possible that a proportion of IL6 will never leave the cell. 
In addition, some of the IL6 secreted by adipose tissue may act in a paracrine 
manner and therefore remain within the tissue rather than enter the circulation, 
though release of IL6 has been demonstrated from peripheral fat (160). Despite   187 
these reservations, it is thought that the circulating levels of IL6 are mainly 
regulated at the level of gene expression (20), making it likely that the difference in 
mRNA expression will be reflected in tissue contribution to IL6 plasma levels. 
It is known that visceral obesity constitutes a greater risk factor for atherosclerosis 
than peripheral adiposity (310). Studies looking at site of production of circulating 
IL6 suggest a greater contribution from visceral fat than from peripheral adipose 
tissue supporting the view that IL6 may be the link between obesity and arterial 
disease (167;168). This study examined subcutaneous fat samples only. It is likely 
that the relative contribution of visceral fat to systemic IL6 is even higher than the 
figures presented here, emphasising the importance of weight loss in decreasing 
circulating levels of IL6. 
Adipose tissue expressed 35 times as much IL6 mRNA as leukocytes in this study. 
However the percentage contribution of adipose tissue to plasma IL6 levels depends 
on levels of adiposity, thus its’ relative importance is decreased in lean subjects. In 
addition IL6 secreted by circulating leukocytes will immediately contribute to IL6 
plasma levels unlike adipose derived IL6 which may remain within the tissue itself. 
Thus leukocyte derived IL6 may play a more important role in plasma levels then the 
figures for mRNA expression suggest. 
In this study the mean mRNA expression in adipose tissue, leukocytes and vein 
tissue was significantly greater than the expression in muscle.  The transcription of 
IL6 in muscle as well as net release from muscle has been shown to increase 
following exercise (311;312).  Although exercise also appears to increase IL6 
expression in adipose tissue, the increase is relatively smaller than the one observed 
in muscle. One would expect exercise to lead to a relatively higher increase in 
contribution from muscle to circulating IL6 levels (313). In addition, it has been 
shown that IL6 release from muscle increases from the fasting level following a high 
fat meal. In this study patients presented to hospital following overnight rest and 
overnight fast. The relative level of IL6 expression in muscle in more active subjects 
and subjects in the postprandial phase may therefore be higher than demonstrated 
here.  
 
Another factor to consider is that in this study IL6 expression was calculated relative 
to a housekeeping gene. Relative quantification is advantageous as it avoids a 
variety of errors that can affect absolute quantification: difference in the quality and 
the amount of the starting material as well as differences in the RNA preparation and 
reverse transcription steps. These errors are avoided as the housekeeping gene is   188 
exposed to the same preparation stages as the target gene (314). However relative 
quantification carries its own drawbacks: Housekeeping genes are thought to be 
constantly expressed in all tissues relative to total mRNA examined as they are 
necessary for basis cell survival. This forms the basis of relative Quantification. 
However it has been shown that levels may vary under certain experimental 
conditions (297;314).  GAPDH, the housekeeping gene used in this experiment, is a 
key enzyme in the control of glycolysis and as such is expected to be present in all 
cells and exhibit minimal variation (314). Gene expression atlas data shows stable 
expression of GAPDH across a variety of different tissues and a number of authors 
have verified the suitability of GAPDH as a reference gene (315-317). 
To date GAPDH has been commonly used in experiments measuring IL6 expression 
(318-320). However, other authors have shown that certain experimental conditions 
and level of cell differentiation may affect expression of GAPDH (321-323). All cell 
types examined in this experiment were obtained from adult tissue and are therefore 
likely to show the same amount of differentiation. Tissue was collected from human 
volunteers without stimulation of cells or induction of hypoxia known to affect 
GAPDH (323;324). Therefore experimental conditions should not have affected 
GAPDH expression, but some variation in expression affecting the final results can 
not be excluded.  
A number of patients had considerably higher IL6 expression compared to other 
subjects in some tissues. Possible reasons include unidentified genetic variables or 
variables such age, smoking, medication or undiagnosed infection at the time of 
sample collection. The design of the study aimed to reduce the influence of such 
variables on the outcome measure of relative tissue expression by performing intra-
individual comparison. However, it can not be excluded that some variables may 
affect individual tissues differently. Investigating potential causes for higher 
expression in some patients requires an inter-individual comparison which may be 
difficult to interpret in a relatively small sample set. Such a comparison was 
therefore not performed.  
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4.6  Relative Expression of IL6 in Different Tissues with Regards to 
SNP G-174C Genotype  
In all tissues the CC group expressed more IL6 than the other genotypes, results 
consistent with the trend seen in the allelic transcription assay. The trend towards 
higher expression in the CC genotype was statistically significant in leukocytes and 
vein tissue. In leukocytes the CC genotype expressed significantly more than the GC 
and the GG genotype. Expression was highest in the CC and lowest in the GG group 
in keeping with an allele effect on expression. In vein there was a significant 
difference in expression between the genotype groups. The CC group expressed 
more than the GC genotype and the CC genotype expressed on average more than 
the GG genotype. In addition the GG group expressed more IL6 than the GC group. 
These findings cannot be explained by a simple allele effect. One possible 
explanation is the effect of haplotype. A cell culture study demonstrated that 
haplotype  G-597A, G-572C, -373AnTn, G-174C may affect gene transcription, with 
higher expression for haplotype GG9/11G  and lower expression for AG8/12G(24). It 
may therefore be that the high expressing haplotype was more prevalent in the SNP 
G-174C GG genotype group in the vein sample. This can not be verified as haplotype 
was not examined in this study. Equally, higher expression in the GG genotype 
group compared to the CC genotype could also be explained by confounding 
variables affecting the results. 
Studying haplotypes may have added value to our study but further subdivision of 
an already small sample group would have made interpretation difficult.  
 
The effect of IL6 promoter SNP G-174C may vary according to the tissue type in 
which the gene is expressed (24). In this study some tissues showed significant 
difference in IL6 mRNA expression between genotypes, while others did not. It is 
difficult to draw conclusions from this with regards to the interaction of genotype and 
tissue type.  Overall there was a trend towards higher expression in the CC genotype 
in all tissues. The fact that this was not significant in some tissues may relate to 
sample size but could equally represent tissue specific variation of expression.  
The observed trend of increase expression in the CC genotype in all tissue types, is 
contrary to the effect of promoter SNP G-174C originally observed in cell culture, 
which showed higher expression in the G-allele (238). The reason for this discrepant 
observation may be the effect of cell culture on gene expression. Cytokine gene 
transcription has been shown to be different in vitro from in vivo when comparing   190 
genotypes in other studies (182;325). In this study the samples were taken from 
human subjects and RNA extracted without intermediate cell culture or stimulation. 
The in vivo RNA profile was preserved by immediate submersion of samples in RNA 
stabilising solution and subsequent storage at -80°C. The above experiment is 
therefore likely to represent a more accurate model of the in vivo effect of the 
promoter SNP then tissue or cell culture. 
However, the results of this experiment have to be interpreted cautiously. This 
experiment was an inter-individual comparison and this, in addition to the small 
sample size, renders it susceptible to the effects of confounding variables such as 
smoking. The distribution of smokers between the genotype groups, with the highest 
percentage of smokers in the CC genotype group, was borderline significantly 
different. Smoking itself was not significantly associated with raised levels of IL6 
RNA in any of the tissues. However the mean expression was higher in smokers than 
in non-smokers in all tissues. IL6 is increased in the serum of smokers (140;148), it 
is therefore possible that smoking increased IL6 expression in the tissues examined. 
It is possible that a significant effect of smoking on IL6 mRNA expression could not 
be shown due to low sample number and therefore the borderline difference in 
distribution of smokers could have affected the results.  
Statistically there was no significant difference in the age of the subjects in each 
genotype group. Thus age should not have influenced the results. A significant 
correlation between age and IL6 expression was demonstrated for fat and vein 
tissue. In both tissues, IL6 expression increases with age. This correlates with 
previous findings showing that IL6 plasma levels are elevated after the menopause 
or andropause (326). As fat tissue may contribute significantly to circulating levels of 
IL6 the increased production in adipose tissue in older subjects may explain some of 
the age related change in plasma levels.  
 
Interpretation of the results of this experiment was difficult due to the small sample 
numbers in each genotype group entered into the study. Sample number was further 
reduced by invalid results, particularly in adipose tissue were 23.8% of the samples 
were invalid. This is most likely related to the poor quality of the fat RNA samples, 
which may have interfered with cDNA synthesis in some cases. RNA extracted from 
adipose tissue is known to be of lesser quality and be more likely to contain partially 
degraded RNA subfractions (297) which can affect down stream applications.  
Due to the laborious nature of RNA studies it would have been difficult to achieve 
larger numbers in this study.    191 
There appeared to be large inter-individual variation in IL6 RNA expression within 
genotype and within tissue type. Confounding variables may have had a far greater 
effect on gene expression than SNP G-174C, thus masking its effect. Hence the need 
for an assay which is well controlled, thus minimising effect of confounding variable, 
and does therefore not require large sample numbers. The allelic transcription assay 
previously developed appeared to be such an assay; however reliability was poor for 
leukocytes and vein tissue. One of the most likely causes for the poor reproducibility 
was low hnRNA copy numbers. It had been shown that adipose tissue expresses 
significantly more IL6 RNA than the other tissues examined. An attempt was 
therefore made to use the allelic transcription assay on adipose tissue samples. 
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4.7  Allelic Transcription Assay for Adipose Tissue  
 
A large proportion (11 out of 17) of samples showed gDNA contamination despite 
rigorous DNase treatment. One sample showed particularly strong bands in repeat 
LDLR assays suggesting substantial gDNA contamination. No cDNA could be detected 
in this sample. The sample was therefore excluded from final analysis but included in 
the study to act as a further positive control with an expected IL6 RNA transcription 
ratio identical to gDNA. The calculated transcription ratio (0.55) for this sample was 
close to the expected ratio (0.56) (calculated ratio of heterozygous gDNA controls) 
(Table_Apx C-45). The small variation between the two ratios may be due to 
inaccuracies in the measurement. Alternatively, a small amount of cDNA could have 
been present in the sample but could not be demonstrated on a gel with out nested 
PCR. A common cause for gDNA contamination is inadequate homogenisation. 
However, adipose tissue was easier to homogenise than the vein samples.  As vein 
had a smaller proportion of contaminated samples than adipose tissue, inadequate 
homogenisation is unlikely to be the sole cause of the residual gDNA contamination. 
It has been recognised that the unique nature of adipose tissue (high lipid content) 
requires specific extraction methods to gain high quality RNA samples (327). This 
study used the same RNA extraction method for vein, muscle and adipose tissue. 
This was preferable due to the added cost of using a tissue specific extraction 
method; however the use of tissue specific RNA isolation methods may have 
improved RNA quality and yield increasing the number of usable samples. gDNA 
contamination reduces any measurement of real difference in allelic transcription 
between the alleles. It is not possible to assess the exact influence gDNA had on 
results, as contribution of hnRNA and gDNA to the final result can not be 
differentiated, however it is likely that the demonstrated difference in allelic 
transcription underestimates the true value.  
 
Genotyping for SNP G3572T was performed to exclude any rare SNP G-174C/SNP 
G3572T GT haplotypes. Inclusion of rare SNP G-174C/SNP G3572T GT haplotypes 
would lead to bias towards higher expression in the C-allele. Only one out of 17 
samples was found to contain the rare haplotype. In the SeattleSNPs Haplotype Data 
(http://pga.gs.washington.edu/data/il6/ilkn6.phase.out) population the ratio of 
haplotype SNP G-174C/SNP G3572T GG to GT was about 2:1. The rare haplotype is 
less common in this study population. This could be explained by the SeattleSNPs   193 
Haplotype Data being derived from a European/Afro American panel, were as 
subjects used in the allelic transcription assay were only Europeans. 
The reproducibility of the allelic transcription assay was improved compared to 
previous experiments by utilising adipose tissue RNA as a template. Mean variance 
for repeat assays for individual adipose tissue samples was 0.008 compared to 0.004 
for gDNA (standard curve) and 0.05 and 0.06 for vein and leukocyte respectively. 
Accuracy of the assay was likely to have been improved by an increase in template 
due to higher IL6 expression in adipose tissue. cDNA yield was further improved by 
placing the start site for reverse transcription into an intron region. This eliminated 
competition from mRNA templates maximising transcription from hnRNA. 
 
There was no statistically significant difference in allelic transcription between the G 
and the C allele. However, expression from the C-allele was three times higher than 
from the G-allele. This correlates with findings from the RT-PCR analysis showing the 
CC genotype to have the highest levels of RNA expression in all tissues. Possibly the 
lack of significance in the allelic transcription assay is related to the low number of 
samples included and the effect of gDNA contamination (328). Further work in 
improving elimination of gDNA contamination and using a greater number of 
samples may be valuable. Results form this study have suggested that, for tissues 
with a relatively high IL6 hnRNA expression, the allelic transcription assay may 
become a suitable assay to assess the effect of promoter SNP G-174C on IL6 RNA 
expression.  The advantage of comparing allelic transcription in heterozygote 
individuals is the exclusion of confounding variables, which may lead to variation in 
gene expression when comparing expression between different individuals. Intra-
individual comparison thus has clear advantages. Further work to improve this assay 
appears justified. 
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5  Summary and Conclusion 
This study aimed to investigate the effect of promoter SNP G-174C and the influence 
of tissue type on IL6 expression in humans. This was to be investigated at the mRNA 
and hnRNA level in human tissue. The aim was ambitious.  
Subject recruitment and sample collection were logistically difficult and hindered by 
changes in the NHS health care provision. However, the majority of patients 
undergoing varicose vein surgery in the study centres were willing to donate tissue 
for scientific research and thus a sufficient number of tissue samples were obtained 
to proceed with the study. Those patients, who were followed up, were satisfied with 
their recruitment and did not feel adversely affected by the additional tissue 
sampling during their procedure. Their average return to normal daily activity and 
pain scores following tissue sampling compared favourably with those previously 
reported for varicose vein surgery. All those questioned were willing to participate in 
future studies and as thus it would appear that the patient experience in this study 
was satisfactory. The tissues collected are a valuable resource of a variety of ex vivo 
tissues from adult individuals, which can be utilised in comparative gene expression 
studies in the future.  
 
Interleukin 6 plays an important role in the development and the progression of 
arterial disease. Greater understanding of the mechanisms controlling IL6 gene 
expression may be useful in the development of treatment strategies. Results in this 
study indicated that promoter SNP G–174C may have an effect on IL6 gene 
transcription. A significant difference in IL6 mRNA expression between genotypes 
was shown in vein tissue and in leukocytes, with the highest expression in the CC 
genotype. No statistically significant difference in IL6 mRNA expression was 
demonstrated in adipose tissue or muscle, though again mean expression was 
highest in the CC genotype. Thus IL6 expression may in part be determined by SNP 
G-174C genotype in some tissues, with a trend towards higher expression from the 
CC genotype.  
This experiment was valuable as it used tissue sampled from human volunteers 
rather than cell culture, thus giving a more accurate picture of the in vivo expression 
profile of IL6. The study measured IL6 mRNA expression rather than circulating 
protein levels. Measuring circulating protein levels is technically easier, as subjects 
are only required to donate blood samples and protein assays allowing high through 
put of samples are commercially available. Thus a greater sample number can be   195 
achieved in protein studies. However, promoter polymorphisms are likely to act at 
the level of primary gene transcription and a variety of steps exist, influencing IL6 
protein expression after primary transcription occurs (see chapter 1.3). Therefore 
RNA expression studies are more likely to show true effects of promoter 
polymorphisms on gene expression. Conversely RNA studies are laborious, leading to 
difficulties in achieving high sample numbers as was demonstrated in this study.  
 
This study suggests that IL6 mRNA expression may not be influenced by a simple 
SNP G-174C allele effect in some tissues. All tissues, with the exception of vein, 
showed a trend towards higher expression of IL6 mRNA associated with numbers of 
C-alleles. However, in vein tissue the CC genotype was associated with the highest 
IL6 mRNA expression, but the GG genotype expressed more than the GC genotype.  
Further studies are necessary to investigate this result.  
It is difficult to draw conclusions as to the effect the interaction of tissue type with 
genotype. Though no significant difference between genotype was found in some 
tissues but significant differences in others, there was a trend towards higher 
expression in the CC genotypes in all tissues. It is possible that the effect of the 
promoter SNP was too small to become statistically significant in the relatively small 
sample number in some tissues. Thus a larger study is required to investigate the 
effect of interaction of genotype and tissue type on gene expression.  
 
A significant correlation was found between increasing age and IL6 mRNA expression 
in adipose tissue and vein tissue. An association between IL6 plasma levels and age 
has been shown in a previous study (326). As adipose tissue may contribute 
significantly to circulating levels of IL6, the increased production of IL6 in adipose 
tissue in older subjects may explain some of the age related changes in plasma 
levels. 
 
Studies with low sample numbers such as this study are susceptible to the influence 
of confounding variables, therefore this study attempted to design an allelic 
transcription assay to minimise the effect of confounding variables, allowing 
conclusions from smaller sample numbers. This is the first study to use a gel based 
assay to assess the effect of promoter SNP G-174C on IL6 hnRNA expression in 
heterozygotes. Assessing allelic transcription in heterozygous individuals is 
advantageous as confounding variables act on both alleles and therefore should not 
influence results. The experiment showed a trend for higher expression in the C-  196 
allele in vein tissue, though this was not statistically significant. The accuracy of the 
assay was reduced by gDNA contamination and high variance in repeat samples. 
Variance was thought to relate to low copy number of IL6 hnRNA in the samples. 
Leukocytes also showed a trend towards higher expression in the C-allele, again the 
difference was not statistically significant. In both the vein and the leukocyte assay 
the variance in repeat samples was greater than the variance seen for gDNA 
samples/standard curve. Thus, the assay may remain inaccurate for vein and 
leukocytes.  
In the adipose tissue allelic transcription assay the mean hnRNA expression from the 
C–allele was greater than from the G-allele. Again the difference was not statistically 
significant. gDNA contamination was again seen in the adipose tissue samples, 
however variance of repeats was improved and was similar to that seen for 
gDNA/standard curve samples suggesting that higher levels of IL6 RNA improved 
assay precision. Employing adipose tissue specific extraction methods to improve 
quality and purity of RNA samples, thus further minimising gDNA contamination, 
may further improve the precision of the assay and allow it to become a more 
accurate tool in future studies.  
This experiment established for the first time that it is possible to demonstrate IL6 
hnRNA expression using a gel based method. Though its use is likely to remain 
limited to tissues with high IL6 expression, the advantages of the intra–individual 
comparison and the likely proximity of hnRNA expression to promoter effect justify 
further development of this technique. 
 
Risk of atherosclerosis is likely to be influenced by circulating levels of IL6. IL6 is 
expressed in a variety of tissues. These contribute to the circulating levels of IL6, 
however the relative contribution individual tissues make to the plasma IL6 level is 
unknown. This study investigated the relative mRNA expression of IL6 in different 
tissues. It was demonstrated that the relative IL6 mRNA expression was significantly 
greater in adipose tissue then in vein tissue, skeletal muscle tissue and leukocytes 
within individuals. This is the first study to demonstrate this difference in IL6 mRNA 
expression in individuals. This may have implications when considering the role of 
obesity in atherosclerotic disease development. It was further demonstrated that the 
relative RNA expression in adipose tissue, leukocytes and vein tissue is significantly 
greater than in muscle. This is the first study using a variety of tissues from one 
individual to compare in vivo RNA expression profiles for IL6.    197 
The study also showed that there is a high inter-individual variation of IL6 RNA 
expression, regardless of genotype. This may be the result of genetic variables not 
examined in this study or confounding variables such as age, smoking and 
medication etc. In this context the advantage of intra-individual studies of IL6 
expression is apparent. Using tissue samples from one individual minimises the 
effects of confounding variables on study outcome as all tissues are exposed to the 
same variables. Equally studying allelic transcription minimises the effect of 
confounding variables. Thus refinement of the techniques established in this study 
may yield valuable results in the future. 
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6  Future work 
 
The aim of this study was to identify the effect of promoter SNP G-174C on IL6 RNA 
expression, thus defining a marker that could be used in Mendelian randomisation 
studies allowing the nature of the IL6/vascular disease association to be explored. 
Though SNP G-174C may affect gene expression the idea that one single 
polymorphism significantly affects circulating protein levels and ultimately disease 
process may be an over-simplification. A promoter SNP may affect RNA expression, 
however beyond this, multiple levels of regulation exist which may influence protein 
levels. Equally other polymorphisms within the IL6 gene may influence expression 
and haplotype studies are likely to be more relevant then the isolated study of one 
polymorphism. Protein levels are also regulated through a variety of positive and 
negative feed back loops involving other mediators. Levels of these mediators may 
in turn be determined by polymorphisms within their genes. Thus IL6 circulating 
levels may be regulated by a number of polymorphisms in a variety of genes. The 
isolated effect of a single promoter SNP on gene expression would have to be 
substantial to show an effect on disease development. This study showed that 
although SNP G-174C may affect RNA expression to an extent, the effect is unlikely 
to be of this magnitude  
  
The results of this study therefore have to be used in conjunction with findings from 
other experiments, e.g. studies investigating IL6 haplotype (24). Besides further 
studies into the regulation of IL6 expression through polymorphisms within the IL6 
gene, the delineation of the pathophysiological pathways of atherosclerosis will 
require further investigation of all mediators involved in vascular disease 
development including those with known effect on IL6 expression. Mediators 
affecting IL6 expression such as TNFα, IL1β, platelet derived growth factor, 
transforming growth factor β (TGFβ), IL13 and IL4 have already been extensively 
investigated and further research into their regulatory mechanisms will help clarify 
the pathophysiological pathways involved in vascular disease development 
(12;24;25). Furthermore recent studies have shown that interleukin 6 receptor 
(IL6R) polymorphisms associate with IL6 plasma levels and the mechanism of this 
association will require further study (329-331). Soluble IL6R (sIL6R) possibly affect 
IL6 expression via negative feed back loops or plasma levels of IL6 could be 
decreased through increased binding and internalisation of IL6/sIL6R complexes   199 
(332;333). Soluble IL6R (sIL6R) is generated by proteolytic cleavage (shedding) of 
cognate IL6R or by alternative splicing of the IL6R mRNA (40;45;334). A IL6R SNP 
known to affect IL6 levels (SNP rs 8192284) occurs at a proteolytic cleavage site of 
IL6R and it has been suggested that variation at this point may affect circulating 
levels of sIL6R (330;335). Further studies examining the effect of IL6R 
polymorphisms on sIL6R levels may help to clarify IL6 regulation. 
The biological activity of IL6 may also be affected through modulation of IL6 
signalling pathways. Recently it has been proposed that a member of the family of 
LIM containing proteins, LIM only 4 (LMO4) can modulate IL6 signalling, possibly by 
stabilising the gp130 complex i.e. LMO4 may act as a positive regulator in IL6 
signalling (336). Proteins containing LIM domains have been previously suggested to 
play a role in the development of arterial disease (337-339). It is possible that 
factors leading to over expression of LMO4 may contribute to increasing IL6 
signalling with a potential role in arterial disease development. Delineation of LMO4 
regulatory processes will be of relevance to the understanding of vascular disease. 
The list of mediators with potential to modulate arterial disease development is 
extensive and includes many not mentioned in this thesis. The ongoing study of 
individual genetic variants of these mediators and their effect on gene expression 
will continue to advance our understanding. However, in terms of association studies 
(phenotype/genotype association) individual polymorphisms are likely to be less 
relevant unless the isolated effect of the individual variant is substantial. This is 
demonstrated by the discrepant observations of association studies of SNP G-174C 
and atherosclerosis.  
In this context, the recent introduction of genome wide association studies (GWAS) 
offers a more rational approach towards identifying disease associated genomic 
variants (340). Given the complexity of biological pathways, the non-hypothesis 
driven approach of GWA studies, investigating disease association with genome wide 
variations, is likely to identify relevant genes more rapidly than has previously been 
possible. The development of micro array technology, allowing detection of a large 
number of genetic variants in a short space of time and the recent completion of the 
Human Genome Project as well as the International HapMap Project have been 
pivotal to the introduction of GWA studies. Locus 9p21.3 has been named as the 
most replicated locus associated with coronary artery disease in GWA studies. It 
contains the sequence of two cyclin-dependent kinase inhibitors, CDKN2A and 
CDKN2B (341). These may affect pathogenesis of atherosclerosis as part of the 
TGFβ-induced growth inhibition pathway (342;343). In addition, a GWAS has   200 
identified loci near the IL6R gene which associate with CRP levels, an independent 
risk factor for myocardial infarction and stroke (344). GWA studies offer an exciting 
opportunity for the future and are likely to accelerate the understanding of the 
pathogenic pathways of arterial disease. 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   201 
Appendix 
Appendix A:  Materials 
a:  Materials for PCR 
 
  DNA Samples 
Control DNA: 
DNA  was  extracted  from  blood  donated  by  volunteers  working  in  the  Human 
Genetics  Division.  Following  extraction,  the  DNA  samples  were  diluted  to  roughly 
equal  concentrations  of  7-10ng/ul.  These  samples  were  used  as  templates  in  the 
optimisation of experiments. 
 
DNA Samples: 
Nine  millilitre  K-EDTA  venous  blood  was  taken  from  patients  participating  in  the 
study.  DNA  was  extracted  from  these  samples  and  quantified  using  Pico  Green 
assay. 
 
  RNA Samples 
Control RNA: 
Control RNA was obtained from blood donated by volunteers in the laboratory. RNA 
was extracted using the PAXgene
TM Kit. 
 
  Primers 
Primers were designed using ‘primer 3’ software. All primers were supplied by MWG-
Biotech (Ebersberg, Germany) except for In/Ex Primer and Exon Primer which was 
supplied by Sigma-Aldrich. (See Appendix 1 for list of primers) 
 
  Enzymes 
Taq DNA polymerase (5U/ul): Purchased from Promega Company; Madison, Wi, 
USA, Catalogue number: M1665 
 
Pwo DNA polymerase: purchased from Roche Diagnostics, Lewes, UK. 
 
Msp I: Restriction endonuclease, purchased from New England BioLabs Inc., 
http://www.neb.com , Cat No: R0106S 
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Dde I: Restriction endonuclease, purchased from New England BioLabs Inc., 
http://www.neb.com , Cat No: R0175S 
 
Mae I: Restriction endonuclease, purchased from Roche Diagnostics GmbH, Roche 
Applied Science, Nonnenweg 2, 82372 Penzberg, Germany, Cat No: 10 822 221 001 
 
 
  PCR Reagents 
10x PCR Buffer: Provided with Taq DNA polymerase by Promega, Madison, WI, USA 
 
10x Long PCR buffer: homemade reagent:  
•  500mM tris-HCL, pH 8.9 
•  140mM ammonium sulphate 
 
Betaine: Purchased from Sigma Chemicals Co. U.S.A. B-2629, [107-43-7], EC NO 
203-490-6 
 
Desoxynucleotide Triphosphates (dNTPs) 100nM, pH: 7.5: Purchased from Promega, 
Madison, WI, USA, Catalogue Number: U1240 
 
Magnesium Chloride 25mM: Provided with Taq DNA polymerase by Promega, 
Madison, WI, USA 
 
Primers 100pmo/ul: purchased from MWG-Biotech, Ebersberg, Germany 
(www.mwgdna.com)  
 
 
b:  Chemicals for Gels 
Acrylamide (Acrylamide-bis-acrylamide) solution (ration 19:1): from Severn Biotech 
Ltd. UK. Catalogue Number 003661 
 
10x TBE: made on site from: 
Tribase,  tris  (hydroxymethyl)  methylamine:  from  Fisher  Scientific  UK  Ltd, 
Product Code: t/3710/60 
 
Boric Acid: from Fisher Scientific UK Ltd, UK. Code B/3800/60   203 
 
EDTA (Ethylenediamietetra-acetic acid sodium salt): from BDH Lab Supplies, 
Poole, UK. Product Number: 10315 
 
Ammonium Persulphate: from Fisher Scientific International Co. UK. Ltd. Product 
Number: 6160/53 
 
TEMED (N,N,N’,N’-Tetramethylethylendediamine): from Sigma Chemical Co., U.S.A. 
EC No203-744-6, Product Code: T-8133 
 
Agarose: purchased from Life Technologies, Paisley. Scotland. 15510-019 
 
 
  Chemicals for staining Gels 
 
Ethidium Bromide 10mg/ml: from Sigma Chemical Co., MO, USA. EEC No214-984-6, 
Product-Code: E-1510 
 
Vistra Green
TM 10000x concentration: Purchased from Amersham Biosciences UK 
Ltd., Product Code: RPN5786 
 
c:  Instruments 
 
Fluorimager: Model 595, Molecular Dynamics, Amersham Pharmacia Biotech, Little 
Chalfont, Bucks, UK 
 
TyphoonTRIO+: variable Mode Imager, Amersham Biosciences UK Ltd. 
 
Thermal Cycler: DNA Engine Tetrad, MJ Research Inc., USA 
 
Centrifuge: IEC Centra MP4, International Equipment Company Inc. USA 
 
Microcentrifuge: IEC Micromax,  International Equipment Company Inc. USA 
 
Centrifuge with swing out rotor: Multifuge
® 3L-R, Heraeus, Kendro Laboratory 
Products GmbH, Post-box 1563, Hanau, Germany   204 
 
Output power supply: 200-220 V, 50-60HZ, Bio-Rad Laboratories Inc., USA 
 
 
d:  Commonly used Materials and Chemicals 
 
Pipettes: Pipetman (2ul, 20ul,200ul, 1000ul), Gilson S.A. Villiers-le-Bel, France 
 
Disposable Lab Tips: 0.5-10ul Elkay Laboratory Products, Unit E Lutyen Industrial 
Centre, Bilton Road, Kingsland Buisness Park, Basingstoke, Hants RG24 8LJ Prod 
Code RESUPIP 010; 2-200ul Code: 94300120 and 101-1000ul Code; 94300220 from 
Thermoscientific www.thermofisher.com  
 
Multiple Channel Finnpipette
®: Labsystem, Helsinki, Finland 
 
Filter Tips 10,20,200,1000: Greiner Labortechnik GmbH, A-4550 Kremsmünster, Bad 
Hallerstr. 32, Austria. Product No: 771288, 774288, 739288, 740288 
 
 
Microtubes (0.5ml and 1.5ml): Purchased from Alpha Laboratories Ltd, Catalogue 
Number: LW2372 & LW 2375, Hampshire, UK 
 
Microtubes (200µl): 8 strip tubes, Alpha Laboratorie Ltd, 40 Parham Drive, Eastleigh, 
Hants SO50 4NU, UK, www.alphlabs.co.uk, Cat No: LW 2510 
 
96(8x12) well “industry-standard” plates: purchased from Thermo-Fast
®, Abgene 
House UK, (www.abgene.com), catalogue-no: AB-0800 
 
384-Well  plate:  skirted,  polypropylene,  white,  Greinerbio-one,  Maybachstr.  2,  72636 
Frichenhausen, Germany www.gbo.com/bioscience  , Part No: 785207 
 
Microseal
TM  ‘A’  Film:  For  sealing  384  Well  plates  for  PCR  MJ  Research, 
www.mjr.com Cat No:MSA 5001 
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Screw Cap MCT: 1.5ml skirted Thermoscientific www.thermofisher.com  Code: 02-
1415-4500 
 
Screw Cap for MCT:  Thermoscientific www.thermofisher.com  Code: 02-1480-0500 
 
Glass plates: were cut from standard glass to 110mmx170mm size; purchased from 
local supplier. 
 
MADGE former: purchased from MADGE BIOLtd., Nottinghan, UK. 
 
50bp DNA Step Ladder: Purchased from Promega, Madison, WI, USA, 
Catalogue#G4521 
 
100bp DNA Step Ladder: Purchased from Promega, Madison, WI, USA, 
Catalogue#G2101 
 
Formamide dye mix: home made from 98% deionised formamide (Sigma Chemicals Co, 
USA) 49ml, 10mM EDTA (pH 8.0, 0.5M) 1ml, Xylene Cyanol FF, Bromophenol blue 
(Sigma Chemical Co, USA) 
 
Chill-Out
TM 14: Liquid Wax: MJ Research, www.mjr.com 
  
 
Magnesium Sulfate (1.00M): purchased from Sigma Chemical Co 
(www.sigmaaldrich.com), PO Box 14508, St. Louis Mo 63178 USA 314-771-5750; 
Cat-No: M-3409 
 
e:  Software 
 
Primer3: http://www.genmewi.mit.du/cgi-bin/priemr/primer3_www.cgi 
 
and http://www.ncbi.nlm.nih.gov/BLAST/    
 
ImageQuant  TL:  Image  Analysis  Software  V2003,  Amersham  Biosciences  for  use 
with Typhoon   206 
 
ImageQuant  Version  5.0:  Image  Analysis  Software,  Molecular
®  Dynamics  for  use 
with Fluorimager 
 
NEBcutter:    http://tools.neb.com/NEBcutter2/index.php  used  to  find  restriction 
enzymes 
 
SPSS 14: Statistics software package 
 
Microsoft Exel: Microsoft Office Excel 2003 
 
RT-PCR quantitation Software: Roche Applied Science LightCycler
® 480 Software Version 1.0 
 
f:  Buffers and Solutions 
  
10xTBE (ph 8.3): This buffer was prepared using 108g Tribase, 55g Orthoboric acid, 
NA-EDTA 9.3g made up to 1liter with distilled water. The buffer was stored at room 
temperature.  
 
Long PCR Buffer: This was made using 140mM ammonium acetate (Sigma-Aldrich 
Company Ltd, Poole, UK). 
 
Betaine (5M): This solution was made from 58.55g Betaine (C5H11NO2) dissolved in 
distilled and autoclaved water to make 100ml. Betaine (5M) was stored at 4ºC for a 
maximum of 2 weeks. 
 
Sticky Silane: This was prepared using 99ml pure ethanol, 500ul glacial acetic acid, 
500ul γ-methylacryloxypropyltrimetoxy silane. Sticky silane was applied to the glass 
surface before it was placed on the gel former. 
 
Ethidium Bromide Staining Solution: This was prepared using 20ul ethidium 
bromide, 20ml 10xTBE and 180ml distilled water. The solution was kept in a light 
excluding container. Gels were stained in this solution for 25 minutes prior to 
electrophoresis. 
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Vistra Green staining Solution: This was prepared using 10ul Vistra Green, 10ml 
10xTBE and 90ml distilled water. The solution was kept in a light excluding container 
up to a maximum of one week. For every gel stained, a further 5ul Vistra Green was 
added to the solution. Gels were stained for 20 minutes after electrophoresis. 
 
Ammonium Persulfate (APS) 25%: This was prepared using 2.5g Ammonium 
Persulfate dissolved in distilled water to make 10mls of solution. APS 25% was 
stored at 4ºC for a maximum of 6 weeks. 
 
g:  Gels 
Polyacrylamide Gel (5%): This was made using 36.7ml distilled water, 8.3ml  30% 
Polyacrylamide, 5ml 10xTBE, 150ul TEMED and 150ul APS. Immediately after mixing 
the solution was poured into a MADGE former. A glass plate (one side previously 
coated with sticky silane) was placed silane side down onto the gel former and the 
gel was left to set. 
 
Agarose Gel (1%): 1g of Agarose was added to 100ml 1xTBE and heated in the 
microwave for 2 minutes on high power. The evaporated water was replaced and 
ethidium bromide was added to the gel (5ul Ethidium bromide per 100ml of Gel), 
before pouring the mixture into the gel former. 
 
Denaturing Urea Acrylamid Gel: 23ml DEPC Water, 3.8ml 30% Acrylamide and 14.4g 
Urea were mixed until the Urea had resolved. Then 3ml of 10x TBE, 32ul TEMED and 
240ul of 25% APS was added to the mixture, which was then poured between two 
Glass plates with a comb fitted into the top of the gel. 
 
h:  Materials used for DNA extraction 
ELB (Erythrocyte lysis bufferx10): This buffer was made up using 5.05g potassium 
hydrogen carbonate, 41g ammonium chloride, 1ml 0.5M EDTA ph 8.0 made up to 
500ml double distilled sterile water. This was diluted 1 in 10 for use and autoclaved 
for 15 minutes at 121°C. The solution was placed in the fridge overnight prior to 
use. 
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NLB (Nucleic lysis buffer): This buffer was made up using 5.0ml 1.0M tris pH 8.0, 
40ml 5.0M sodium chloride, 2.0ml 0.5M EDTA pH 8.0 made up to 500ml distilled 
sterile water. 
 
10% SDS (sodium dodecyle sulphate): 10g SDS dissolved in distilled sterile water, 
made up to 100ml.  
 
Protease 40g/ml: from Sigma-Aldrich Co, Code: P6911, 800mg of Protease was 
made up to 20ml with distilled sterile water. 
 
Saturated sodium chloride (6M): 35g NaCl in 100ml distilled sterile water. 
 
70% Ethanol: 350ml Ethanol was mixed with distilled sterile water. 
 
10mM tris/1.0mM EDTA buffer pH 7.5: 5ml 1.0M tris pH 7.5 and 1ml 0.5M EDTA pH 
8.0 was made up to 500ml with distilled sterile water. It was then autoclaved for 15 
minutes at 121°C. 
 
PicoGreen: Molecular Probe Cambridge Bioscience, Cambridge, UK, Code: P 7581 
 
Absolute ethanol: Fisher Scientific, Code: E/0650DF/25 www.fisher.co.uk   
 
50ml conical tubes: Greiner bio-one, Maybachstr.2, 72636 Frickenhausen, Germany 
www.gbo.com/bioscience  Part-No: 227261 
 
15ml conical tubes: Greiner bio-one, Maybachstr.2, 72636 Frickenhausen, Germany 
www.gbo.com/bioscience  Part-No: 227261 
 
 
Sorvall RT 7: centrifuge with swing out rotor and buckets, Sorvall, Newtown, Ct, USA 
 
Roller SRT 2: roller mixer, Stuart Scientific Holmethorpe Ave. Holmethorpe Industrial 
Estate Redhill Surrey RH1 2NB UK, Tel: +44 1737 766431 
 
G24 Environmental Incubator Shaker: New Brunswick Scientific Co. Inc., Edison, 
N.J., USA   209 
 
i:  Materials used for RNA extraction 
Disposable Scalpel: Size 21 Ref 0207, Swann Morton, Sheffield, England 
 
Disposable Syringe: 5ml Ref: SS05S, Terumo Europe N.V., 3001 Leuven, Belgium 
 
Disposable Needle: 18G Ref: NN1838R and 21G Ref: 2138R, Terumo Europe N.V., 
3001 Leuven, Belgium 
 
Vacutainer Systems: Safety-LokTM Blood Collection System, Becton Dickinson 
Vacutainer Systems, 1 Becton Drive, Franklin Lakes, NJ,USA 
 
Microtubes 1.5ml: Alpha Laboratories Ltd, 40 Paxham Drive, Eastleigh, Hants, SO50 
4NU, UK, Prod-No: LW2375 
 
RNAlater
TM: RNA Stabilization Solution for Tissue, Sigma (www.sigmaaldrich.com), 
3050 Spruce Street, Saint Louis, Missouri 63103, USA; Product number: R 0901 
 
TRI REAGENT
TM: Purchased from SIGMA (www.sigmaaldrich.com), 3050 Spruce 
Street, Saint Louis, Missouri 63103, USA; Product number: T 9424 
 
Homogenisation pestle (1.5ml): Purchased from Bioquote limited, The Royal Centre, 
James St.York, YO10 3DW, UK; catalogue number: PMT - 15 
 
Chloroform: Purchased from SIGMA (www.sigmaaldrich.com), 3050 Spruce Street, 
Saint Louis, Missouri 63103, USA; Product number: C 2432 
 
Isopropanol: Purchased from SIGMA (www.sigmaaldrich.com), 3050 Spruce Street, 
Saint Louis, Missouri 63103, USA; Product number: I 9516 
 
DNA-free
TM: Purchased from Ambion (www.ambion.com); Catalogue number: 1906< 
contains: DNase I, RNase free (2units/ul), 10x DNase Buffer, DNase Inactivating 
reagent, Nuclease-free Water/0.1 mM EDTA 
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RNA storage solution: Purchased from Ambion (www.ambion.com), pH = 6.4; 
Catalogue number: 7001 
 
PAXgene
TM Blood RNA Kit: purchased from Qiagen, PreAnalytiX, Qiagen House 
Fleming Way, Crawley, West Sussex, RH10 9NQ Product No: 762174 
 
PAXgene
TM Blood RNA Tubes: purchased from Qiagen, PreAnalytiX, Qiagen House 
Fleming Way, Crawley, West Sussex, RH10 9NQ Product No: 761125 
 
Urea Polyacrylamide Gel Sample Buffer: 10mg sucrose, 20mg Bromophenol Blue, 
20mg Xylene Cyanol, 90ml deionised Formamide, brought up to a final volume of 
100ml with water. 
 
Fridge Centrifuge: Biofuge fresco, Heraeus, Kendro Laboratory Products, Germany 
 
Sorvall RT 7: centrifuge with swing out rotor and buckets, Sorvall, Newtown, Ct, USA 
 
G24 Environmental Incubator Shaker: New Brunswick Scientific Co. Inc., Edison, 
N.J., USA 
 
DU
®7500 Spectrophotometer: BeckmanCoulter, Buckinghamshire, UK 
 
NanoDrop: Spectrophotometer ND-1000, Labtech International, www.Labtech.co.uk 
 
Hotbox Oven with fan size 2(Baker): Sanyo Gallenkamp plc. Loughborough, UK 
 
RNaseZap
®: Ambion
® (www.ambion.com), catalogue number: 9780.9782 
 
Diethylpyrocarbonate (DEPC): Sigma Chemicals Co (www.sigmaaldrich.com), PO Box 
14508, Saint Louis, Mo 63178, USA; Product number: D-5758 
 
DEPC-treated Water: Ambion
® (www.ambion.com), catalogue number: 9906 
 
Dri-Block DB-1 (Heat Block): Tecam
® (Cambridge) Ltd., Duxford, Cambridge, 
England  
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j:  Materials used for cDNA Synthesis 
 
M-MLV-RT:  Moloney  Murine  Leukemia  Virus  Reverse  Reverse  Transcriptase, 
Promega, www.promega.com,  Part-No: M368B 
 
M-MLV RT 5x Reaction Buffer: Promega, www.promega.com supplied with reverse 
transcriptase 
 
Oligo (dT)15 Primer: Promega, www.promega.com, Cat No: C1101 
 
Specific Primers: MWG-Biotech (Ebersberg, Germany)  
 
RT kit for 50 reactions with random hexamer primer:  RT-Hex, PrimerDesign Ltd, 
Building 27, Southampton University, Highfield Campus, Southampton, Hants, UK, 
SO17 1BJ. (www.primerdesign.co.uk) 
 
dNTPs:  Desoxynucleotide  Triphosphates,  Promega,  www.promega.com,  Cat  No: 
U1240 
 
k:  Materials used for TaqMan assay 
 
Mastermix-R: Realtime qPCR Mastermix, PrimerDesign Ltd, Building 27, 
Southampton University, Highfield Campus, Southampton, Hants, UK, SO17 1BJ. 
(www.primerdesign.co.uk) 
 
IL6 RT-PCR assay: Cat-No: Hs00174131_m1, Applied Biosystems, Division 
Headquarters, 850 Lincoln Centre Drive, Foster City, CA 94404, U.S.A. 
(www.appliedbiosystems.com) 
 
GAPDH RT PCR assay: Roche Universal ProbeLibrary Probe #60, Roche Diagnostics 
GmbH, Roche Applied Science, 68298 Mannheim, Germany 
 
 
Plates: LightCycler
® 480 Multiwell Plates 384, Roche, 68298 Mannheim, Germany, 
#04 729 749 001   212 
 
 
Plate sealers: LightCycler
® 480 Sealing Foil, Roche, 68298 Mannheim, Germany, 
#04 729 757 001 
 
 
ROCHE LightCycler LC480: Roche Instrument Centre AG, Forrenstrasse, CH-6343 
Rotkreuz, Switzerland 
 
RT-PCR quantitation Software: Roche Applied Science LightCycler
® 480 Software 
Version 1.0 
 
 
 
Appendix B:  Primer Sequences  
a:  PCR Primers 
LDLR-Promoter    F     5’-aggactggagtgggaatcagagc-3' 
        R     5'- tgctgtgtcctagctggaaaccc -3’ 
 
 
G-174C        F  5’-  cgctagcctcaatgacga - 3’ 
           R    5’ – tctttgttggagggtgagg - 3’ 
  
 
 
Ex3/In3/Ex4 Primer pair  F        5’- gaaagcagcaaagaggcact – 3’ 
           R       5’ – agctctggcttgttcctcac -3’ 
   
T2529C      F  5’ - ctgaaaggcatgttcagcttc -3’ 
                       R  5’ – atctccccactttcaatgca – 3’ 
 
G3572T      F  5’ - ggcagtttattcttggacagg – 3’ 
R  5’ – ataaaaggaggttccagccc -3’ 
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G3572T new          F  5’ – ggcagtttattcttggacagg – 3’ 
        R  5’ –caatgtcccaaaacatgctg – 3’ 
 
A5014G      F   5’ – ggtgggtctatggaaaggtg - 3 
R  5’ – caaacaaataagatagtgatgctgg – 3’        
 
Intron3/Exon3 continuity     F  5’ – gaaagcagcaaagaggcact - 3’ 
         R        5’ – gcagccagagagggaaaag – 3’ 
 
 
 
 
b:  Probes 
 
SNP G-174C Assay: 
FITC Probe:             5’-ctttagcatCgcaagacac- 3’ 
DABCYL Probe:     5’-aaccttattaagattgtgcaatgtgacg- 3’ 
 
 
c:  Primers used in cDNA Synthesis 
 
Reverse Primer for RT Intron3  5’- cttgcccttgttaatgct – 3’ 
 
Reverse Primer for RT Intron2  5’ - agtgtgggctcccaatctc - 3’ 
 
Reverse Primer for RT Exon4    5’ - tttctgcaggaactggatca - 3’ 
 
Reverse Primer for RT Intron4  5’ – gaatgaggacacacccacct – 3’   214 
Appendix C:  Statistical analysis 
 
 
a:  Allelic transcription assay for vein tissue 
 
    Ranks 
 
   sample_type  N  Mean Rank  Sum of Ranks 
cDNA  16  9.63  154.00 
gDNA  2  8.50  17.00 
allelic_ratio 
Total  18       
 
  Test Statistics(b) 
 
   allelic_ratio 
Mann-Whitney U  14.000 
Wilcoxon W  17.000 
Z  -.281 
Asymp. Sig. (2-tailed)  .779 
Exact Sig. [2*(1-tailed 
Sig.)]  .837(a) 
a  Not corrected for ties. 
b  Grouping Variable: sample_type     
Table_Apx C-1: Mann Whitney test for vein ratiometric analysis, testing for difference between the 
mean allelic transcription ratio for cDNA samples and heterozygous gDNA samples. 
 
 
b:  Allelic Transcription Assay for Leukocytes 
 
  Ranks 
 
   sample_type  N  Mean Rank  Sum of Ranks 
cDNA  12  7.83  94.00 
gDNA  2  5.50  11.00 
allelic_ratio 
Total  14       
 
  Test Statistics(b) 
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   allelic_ratio 
Mann-Whitney U  8.000 
Wilcoxon W  11.000 
Z  -.730 
Asymp. Sig. (2-tailed)  .465 
Exact Sig. [2*(1-tailed 
Sig.)]  .549(a) 
a  Not corrected for ties. 
b  Grouping Variable: sample_type 
 
Table_Apx C-2:  Mann Whitney test for leukocyte ratiometric analysis testing for difference between 
the mean allelic transcription ratio for cDNA samples and heterozygous gDNA samples. 
 
 
 
 
c:  Kruskal Wallis for difference in IL6 mRNA expression in 
different SNP G-174C genotypes in different tissues 
 
Test Statisticsa,b,c
1.961
2
.375
Chi-Square
df
Asymp. Sig.
normConc
Ratio
Kruskal Wallis Test a. 
Grouping Variable: Numeric_Genotype b. 
numertissue = Fat c. 
 
Table_Apx C-3: Kruskal Wallis test for difference in IL6 RNA expression in different genotypes in 
adipose tissue 
 
Test Statisticsa,b,c
7.469
2
.024
Chi-Square
df
Asymp. Sig.
normConc
Ratio
Kruskal Wallis Test a. 
Grouping Variable: Numeric_Genotype b. 
numertissue = Leukocytes c. 
 
Table_Apx C-4: Kruskal Wallis test for difference in IL6 RNA expression in different genotypes in 
leukocytes.   216 
 
Test Statisticsa,b,c
6.367
2
.041
Chi-Square
df
Asymp. Sig.
normConc
Ratio
Kruskal Wallis Test a. 
Grouping Variable: Numeric_Genotype b. 
numertissue = Vein c. 
 
Table_Apx C-5: Kruskal Wallis test for difference in IL6 RNA expression in different genotypes in 
vein tissue 
 
Test Statisticsa,b,c
2.521
2
.284
Chi-Square
df
Asymp. Sig.
normConc
Ratio
Kruskal Wallis Test a. 
Grouping Variable: Numeric_Genotype b. 
numertissue = Muscles c. 
 
Table_Apx C-6: Kruskal Wallis test for difference in IL6 RNA expression in different genotypes in 
skeletal muscle tissue 
 
 
 
d:  ANOVA for age distribution in different genotype groups 
 
 
  ANOVA for fat tissue 
 
age  
  
Sum of 
Squares  df  Mean Square  F  Sig. 
Between Groups  133.896  2  66.948  .359  .701 
Within Groups  5404.979  29  186.379       
Total  5538.875  31          
a  tissueType = fat 
Table_Apx C-7: ANOVA for age in adipose tissue. 
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  ANOVA for leukocytes 
 
age  
  
Sum of 
Squares  df  Mean Square  F  Sig. 
Between Groups  68.327  2  34.164  .194  .825 
Within Groups  5455.790  31  175.993       
Total  5524.118  33          
a  tissueType = leukocytes 
Table_Apx C-8: ANOVA for age in leukocytes 
 
  ANOVA for vein tissue 
 
age  
  
Sum of 
Squares  df  Mean Square  F  Sig. 
Between Groups  110.738  2  55.369  .313  .733 
Within Groups  6196.340  35  177.038       
Total  6307.079  37          
a  tissueType = vein 
Table_Apx C-9: ANOVA for age in vein tissue 
 
 
 
 
  ANOVA for muscle tissue 
 
age  
  
Sum of 
Squares  df  Mean Square  F  Sig. 
Between Groups  114.832  2  57.416  .317  .731 
Within Groups  5615.286  31  181.138       
Total  5730.118  33          
a  tissueType = muscle 
Table_Apx C-10: ANOVA for age in muscle tissue 
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e:  Spearman Correlation Coefficient 
 
Testing for linear relationship between age and IL6 expression in different tissues. 
 
Correlations a
1.000 .447*
. .010
32 32
.447* 1.000
.010 .
32 32
Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
age
normConcRatio
Spearman's rho
age
normConc
Ratio
Correlation is significant at the 0.05 level (2-tailed). *. 
numertissue = Fat a. 
 
Table_Apx C-11: Spearman correlation coefficient for relationship between age and IL6 expression 
in adipose tissue 
Correlations a
1.000 -.165
. .352
34 34
-.165 1.000
.352 .
34 34
Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
age
normConcRatio
Spearman's rho
age
normConc
Ratio
numertissue = Leukocytes a. 
 
Table_Apx C-12: Spearman correlation coefficient for relationship between age and IL6 expression 
in leukocytes 
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Correlations a
1.000 .424**
. .008
38 38
.424** 1.000
.008 .
38 38
Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
age
normConcRatio
Spearman's rho
age
normConc
Ratio
Correlation is significant at the 0.01 level (2-tailed). **. 
numertissue = Vein a. 
 
Table_Apx C-13: Spearman correlation coefficient for relationship between age and IL6 expression 
in vein tissue 
 
Correlations a
1.000 .301
. .084
34 34
.301 1.000
.084 .
34 34
Correlation Coefficient
Sig. (2-tailed)
N
Correlation Coefficient
Sig. (2-tailed)
N
age
normConcRatio
Spearman's rho
age
normConc
Ratio
numertissue = Muscles a. 
 
Table_Apx C-14: Spearman correlation coefficient for relationship between age and IL6 expression 
in muscle tissue 
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f:   Testing for difference in distribution of smokers 
 
 
Crosstab
15 9 24
62.5% 37.5% 100.0%
34 14 48
70.8% 29.2% 100.0%
48 8 56
85.7% 14.3% 100.0%
97 31 128
75.8% 24.2% 100.0%
Count
% within genotype
Count
% within genotype
Count
% within genotype
Count
% within genotype
C/C
G/C
G/G
genotype
Total
Non-smokers Smokers
smoke
Total
 
Chi-Square Tests
5.957a 2 .051 .048
6.081 2 .048 .052
6.091 .048
128
Pearson Chi-Square
Likelihood Ratio
Fisher's Exact Test
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
Exact Sig.
(2-sided)
0 cells (.0%) have expected count less than 5. The minimum
expected count is 5.81.
a. 
 
Table_Apx C-15: Testing for difference in distribution of smokers 
 
 
 
 
g:  Linear regression  
   
    
Model Summary 
    
 
a  Predictors: (Constant), ConcSquared 
Table_Apx C-16: Linear regression for standard curve: Result of PCR 1 for ratio metric analysis. 
   
   
Model  R  R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate  Change Statistics 
              
R Square 
Change  F Change  df1  df2  Sig. F Change 
1  .989(a)  .978  .977  .04997  .978  1380.299  1  31  .000   221 
   
 
  Model Summary 
 
a  Predictors: (Constant), ConcSquared 
Table_Apx C-17: Linear regression for standard curve: Result of PCR 2 for ratio metric analysis. 
   
   
  Model Summary 
 
a  Predictors: (Constant), ConcSquared 
Table_Apx C-18: Linear regression for standard curve: Result of PCR 3 for ratio metric analysis. 
 
 
h:  Allelic Transcription Assay for Adipose tissue  
 
  Ranks 
 
   sample  N  Mean Rank  Sum of Ranks 
TIG sample  7  5.43  38.00 
control genomic DNA  2  3.50  7.00 
allelic_ratio 
Total  9       
 
   
  Test Statistics(b) 
 
   allelic_ratio 
Mann-Whitney U  4.000 
Wilcoxon W  7.000 
Z  -.878 
Asymp. Sig. (2-tailed)  .380 
Exact Sig. [2*(1-tailed 
Sig.)]  .500(a) 
a  Not corrected for ties. 
b  Grouping Variable: sample 
 
Table_Apx C-19: Mann Whitney test for adipose tissue: Testing for difference between the mean 
allelic transcription ratio for cDNA samples and heterozygous gDNA samples. 
Model  R  R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate  Change Statistics 
              
R Square 
Change  F Change  df1  df2  Sig. F Change 
1  .948(a)  .900  .895  .09992  .900  179.168  1  20  .000 
Model  R  R Square 
Adjusted 
R Square 
Std. Error of 
the Estimate  Change Statistics 
              
R Square 
Change  F Change  df1  df2  Sig. F Change 
1  .985(a)  .969  .968  .05934  .969  882.362  1  28  .000   222 
 
 
i:  RT-PCR experiment in paired tissue samples 
 
  Test Statistics(a) 
 
   NormConRatio 
Mann-Whitney U  32.000 
Wilcoxon W  263.000 
Z  -4.742 
Asymp. Sig. (2-tailed)  .000 
a  Grouping Variable: TissueType 
Table_Apx C-20: Mann Whitney U test for adipose tissue and leukocytes 
 
 
 
  Test Statistics(a) 
 
   NormConRatio 
Mann-Whitney U  46.500 
Wilcoxon W  277.500 
Z  -4.377 
Asymp. Sig. (2-tailed)  .000 
a  Grouping Variable: TissueType 
Table_Apx C-21: Mann Whitney U test for adipose tissue and vein tissue 
 
 
  Test Statistics(a) 
 
   NormConRatio 
Mann-Whitney U  20.500 
Wilcoxon W  251.500 
Z  -5.040 
Asymp. Sig. (2-tailed)  .000 
a  Grouping Variable: TissueType 
Table_Apx C-22: Mann Whitney U test for adipose tissue and muscle tissue 
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  Test Statistics(a) 
 
   NormConRatio 
Mann-Whitney U  197.000 
Wilcoxon W  428.000 
Z  -.591 
Asymp. Sig. (2-tailed)  .554 
a  Grouping Variable: TissueType 
Table_Apx C-23: Mann Whitney U test for leukocytes and vein tissue 
 
 
  Test Statistics(a) 
 
   NormConRatio 
Mann-Whitney U  19.000 
Wilcoxon W  250.000 
Z  -5.078 
Asymp. Sig. (2-tailed)  .000 
a  Grouping Variable: TissueType 
Table_Apx C-24: Mann Whitney U test for leukocytes and muscle tissue 
 
 
  Test Statistics(a) 
 
   NormConRatio 
Mann-Whitney U  40.500 
Wilcoxon W  271.500 
Z  -4.536 
Asymp. Sig. (2-tailed)  .000 
a  Grouping Variable: TissueType 
Table_Apx C-25: Mann Whitney U test for vein and muscle tissue 
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j:  Independent sample t-test 
 
Independent Samples Test
6.557 .014 8.005 39 .000 3.13439 .39156 2.34238 3.92639
7.908 30.390 .000 3.13439 .39637 2.32532 3.94345
Equal variances
assumed
Equal variances
not assumed
LN_norm_conc_ratio
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
 
Table_Apx C-26: Independent sample t-test for adipose tissue and leukocytes 
 
 
 
Independent Samples Test
.399 .531 6.828 38 .000 3.10361 .45451 2.18350 4.02371
6.828 37.210 .000 3.10361 .45451 2.18286 4.02435
Equal variances
assumed
Equal variances
not assumed
LN_norm_conc_ratio
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
 
Table_Apx C-27: Independent sample t-test for adipose tissue and vein tissue 
 
 
 
 
Independent Samples Test
.222 .640 12.562 38 .000 6.55821 .52205 5.50138 7.61504
12.562 37.354 .000 6.55821 .52205 5.50078 7.61564
Equal variances
assumed
Equal variances
not assumed
LN_norm_conc_ratio
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
 
Table_Apx C-28: Independent sample t-test for adipose tissue and muscle tissue 
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Independent Samples Test
4.352 .044 -.087 39 .931 -.03078 .35311 -.74501 .68345
-.086 33.264 .932 -.03078 .35638 -.75563 .69406
Equal variances
assumed
Equal variances
not assumed
LN_norm_conc_ratio
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
 
Table_Apx C-29: Independent sample t-test for vein tissue and leukocytes 
 
 
 
Independent Samples Test
1.636 .208 7.909 39 .000 3.42382 .43292 2.54816 4.29949
7.794 28.070 .000 3.42382 .43928 2.52411 4.32354
Equal variances
assumed
Equal variances
not assumed
LN_norm_conc_ratio
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
 
Table_Apx C-30: Independent sample t-test for leukocytes and muscle 
 
 
Independent Samples Test
.001 .972 7.016 38 .000 3.45461 .49237 2.45785 4.45136
7.016 35.381 .000 3.45461 .49237 2.45542 4.45379
Equal variances
assumed
Equal variances
not assumed
LN_norm_conc_ratio
F Sig.
Levene's Test for
Equality of Variances
t df Sig. (2-tailed)
Mean
Difference
Std. Error
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
 
Table_Apx C-31: Independent sample t-test for vein tissue and muscle 
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k:  Wilcoxon Signed Ranks Test 
 
  Test Statistics(c) 
 
   leuko - fat  vein - fat  muscle - fat  vein - leuko 
muscle - 
leuko  muscle - vein 
Z  -3.980(a)  -3.980(a)  -3.980(a)  -.365(b)  -4.015(a)  -3.980(a) 
Asymp. Sig. (2-tailed)  .000  .000  .000  .715  .000  .000 
a  Based on positive ranks. 
b  Based on negative ranks. 
c  Wilcoxon Signed Ranks Test 
 
Table_Apx C-32: Wilcox signed rank test for paired tissue samples IL6 expression patterns 
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l:  Genotyping Data G-174C: 
  AN 001 
AN001 
1 
 AN001 
2  AN 001 4  Array num 
?T21  G/C  G/C  G/C  G/C  AN001H05 
?T27  Unk  G/C  G/C  G/C  AN001H04 
blank  Unk  Unk  Unk  Unk  AN001A01 
blank  Unk  Unk  Unk  Unk  AN001B01 
blank  Unk  Unk  Unk  Unk  AN001C05 
blank  Unk  Unk  Unk  Unk  AN001D05 
blank  Unk  Unk  Unk  Unk  AN001F07 
blank  Unk  Unk  Unk  Unk  AN001G07 
blank  Unk  Unk  Unk  Unk  AN001H07 
C24  G/G  G/G  Unk  G/G  AN001C07 
C26  G/C  Unk  G/C  G/C  AN001D07 
C27  C/C  Unk  C/C  Unk  AN001E07 
neg control  Unk  Unk  Unk  Unk  AN001A07 
neg control  Unk  Unk  Unk  Unk  AN001B07 
T02  Unk  G/C  G/C  G/C  AN001H06 
T03  G/C  Unk  G/C  G/C  AN001F01 
T04  Unk  Unk  C/C  C/C  AN001A05 
T05  G/G  G/G  G/G  G/G  AN001B02 
T06  G/G  G/G  G/G  Unk  AN001F05 
T07  C/C  C/C  C/C  C/C  AN001D06 
T08  Unk  G/C  G/C  G/C  AN001G01 
T09  G/C  G/C  G/C  G/C  AN001B05 
T10  Unk  C/C  C/C  C/C  AN001A02 
T11  Unk  G/C  Unk  G/C  AN001C04 
T12  G/C  G/C  G/C  Unk  AN001C03 
T13  G/C  Unk  G/C  G/C  AN001A03 
T14  G/G  Unk  G/G  G/G  AN001E06 
T15  G/G  G/G  Unk  G/G  AN001D04 
T16  G/G  G/G  G/G  G/G  AN001C06 
T17  G/C  G/C  G/C  Unk  AN001A06 
T18  Unk  C/C  C/C  C/C  AN001A04 
T19  G/G  G/G  G/G  G/G  AN001E01 
T20  G/C  G/C  G/C  G/C  AN001E02 
T22  Unk  Unk  G/C  G/C  AN001D03 
T23  G/G  G/G  G/G  G/G  AN001B06 
T24  G/G  Unk  G/G  G/G  AN001B04 
T25  G/G  G/G  Unk  G/G  AN001E04 
T26  G/C  Unk  G/C  Unk  AN001F06 
T28  G/C  G/C  G/C  G/C  AN001G05 
T29  C/C  C/C  C/C  C/C  AN001H03 
T30  C/C  C/C  C/C  C/C  AN001E05 
T31  G/G  G/G  G/G  G/G  AN001F02 
T32  Unk  G/G  G/G  Unk  AN001G06 
T34  G/G  G/G  G/G  G/C  AN001H02 
T35  G/G  G/G  G/G  G/G  AN001C01 
T36  G/G  G/G  G/G  G/G  AN001G04   228 
T37  G/C  G/C  G/C  G/C  AN001D01 
T38  G/G  G/G  G/G  G/G  AN001F03 
T41  G/C  G/C  G/C  G/C  AN001G02 
T42  C/C  C/C  C/C  C/C  AN001F04 
T43  G/C  G/C  G/C  G/C  AN001H01 
T44  G/C  G/C  G/C  G/C  AN001B03 
T45  G/G  G/G  G/G  G/G  AN001E03 
T46  G/C  G/C  G/C  G/C  AN001C02 
T47  G/G  G/G  G/G  G/G  AN001D02 
T48  G/G  G/G  G/G  G/G  AN001G03 
 
Table_Apx C-33: Genotyping data for SNP G-174C 
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m:  Results of Real Time PCR 
 
 
Fat 
Cp 
Median 
Concentration 
Ratio 
Concentration 
Ratio STD 
Normalized 
Ratio 
Normalized 
Ratio STD 
male=1/ 
female=2 
non 
smoker=1 
smoker=2  Genotype 
TIG 002  27.55  48.61  1.44  1.28E+02  40.41  2  1  G/C 
TIG 003  32.96  12.73  1.36  33.44  11.13  2  2  G/C 
TIG 004  37.23  1.49  0.12  3.91  1.27  2  1  C/C 
TIG 005  30.07  12.27  0.56  32.24  10.26  2  ?  G/G 
TIG 006  33.8  0.43  0.02  1.12  0.36  2  1  G/G 
TIG 007  26.14  2.55E+02  31.92  6.71E+02  2.28E+02  1  2  C/C 
TIG 008    Invalid  Invalid  Invalid  Invalid  1  1  G/C 
TIG 009  27.63  1.27E+03  44.31  3.35E+03  1.06E+03  2  2  G/C 
TIG 010  29.89  5.67  0.43  14.9  4.83  2  1  C/C 
TIG 011    Invalid  Invalid  Invalid  Invalid  2  1  G/C 
TIG 012    Invalid  Invalid  Invalid  Invalid  1  1  G/C 
TIG 013  34.74  2.47  1.1  6.5  3.58  2  2  G/C 
TIG 014  32.57  0.95  0.11  2.49  0.84  2  1  G/G 
TIG 015  26.37  41.13  15.03  1.08E+02  52.46  2  1  G/G 
TIG 016  29.27  40.46  4.96  1.06E+02  35.98  2  1  G/G 
TIG 017  29.16  37.35  6.55  98.16  35.47  2  2  G/C 
TIG 018  30.45  1.15E+02  21.43  3.03E+02  1.11E+02  1  2  C/C 
TIG 019  32.06  5.03  0.35  13.23  4.27  1  2  G/G 
TIG 020    Invalid  Invalid  Invalid  Invalid  2  2  G/C 
TIG 021  31.6  1.05E+02  56.31  2.77E+02  1.73E+02  2  1    
TIG 022  35.22  1.15  0.21  3.03  1.11  2  1  G/C 
TIG 024  30.27  14.62  1.18  38.42  12.5  1  1  G/G 
TIG 025  33.81  2.35  0.05  6.17  1.95  2  1  G/G 
TIG 026  33.62  4.56  1.13  11.97  4.82  2  1   G/C 
TIG 028  30.85  66.15  4.03  1.74E+02  55.75  1  1  G/C 
TIG 029  32.59  10.51  0.43  27.61  8.77  1  1  C/C 
TIG 030  32.63  8.31  1.82  21.85  8.41  2  1  C/C 
TIG 031  34.83  0.91  0.38  2.38  1.25  2  1  G/G 
TIG 032  33.39  4.99  1.19  13.13  5.2  2  1  G/G 
TIG 034  32.5  4.25  0.55  11.16  3.81  1  1  G/G 
TIG 035  33.47  2.21  0.53  5.8  2.3  1  1  G/G 
TIG 036  31.36  6.33  2.73  16.63  8.94  1  2  G/G 
TIG 037  34.09  1.75  0.14  4.6  1.5  2  1  G/C 
TIG 038  34.2  21.84  10.83  57.38  33.97  2  1  G/G 
TIG 041  32.36  5.73  1.82  15.07  6.77  1  1  G/C 
TIG 042    Invalid  Invalid  Invalid  Invalid  2  2  C/C 
TIG 043  36.61  0.95  0.24  2.48  1  2  1  G/C 
TIG 044     0  0  0  0  1  1   G/C 
TIG 045    Invalid  Invalid  Invalid  Invalid  1  1  G/G 
TIG 046     0  0  0  0  2  1  G/C 
TIG 047     0  0  0  0  1  1  G/G   230 
TIG 048   33.45  4.5  1.94  11.84  6.37  2  1  G/G 
TIG 057    Invalid  Invalid  Invalid  Invalid  1  2    
TIG 061     Invalid  Invalid  Invalid  Invalid  2  2    
Table_Apx C-34: Results of real time PCR for fat tissue 
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Leukocytes 
Cp 
Median 
Concentration 
Ratio 
Concentration 
Ratio STD 
Normalized 
Ratio 
Normalized 
Ratio STD 
male=1/ 
female=2 
non 
smoker=1 
smoker=2  Genotype 
TIG 008  34.24  0.39  0.01  0.54  0.05  1  1  G/C 
TIG 009  31.79  9.64  0.23  13.42  1.22  2  2  G/C 
TIG 010  33.07  1.07  0.09  1.49  0.18  2  1  C/C 
TIG 011  33.42  0.44  0.08  0.62  0.11  2  1  G/C 
TIG 012  32.93  [0.51  0.02  0.71  0.07  1  1  G/C 
TIG 013    Invalid  Invalid  Invalid  Invalid  2  2  G/C 
TIG 014  33.7  0.55  0.12  0.76  0.16  2  1  G/G 
TIG 015  32.53  1.3  0.28  1.81  0.39  2  1  G/G 
TIG 016  33.52  0.77  0.00673  1.07  0.09  2  1  G/G 
TIG 017  32.86  0.52  0.1  0.72  0.14  2  2  G/C 
TIG 018  34.61  4.39  0.09  6.11  0.55  1  2  C/C 
TIG 019  34.03  0.29  0.05  0.4  0.07  1  2  G/G 
TIG 020  33.49  0.59  0.11  0.82  0.15  2  2  G/C 
TIG 021  33.15  7.43  0.31  10.35  1  2  1    
TIG 022  33.51  0.6  0.1  0.83  0.15  2  1  G/C 
TIG 023    Invalid  Invalid  Invalid  Invalid  2  1  G/G 
TIG 024  33.08  0.33  0.09  0.47  0.13  1  1  G/G 
TIG 025  33.77  0.99  0.07  1.37  0.15  2  1  G/G 
TIG 026    Invalid  Invalid  Invalid  Invalid  2  1   G/C 
TIG 027    Invalid  Invalid  Invalid  Invalid  2  1    
TIG 028  34.48  0.33  6.64E-03  0.46  0.04  1  1  G/C 
TIG 029  32.93  0.59  0.07  0.83  0.11  1  1  C/C 
TIG 030  33  1.09  0.02  1.52  0.14  2  1  C/C 
TIG 031  34  0.43  0.01  0.6  0.05  2  1  G/G 
TIG 032  32.97  0.39  0.06  0.55  0.08  2  1  G/G 
TIG 033  35.1  0.22  0.24  0.31  0.3  2  1    
TIG 034  32.69  1.1  0.1  1.53  0.19  1  1  G/G 
TIG 035  33.04  0.64  0.17  0.9  0.22  1  1  G/G 
TIG 036  33.61  0.48  0.01  0.66  0.06  1  2  G/G 
TIG 037  33.54  0.46  0.09  0.64  0.13  2  1  G/C 
TIG 038  35.22  0.17  0.18  0.24  0.22  2  1  G/G 
TIG 039  33.49  0.68  0.01  0.95  0.09  2  1    
TIG 040  33.36  1.03  0.11  1.43  0.18  2  1    
TIG 041  33.92  0.25  0.05  0.35  0.07  1  1  G/C 
TIG 042  32.91  1.4  0.08  1.95  0.2  2  2  C/C 
TIG 043  33.54  0.61  0.01  0.85  0.08  2  1  G/C 
TIG 044  31.45  6.31  0.58  8.78  1.07  1  1   G/C 
TIG 045  34.66  0.38  0.06  0.53  0.09  1  1  G/G 
TIG 046  32.16  0.31  0.02  0.43  0.05  2  1  G/C 
TIG 047     Invalid  Invalid  Invalid  Invalid  1  1  G/G 
Table_Apx C-35: Results of real time PCR for leukocytes 
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vein  Cp Median 
Concentration 
Ratio 
Concentratio
n Ratio STD 
Normalized 
Ratio 
Normalized 
Ratio STD 
male=1/ 
female=2 
non 
smoker=1 
smoker=2  Genotype 
TIG 002  33.58 0.15 0.26 0.15  0.29  2 1 G/C 
TIG 003  33.54 0.73 0.03 0.73  0.3  2 2 G/C 
TIG 004  37.52 0.43 0.15 0.43  0.37  2 1 C/C 
TIG 005  32.31 1.46 0.47 1.46  0.77  2 ? G/G 
TIG 006  33.88 0.48 0.36 0.48  0.43  2 1 G/G 
TIG 007  32.7 4.69 0.49 4.69  1.97  1 2 C/C 
TIG 008  34.83 0.66 0.15 0.66  0.31  1 1 G/C 
TIG 009  33.74 8.86 1.06 8.87  3.75  2 2 G/C 
TIG 010  33.51 0.4 0.08 0.4  0.18  2 1 C/C 
TIG 011  34.75 0.32 0.18 0.32  0.23  2 1 G/C 
TIG 012  0 0 0  0  1 1 G/C 
TIG 013  34.26 0.21 0.34 0.21  0.37  2 2 G/C 
TIG 014  32.53 0.24 0.2 0.24  0.24  2 1 G/G 
TIG 015  34.08 7.56 1.14 7.56  3.29  2 1 G/G 
TIG 016  35.79 0.83 0.23 0.83  0.42  2 1 G/G 
TIG 017  32.9 0.82 0.17 0.82  0.38  2 2 G/C 
TIG 018  33.06 15.52 17.88 15.52  20.28  1 2 C/C 
TIG 019  30.18 5.21 0.28 5.21  2.12  1 2 G/G 
TIG 020  33.32 0.26 0.06 0.26  0.12  2 2 G/C 
TIG 021  34.73 3.66 1.87 3.66  2.5  2 1   
TIG 022  0 0 0  0  2 1 G/C 
TIG 023  34.39 0.67 0.21 0.67  0.35  2 1 G/G 
TIG 024  33 0.38 0.03 0.38  0.16  1 1 G/G 
TIG 025  31.47 1.63 1.09 1.63  1.35  2 1 G/G 
TIG 026  34.34 0.29 0.05 0.29  0.13  2 1  G/C 
TIG 028  31.62 0.66 0.01 0.66  0.27  1 1 G/C 
TIG 029  33.43 0.23 0.41 0.24  0.45  1 1 C/C 
TIG 030  32.71 4.34 0.23 4.34  1.77  2 1 C/C 
TIG 031  36.96 1.28 0.12 1.28  0.53  2 1 G/G 
TIG 032  Invalid Invalid Invalid  Invalid  2 1 G/G 
TIG 034  33.57 0.22 0.32 0.22  0.35  1 1 G/G 
TIG 035  39.18 1.65 5.57 1.65  6.12  1 1 G/G 
TIG 036  32.4 0.64 0.07 0.64  0.27  1 2 G/G 
TIG 037  33.09 0.16 0.07 0.16  0.1  2 1 G/C 
TIG 038  0 0 0  0  2 1 G/G 
TIG 041  33.41 0.23 0.05 0.23  0.11  1 1 G/C 
TIG 042  33.16 2.81 1.13 2.81  1.67  2 2 C/C 
TIG 043  33.23 0.41 0.04 0.41  0.17  2 1 G/C 
TIG 044  32.23 4.53 1.14 4.54  2.21  1 1  G/C 
TIG 045  36.11 0.7 0.21 0.7  0.37  1 1 G/G 
TIG 046  31.53 0.9 0.15 0.9  0.4  2 1 G/C 
TIG 047  0 0 0  0  1 1 G/G 
TIG 048   Invalid Invalid Invalid  Invalid  2 1 G/G   233 
TIG 057  Invalid Invalid Invalid  Invalid  1 2   
TIG 061  0 0 0  0  2 2   
  
Table_Apx C-36: Results of real time PCR for vein tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   234 
muscle 
Cp 
Median 
Concentration 
Ratio 
Concentration 
Ratio STD 
Normalized 
Ratio 
Normalized 
Ratio STD 
male=1/ 
female=2 
non  
smoker=1 
smoker=2  Genotype 
TIG 002  32.88  0.03  0.02  0.05  0.03  2  1  G/C 
TIG 003  35.64  0.02  6.83E-03  0.04  0.02  2  2  G/C 
TIG 004  34.02  0.02  0.01  0.03  0.02  2  1  C/C 
TIG 005  33.44  0.02  1.96E-03  0.03  0.01  2  ?  G/G 
TIG 008  38.24  0.01  1.01E-03  0.02  5.32E-03  1  1  G/C 
TIG 009  33.51  0.27  0.09  0.41  0.19  2  2  G/C 
TIG 010  36.02  7.60E-03  4.03E-03  0.01  7.35E-03  2  1  C/C 
TIG 011  35.17  4.62E-03  1.28E-03  7.11E-03  3.07E-03  2  1  G/C 
TIG 012  35.81  0.11  0.03  0.16  0.07  1  1  G/C 
TIG 013  33.74  0.03  6.23E-04  0.05  0.02  2  2  G/C 
TIG 014  39.45  9.23E-05  5.47E-03  1.42E-04  8.57E-03  2  1  G/G 
TIG 015  35.76  0.02  6.37E-03  0.03  0.01  2  1  G/G 
TIG 016    Invalid  Invalid  Invalid  Invalid  2  1  G/G 
TIG 017  35.39  0.01  2.13E-03  0.02  6.59E-03  2  2  G/C 
TIG 018  35.27  0.47  0.13  0.72  0.31  1  2  C/C 
TIG 019  32.69  0.06  7.09E-03  0.09  0.03  1  2  G/G 
TIG 020  35.71  8.91E-03  4.02E-03  0.01  7.69E-03  2  2  G/C 
TIG 021  36.76  0.47  0.06  0.72  0.25  2  1    
TIG 022  28.46  37.12  2.72E+04  57.07  4.27E+04  2  1  G/C 
TIG 023  33.71  0.03  2.86E-03  0.05  0.02  2  1  G/G 
TIG 024  32.77  0.03  3.52E-03  0.04  0.01  1  1  G/G 
TIG 025  35.09  0.02  5.48E-03  0.04  0.01  2  1  G/G 
TIG 026  35.53  0.01  0.01  0.02  0.02  2  1   G/C 
TIG 028  34.5  0.01  4.65E-04  0.02  7.41E-03  1  1  G/C 
TIG 029  33.68  0.02  1.61E-03  0.04  0.01  1  1  C/C 
TIG 030  34.44  0.05  0.01  0.08  0.03  2  1  C/C 
TIG 031  34.67  0.01  6.01E-03  0.02  0.01  2  1  G/G 
TIG 032  34.24  9.48E-03  7.18E-04  0.01  4.90E-03  2  1  G/G 
TIG 034     0  0  0  0  1  1  G/G 
TIG 035  38.63  3.15E-03  8.88E-03  4.84E-03  0.01  1  1  G/G 
TIG 036  35.57  0.03  1.67E-03  0.04  0.01  1  2  G/G 
TIG 037  34.9  5.13E-03  7.10E-04  7.89E-03  2.81E-03  2  1  G/C 
TIG 038  35.77  0.03  3.01E-03  0.04  0.01  2  1  G/G 
TIG 041  34.32  0.02  4.98E-03  0.03  0.01  1  1  G/C 
TIG 042  39.23  0.03  0.05  0.05  0.09  2  2  C/C 
TIG 043  34.48  0.03  6.30E-03  0.05  0.02  2  1  G/C 
TIG 045  36.15  1.2  0.62  1.85  1.14  1  1  G/G 
TIG 046  32.71  0.03  2.23E-03  0.04  0.01  2  1  G/C 
TIG 047    Invalid  Invalid  Invalid  Invalid  1  1  G/G 
TIG 048   38.01  0.01  3.51E-03  0.02  8.82E-03  2  1  G/G 
TIG 057     0  0  0  0  1  2    
TIG 061  38.55  8.47E-04  1.94E-03  1.30E-03  3.06E-03  2  2    
 
Table_Apx C-37: Results of real time PCR for muscle tissue   235 
n:  Allelic Transcription Assay 
 
  Standard curve PCR 1: 
PCR 1     Band A  Band B  B/(299/418*A+B) 
(known 
conc.ratio)^2 
mean of 
EB,dest1,dest2 
first loading on gel:                   
ethidium bromide  Lane 2  2039.23  77265.87  0.98       
de-stained once  Lane 2  1309.48  76103.36  0.99       
de-stained twice  Lane 2  316.29  32311.19  0.99  1  0.99 
ethidium bromide  Lane 3  26840.84  106200.85  0.85       
de-stained once  Lane 3  24460.38  107722.42  0.86       
de-stained twice  Lane 3  8974.27  52404.77  0.89  0.81  0.87 
ethidium bromide  Lane 4  29449.31  43569.3  0.67       
de-stained once  Lane 4  30627.02  54617.34  0.71       
ethidium bromide  Lane 4  11702.03  29059.66  0.78  0.64  0.72 
de-stained once  Lane 5  60774.75  54289.95  0.56       
de-stained twice  Lane 5  59405.07  58857.77  0.58       
ethidium bromide  Lane 5  26739.63  46051.37  0.71  0.49  0.61 
de-stained once  Lane 6  57959.81  34669.09  0.46       
de-stained twice  Lane 6  62154.1  32861.46  0.43       
ethidium bromide  Lane 6  29483.83  29979.32  0.59  0.36  0.49 
de-stained once  Lane 7  101804.39  37501.19  0.34       
ethidium bromide  Lane 7  102687.41  39602.1  0.35       
de-stained once  Lane 7  56904.16  37325.69  0.48  0.25  0.39 
de-stained twice  Lane 8  91038.18  20503.09  0.24       
ethidium bromide  Lane 8  101953.92  22704.15  0.24       
de-stained once  Lane 8  64020.28  22747.94  0.33  0.16  0.27 
de-stained twice  Lane 9  124815.57  19089.61  0.18       
ethidium bromide  Lane 9  133791.96  18181.14  0.16       
de-stained once  Lane 9  88195.23  20781.16  0.25  0.09  0.19 
ethidium bromide  Lane 10  102398.45  5493.37  0.07       
de-stained once  Lane 10  110426.45  7172.98  0.08       
de-stained twice  Lane 10  69778.17  7578.57  0.13  0.04  0.09 
ethidium bromide  Lane 11  115782.33  1698.9  0.02       
de-stained once  Lane 11  121769.75  1823.19  0.02       
de-stained twice  Lane 11  75570.33  4602.81  0.08  0.01  0.04 
ethidium bromide  Lane 12  103060.94  0  0.00       
de-stained once  Lane 12  119541.1  495.36  0.01       
de-stained twice  Lane 12  66753.7  373.59  0.01  0  0.00 
second loading on gel:                
ethidium bromide  Lane 2  853.09  59730.38  0.99       
de-stained once  Lane 2  978.29  68732.07  0.99       
de-stained twice  Lane 2  472.53  56281.61  0.99  1  0.99 
ethidium bromide  Lane 3  19790.45  86299.99  0.86       
de-stained once  Lane 3  18868.45  91972.66  0.87       
de-stained twice  Lane 3  6773.92  71294.63  0.94  0.81  0.89 
ethidium bromide  Lane 4  29980.47  41495.61  0.66       
de-stained once  Lane 4  22088.63  42657.52  0.73       
de-stained twice  Lane 4  7876.87  26878.38  0.83  0.64  0.74 
ethidium bromide  Lane 5  49352.56  37440.65  0.51       
de-stained once  Lane 5  29257.03  40880.85  0.66         236 
de-stained twice  Lane 5  12077.11  22310.29  0.72  0.49  0.63 
ethidium bromide  Lane 6  55778.07  28574.45  0.42       
de-stained once  Lane 6  37844.67  29593.05  0.52       
de-stained twice  Lane 6  14848.89  10929.49  0.51  0.36  0.48 
ethidium bromide  Lane 7  65951.52  24510.37  0.34       
de-stained once  Lane 7  42963.76  28466.78  0.48       
de-stained twice  Lane 7  18956.66  8566.64  0.39  0.25  0.40 
ethidium bromide  Lane 8  153510.65  19054.09  0.15       
de-stained once  Lane 8  119455.2  17939.68  0.17       
de-stained twice  Lane 8  70265.19  18221.44  0.27  0.16  0.20 
ethidium bromide  Lane 9  93433.98  12004.17  0.15       
de-stained once  Lane 9  53951.64  7058.5  0.15       
de-stained twice  Lane 9  22843.81  3173.5  0.16  0.09  0.16 
ethidium bromide  Lane 10  98360.57  6581.19  0.09       
de-stained once  Lane 10  55418.19  4700.13  0.11       
de-stained twice  Lane 10  24197.51  1673.17  0.09  0.04  0.09 
ethidium bromide  Lane 11  109613.21  1129.66  0.01       
de-stained once  Lane 11  56073.09  1396.17  0.03       
de-stained twice  Lane 11  25231.28  836.17  0.04  0.01  0.03 
ethidium bromide  Lane 12  121147.88  32.07  0.00       
de-stained once  Lane 12  65477.08  168.24  0.00       
de-stained twice  Lane 12  26933.68  102.92  0.01  0  0.00 
third loading on gel:                   
ethidium bromide  Lane 16  1316.01  55129.15  0.98       
de-stained once  Lane 16  499.25  62645.53  0.99       
de-stained twice  Lane 16  2372.32  63191.61  0.97  1  0.98 
ethidium bromide  Lane 17  22684.98  95684.59  0.86       
de-stained once  Lane 17  25615.66  112014.51  0.86       
de-stained twice  Lane 17  29253.65  112868.59  0.84  0.81  0.85 
ethidium bromide  Lane 18  24601.79  38122.46  0.68       
de-stained once  Lane 18  37856.49  41700.8  0.61       
de-stained twice  Lane 18  29221.01  39812.76  0.66  0.64  0.65 
ethidium bromide  Lane 19  45095.29  42356.85  0.57       
de-stained once  Lane 19  52354.62  45619.35  0.55       
de-stained twice  Lane 19  52133.6  47736.17  0.56  0.49  0.56 
ethidium bromide  Lane 20  48688.31  26621.55  0.43       
de-stained once  Lane 20  54234.93  29057.39  0.43       
de-stained twice  Lane 20  55557.71  32166.93  0.45  0.36  0.44 
ethidium bromide  Lane 21  59432.22  21969.59  0.34       
de-stained once  Lane 21  68541.4  24470.38  0.33       
de-stained twice  Lane 21  68053.38  23197.95  0.32  0.25  0.33 
ethidium bromide  Lane 22  68087.14  15949.96  0.25       
de-stained once  Lane 22  75783.93  16437.58  0.23       
de-stained twice  Lane 22  80370.08  18934.77  0.25  0.16  0.24 
ethidium bromide  Lane 23  76500.49  11858.55  0.18       
de-stained once  Lane 23  89272.39  15346.69  0.19       
de-stained twice  Lane 23  93069.53  14382.95  0.18  0.09  0.18 
ethidium bromide  Lane 24  79924.13  6922.65  0.11       
de-stained once  Lane 24  95172.2  4315.83  0.06       
de-stained twice  Lane 24  101257.17  5391.12  0.07  0.04  0.08 
ethidium bromide  Lane 25  74755.39  558.26  0.01         237 
de-stained once  Lane 25  88353.62  1039.06  0.02       
de-stained twice  Lane 25  95743.37  1226.82  0.02  0.01  0.01 
ethidium bromide  Lane 26  79397.81  815.69  0.01       
de-stained once  Lane 26  92457.01  0  0.00       
de-stained twice  Lane 26  95885.41  0  0.00  0  0.00 
 
Table_Apx C-38: Results for standard curve PCR 1 -  ratiometric analysis 
 
 
 
  Standard Curve PCR 2 
PCR 2     Band A  Band B  B/(299/418*A+B) 
(known 
conc.ratio)^2 
mean of 
EB,dest1,dest2 
first loading on gel:               
ethidium bromide  Lane 2  911.85  21986.43  0.97       
de-stained once  Lane 2  309.05  13134.68  0.98       
de-stained twice  Lane 2  598.53  5667.54  0.93  1  0.96 
ethidium bromide  Lane 3  6413.89  30871.11  0.87       
de-stained once  Lane 3  1870.77  13025.28  0.91       
de-stained twice  Lane 3  668.47  1702.64  0.78  0.81  0.85 
ethidium bromide  Lane 4  7790.02  13690.05  0.71       
de-stained once  Lane 4  1658.45  7236.03  0.86       
de-stained twice  Lane 4  800.46  1133.57  0.66  0.64  0.74 
ethidium bromide  Lane 5  11421.7  6378.88  0.44       
de-stained once  Lane 5  2959.63  6103.38  0.74       
de-stained twice  Lane 5  856.77  853.49  0.58  0.49  0.59 
ethidium bromide  Lane 6  16452.34  8590.28  0.42       
de-stained once  Lane 6  3838.33  6092.77  0.69       
de-stained twice  Lane 6  895.76  971.37  0.60  0.36  0.57 
ethidium bromide  Lane 7  49562.47  17044.8  0.32       
de-stained once  Lane 7  12279.07  11044.25  0.56       
de-stained twice  Lane 7  3841.23  1486.64  0.35  0.25  0.41 
ethidium bromide  Lane 8  27377.93  4978.66  0.20       
de-stained once  Lane 8  6579.27  3307.46  0.41       
de-stained twice  Lane 8  1924.93  212.59  0.13  0.16  0.25 
ethidium bromide  Lane 9  41395.98  5010.03  0.14       
de-stained once  Lane 9  12105.66  3840.98  0.31       
de-stained twice  Lane 9  2219.44  1003.79  0.39  0.09  0.28 
ethidium bromide  Lane 10  41153.1  30132.76  0.51       
de-stained once  Lane 10  12204.9  44566.74  0.84       
de-stained twice  Lane 10  2064.59  469.97  0.24  0.04  0.53 
ethidium bromide  Lane 11  36141.24  785.9  0.03       
de-stained once  Lane 11  14547.93  1190.28  0.10       
de-stained twice  Lane 11  2895.67  768.18  0.27  0.01  0.13 
ethidium bromide  Lane 12  67726.28  44.35  0.00       
de-stained once  Lane 12  16616.39  3761.15  0.24       
de-stained twice  Lane 12  2699.95  725.49  0.27  0  0.17 
second loading on gel:                   
ethidium bromide  Lane 16  236.34  33810.8  1.00       
de-stained once  Lane 16  199.68  38825.99  1.00         238 
de-stained twice  Lane 16  626.8  14385.79  0.97  1  0.99 
ethidium bromide  Lane 17  10674.18  45825.14  0.86       
de-stained once  Lane 17  11268.83  49854.73  0.86       
de-stained twice  Lane 17  4032.55  17293.26  0.86  0.81  0.86 
ethidium bromide  Lane 18  9965.25  20788.58  0.74       
de-stained once  Lane 18  11520.21  19552.93  0.70       
de-stained twice  Lane 18  4070.93  6584.38  0.69  0.64  0.71 
ethidium bromide  Lane 19  13657.6  14668.97  0.60       
de-stained once  Lane 19  15865.87  18301.47  0.62       
de-stained twice  Lane 19  5773.5  4885.85  0.54  0.49  0.59 
ethidium bromide  Lane 20  21933.63  11690.69  0.43       
de-stained once  Lane 20  24433.54  13306.76  0.43       
de-stained twice  Lane 20  7261.87  3415.41  0.40  0.36  0.42 
ethidium bromide  Lane 21  59140.24  20723.19  0.33       
de-stained once  Lane 21  69776.46  25316.13  0.34       
de-stained twice  Lane 21  24382.52  8100.69  0.32  0.25  0.33 
ethidium bromide  Lane 22  23213.7  5182.27  0.24       
de-stained once  Lane 22  31264.29  6025.65  0.21       
de-stained twice  Lane 22  13105.16  3723.11  0.28  0.16  0.24 
ethidium bromide  Lane 23  59435.87  8739.24  0.17       
de-stained once  Lane 23  66949.2  9724.34  0.17       
de-stained twice  Lane 23  24753.37  3710.71  0.17  0.09  0.17 
ethidium bromide  Lane 24  50458.19  3272.07  0.08       
de-stained once  Lane 24  55886.86  3033.58  0.07       
de-stained twice  Lane 24  23718.39  1177.8  0.06  0.04  0.07 
ethidium bromide  Lane 25  47338.25  797.61  0.02       
de-stained once  Lane 25  52210.23  1582.68  0.04       
de-stained twice  Lane 25  20707.04  765.46  0.05  0.01  0.04 
ethidium bromide  Lane 26  49628.57  90.08  0.00       
de-stained once  Lane 26  55784.98  416.54  0.01       
de-stained twice  Lane 26  20982.37  0  0.00  0  0.00 
 
Table_Apx C-39: Results for standard curve PCR 2 -  ratiometric analysis 
 
   
   
  Standard Curve PCR 3 
PCR 3A     Band A  Band B  B/(299/418*A+B) 
(known 
conc.ratio)^2 
mean of 
EB,dest1,dest2 
first loading on gel:                   
ethidium bromide  Lane 2  97.53  27879.61  1.00       
de-stained once  Lane 2  35.15  4705.66  0.99       
de-stained twice  Lane 2  90.58  2560.49  0.98  1  0.99 
ethidium bromide  Lane 3  8403.45  38072.74  0.86       
de-stained once  Lane 3  1337.46  6241.01  0.87       
de-stained twice  Lane 3  883.35  3242.21  0.84  0.81  0.86 
ethidium bromide  Lane 4  3317.82  7324.52  0.76       
de-stained once  Lane 4  400.02  678.62  0.70       
de-stained twice  Lane 4  298.81  400.76  0.65  0.64  0.70 
ethidium bromide  Lane 5  3496.94  4740.78  0.65         239 
de-stained once  Lane 5  364.26  779.71  0.75       
de-stained twice  Lane 5  407.64  649.55  0.69  0.49  0.70 
ethidium bromide  Lane 6  37329.76  23764.25  0.47       
de-stained once  Lane 6  5820.6  4343.36  0.51       
de-stained twice  Lane 6  3550.88  2477.85  0.49  0.36  0.49 
ethidium bromide  Lane 7  37108.35  13492.46  0.34       
de-stained once  Lane 7  5909.37  2188.87  0.34       
de-stained twice  Lane 7  3411.16  1301.84  0.35  0.25  0.34 
ethidium bromide  Lane 8             
de-stained once  Lane 8             
de-stained twice  Lane 8        0.16    
ethidium bromide  Lane 9  49720.39  5813.29  0.14       
de-stained once  Lane 9  8094.35  1091.43  0.16       
de-stained twice  Lane 9  4358.86  1069.85  0.26  0.09  0.18 
ethidium bromide  Lane 10  57733.08  3006.47  0.07       
de-stained once  Lane 10  9631.57  1204.35  0.15       
de-stained twice  Lane 10  5425.11  493.76  0.11  0.04  0.11 
ethidium bromide  Lane 11  32774.06  1079.44  0.04       
de-stained once  Lane 11  6312.4  1224.29  0.21       
de-stained twice  Lane 11  3494.13  980.55  0.28  0.01  0.18 
ethidium bromide  Lane 12  37780.67  0  0.00       
de-stained once  Lane 12  5964.01  170.66  0.04       
de-stained twice  Lane 12  3484.98  245.15  0.09  0  0.04 
second loading on gel:                   
ethidium bromide  Lane 2  0  6957.65  1.00       
de-stained once  Lane 2  0  6608.78  1.00       
de-stained twice  Lane 2  0  4485.14  1.00  1  1.00 
ethidium bromide  Lane 3  222.68  1424.54  0.90       
de-stained once  Lane 3  34.3  1019.88  0.98       
de-stained twice  Lane 3  261.74  553.32  0.75  0.81  0.87 
ethidium bromide  Lane 4  782.7  1638.24  0.75       
de-stained once  Lane 4             
de-stained twice  Lane 4        0.64  0.75 
ethidium bromide  Lane 5  1747.97  1937.36  0.61       
de-stained once  Lane 5  350.04  1000.2  0.80       
de-stained twice  Lane 5        0.49  0.70 
ethidium bromide  Lane 6  8444.5  5572.87  0.48       
de-stained once  Lane 6  2268.33  2746  0.63       
de-stained twice  Lane 6  1179.14  778.93  0.48  0.36  0.53 
ethidium bromide  Lane 7  10995.7  3479.66  0.31       
de-stained once  Lane 7  2373.09  1371.91  0.45       
de-stained twice  Lane 7  890.18  459.49  0.42  0.25  0.39 
ethidium bromide  Lane 8             
de-stained once  Lane 8             
de-stained twice  Lane 8        0.16   
ethidium bromide  Lane 9  14579.75  1460.95  0.12       
de-stained once  Lane 9  4009.85  1694.83  0.37       
de-stained twice  Lane 9  1400.97  353.45  0.26  0.09  0.25 
ethidium bromide  Lane 10  16969.15  869.03  0.07       
de-stained once  Lane 10  4422.72  652.27  0.17       
de-stained twice  Lane 10  2216.34  519.97  0.25  0.04  0.16   240 
ethidium bromide  Lane 11  12832.31  120.27  0.01       
de-stained once  Lane 11  2504.79  158.86  0.08       
de-stained twice  Lane 11        0.01  0.05 
ethidium bromide  Lane 12  13814.44  5.24  0.00       
de-stained once  Lane 12  4464.15  60.26  0.02       
de-stained twice  Lane 12  3225.47  598.57  0.21  0  0.08 
third loading on gel:               
ethidium bromide  Lane 16  175.26  9882.17  0.99       
de-stained once  Lane 16  258.76  13053.29  0.99       
de-stained twice  Lane 16  184.31  12149.62  0.99  1  0.99 
ethidium bromide  Lane 17  2542.1  9076.21  0.83       
de-stained once  Lane 17  3721.13  11984.1  0.82       
de-stained twice  Lane 17  3274.03  12064.4  0.84  0.81  0.83 
ethidium bromide  Lane 18             
de-stained once  Lane 18  1782.4  3206.08  0.72       
de-stained twice  Lane 18  1705.16  3129.88  0.72  0.64  0.72 
ethidium bromide  Lane 19  1126.62  1177.61  0.59       
de-stained once  Lane 19             
de-stained twice  Lane 19        0.49  0.59 
ethidium bromide  Lane 20  8536.52  5192.96  0.46       
de-stained once  Lane 20  11616.95  6734.27  0.45       
de-stained twice  Lane 20  11303.71  6346.12  0.44  0.36  0.45 
ethidium bromide  Lane 21  9555.11  3485.52  0.34       
de-stained once  Lane 21  13013.02  4919.07  0.35       
de-stained twice  Lane 21  12978.91  4993.96  0.35  0.25  0.34 
ethidium bromide  Lane 22             
de-stained once  Lane 22             
de-stained twice  Lane 22        0.16    
ethidium bromide  Lane 23  9431.93  1013.09  0.13       
de-stained once  Lane 23  12916.78  1727.37  0.16       
de-stained twice  Lane 23  12429.71  1605.78  0.15  0.09  0.15 
ethidium bromide  Lane 24  12556.32  1143.68  0.11       
de-stained once  Lane 24  16370.4  1078.5  0.08       
de-stained twice  Lane 24  15748.39  852.49  0.07  0.04  0.09 
ethidium bromide  Lane 25  7052.41  87.6  0.02       
de-stained once  Lane 25  10590.74  175.1  0.02       
de-stained twice  Lane 25  10186.02  177.03  0.02  0.01  0.02 
ethidium bromide  Lane 26  9462.26  110.77  0.02       
de-stained once  Lane 26  13126.04  4.04  0.00       
de-stained twice  Lane 26  12619.76  771.9  0.08  0  0.03 
 
Table_Apx C-40: Results for standard curve PCR 3 -  ratiometric analysis 
 
   
 
 
 
 
   241 
  Standard curve  
Standard  Band A  Band B 
ratio 
squared  y value 
1  31286.35  972104.2  1  0.977496 
0.9  241781.6  941649.5  0.81  0.844833 
0.8  349303.5  636079.6  0.64  0.717971 
0.7  452541.4  460563.7  0.49  0.58725 
0.6  685199.1  440694  0.36  0.473445 
0.5  903416.6  366885.6  0.25  0.362138 
0.4  1148361  323404.2  0.16  0.282489 
0.3  1025607  165403.5  0.09  0.18398 
0.2  1327537  125233.1  0.04  0.116514 
0.1  1198757  42106.31  0.01  0.046806 
0  1171727  1507.43  0  0.001795 
1  21863.61  1094457  1  0.985912 
0.9  174596.9  774910.1  0.81  0.861201 
0.8  252062.7  490392.2  0.64  0.73117 
0.7  497739.9  506636.9  0.49  0.587285 
0.6  756588.4  496528.1  0.36  0.478478 
0.5  1022896  415959  0.25  0.362445 
0.4  1343940  375204.8  0.16  0.280729 
0.3  1199560  192560.8  0.09  0.183283 
0.2  1582240  154757  0.04  0.120288 
0.1  1464074  51863.16  0.01  0.047186 
0  1417755  3627.44  0  0.003564 
1  58329.24  2225888  1  0.9816 
0.9  349850.9  1764678  0.81  0.875801 
0.8  547607.8  912380.4  0.64  0.69963 
0.7  1726741  1795804  0.49  0.592487 
0.6  2240431  1740907  0.36  0.520682 
0.5  2708639  1351079  0.25  0.410837 
0.4  3131069  1294833  0.16  0.366339 
0.3  2949761  609680  0.09  0.224174 
0.2  3275824  502402.4  0.04  0.176552 
0.1  3052578  183880.9  0.01  0.077671 
0  2575844  5790.64  0  0.003133 
 
Table_Apx C-41: Results for standard curve  -  ratiometric analysis of control leukocyte samples 
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  Results of the three PCRs for leukocytes  
 
 PCR 
template 
transcrip
tion ratio 
squared=
x-value  y-value 
transcription 
ratioratio 
mean 
transcription 
ratio 
squared  
mean 
measured 
band 
intensity 
ratio 
mean 
transcription 
ratio 
gDNA 26  0.31  0.39  0.56         
gDNA 26  0.32  0.40  0.57         
gDNA 26  0.34  0.42  0.58         
gDNA 33  0.31  0.39  0.55         
gDNA 33  0.30  0.38  0.54         
gDNA 33  0.28  0.37  0.53  0.31  0.39  0.56 
cDNA-Ex1  0.58  0.65  0.76          
cDNA-Ex1  0.30  0.38  0.55          
cDNA-Ex1  0.93  0.97  0.96  0.60  0.67  0.76 
cDNA-Ex2  -0.11  0.00  0.00         
cDNA-Ex2  -0.10  0.01  0.00         
cDNA-Ex2  -0.09  0.01  0.00  -0.10  0.01  0.00 
cDNA-Ex3                 
cDNA-Ex3  0.93  0.98  0.97          
cDNA-Ex3  0.37  0.45  0.61  0.65  0.71  0.79 
cDNA-Ex4  0.42  0.50  0.65         
cDNA-Ex4  0.47  0.55  0.69         
cDNA-Ex4  0.01  0.11  0.11  0.30  0.38  0.48 
cDNA-Ex5                 
cDNA-Ex5                 
cDNA-Ex5  0.92  0.97  0.96          
cDNA-Ex6  0.95  0.99  0.97         
cDNA-Ex6  0.91  0.95  0.95         
cDNA-Ex6           0.93  0.97  0.96 
cDNA-Ex7  0.23  0.32  0.48          
cDNA-Ex7  0.83  0.88  0.91          
cDNA-Ex7  0.28  0.37  0.53  0.45  0.52  0.64 
cDNA-Ex8                  
cDNA-Ex8  0.52  0.59  0.72         
cDNA-Ex8                   
cDNA-In1  0.30  0.38  0.54          
cDNA-In1  -0.10  0.01  0.00          
cDNA-In1  0.55  0.62  0.74  0.25  0.34  0.43 
cDNA-In2  0.48  0.55  0.69         
cDNA-In2  0.44  0.51  0.66         
cDNA-In2  -0.10  0.01  0.00  0.27  0.36  0.45 
cDNA-In3  0.03  0.13  0.18          
cDNA-In3  0.93  0.97  0.96            243 
cDNA-In3  0.38  0.45  0.61  0.45  0.52  0.59 
cDNA-In4  0.91  0.96  0.95         
cDNA-In4  0.49  0.56  0.70         
cDNA-In4  0.93  0.98  0.97  0.78  0.83  0.87 
cDNA-In5  0.58  0.65  0.76          
cDNA-In5  0.93  0.98  0.96          
cDNA-In5  0.94  0.98  0.97  0.82  0.87  0.90 
cDNA-In6  0.93  0.98  0.96         
cDNA-In6                
cDNA-In6                   
cDNA-In7  0.94  0.98  0.97          
cDNA-In7  0.92  0.97  0.96          
cDNA-In7  0.93  0.97  0.96  0.93  0.97  0.96 
cDNA-In8  0.56  0.63  0.75          
cDNA-In8                 
cDNA-In8                   
 
Table_Apx C-42: Results for leukocyte samples  -  ratiometric analysis of control leukocyte samples 
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  Standard curve  
allelic 
ratio 
squared  Band A  Band B  A* 
measured 
band 
intensity 
ratio 
1  9647.347  251943.9  6900.853  0.97334 
1  22294.59  706510  15947.57  0.977926 
1  17473.78  578036.9  12499.18  0.978834 
0.81  45118.73  138313.3  32273.93  0.810807 
0.81  174902.2  533710.4  125109.5  0.810101 
0.81  175967.4  516757.2  125871.4  0.80413 
0.64  82504.67  117342.4  59016.5  0.665361 
0.64  332478.8  482542.7  237825.7  0.669855 
0.64  336707.3  509606.5  240850.5  0.679062 
0.49  274835.2  213880.9  196592.7  0.521059 
0.49  829827.2  710547.8  593584.6  0.544843 
0.49  294014.9  246399  210312.1  0.539507 
0.36  296112  145881.5  211812.2  0.407839 
0.36  1224445  629322.9  875859.3  0.418104 
0.36  371566.1  187474.7  265785.3  0.413614 
0.25  362012.7  115156.2  258951.7  0.307815 
0.25  1574394  499394.3  1126181  0.307211 
0.25  467782.9  148768.7  334610.3  0.307768 
0.16  256206.2  51493.76  183267.1  0.219346 
0.16  1925163  453642.5  1377090  0.247793 
0.09  298882.1  38470.03  213793.6  0.152499 
0.09  1892228  194268.2  1353532  0.125512 
0.09  498974.8  48781.54  356922.1  0.120239 
0.04  282939.5  15683.18  202389.7  0.071917 
0.04  2100353  137710.1  1502406  0.083964 
0.04  229588.7  13870.58  164227.3  0.077882 
0.01  335201.4  7171.007  239773.3  0.029039 
0.01  2219223  48138.71  1587435  0.029432 
0.01  231679.3  4257.387  165722.7  0.025046 
0  217244.5  116.3367  155397.3  0.000748 
0  1683863  181.4467  1204486  0.000151 
0  123872.6  290.32  88607.43  0.003266 
Table_Apx C-43: Results for standard curve – ratiometric analysis of vein samples  
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  Allelic Transcription Assay for vein samples  
TIG  Band A   Band B   band A*  allelic ratio squared  y axis  allelic ratio  variance 
2  338952.3  83784.19  242456.3  0.222379  0.256817  0.471571    
2  704243.3  443701.6  503753  0.442545  0.468309  0.665241    
2  146714.9  112579.9  104946.8  0.493801  0.517545  0.70271  0.015 
3  6841.99  272602.6  4894.151  0.977684  0.982363  0.988779    
3  5085.337  120887.1  3637.597  0.965634  0.970788  0.982667  0 
8  16708.31  218958.1  11951.64  0.942162  0.948241  0.97065    
8  772535.3  307.7167  552603  -0.04439  0.000557  0  0.471 
9  266310.1  108309.3  190494.5  0.332372  0.362476  0.576517    
9  585784.5  551004  419018.1  0.546359  0.568032  0.739161    
9  186457.9  18715.3  133375.4  0.083129  0.123054  0.288321  0.052 
11  303474  85256.54  217078.3  0.248588  0.281994  0.498586    
11  1106684  151907.8  791623.1  0.122631  0.160999  0.350187    
11  277573.3  99753.11  198551.2  0.303144  0.3344  0.550585  0.011 
13  303480.5  109837.2  217082.9  0.304784  0.335976  0.552073    
13  513266.9  306741.3  367145.4  0.42888  0.455182  0.654889    
13  240589.6  32103.34  172096.4  0.118692  0.157215  0.344517  0.025 
17  335440.3  54980.92  239944.1  0.149098  0.186423  0.386132    
17  618589.8  634856.6  442484.1  0.568479  0.589281  0.753976    
17  171379  17318.72  122589.3  0.083892  0.123786  0.289641  0.06 
20  336808.9  38426.91  240923.1  0.098228  0.137558  0.313414    
20  929701.5  324621.4  665025.7  0.296499  0.328017  0.544518    
20  49404.27  165335.3  35339.42  0.812718  0.823897  0.901509  0.088 
22  390613.3  1968.853  279410  -0.03769  0.006997  0    
22  82325.21  1067.067  58888.13  -0.02644  0.017798  0    
26  97015.83  194825  69396.49  0.722626  0.737355  0.850074    
26  572093.5  742628.5  409224.8  0.626197  0.644725  0.791326    
26  201825.7  171262.2  144368.2  0.519887  0.542604  0.721032  0.004 
28  86783.15  306912.1  62076.94  0.820909  0.831765  0.90604    
28  1268338  542298.3  907256.3  0.344487  0.374114  0.58693    
28  798834.1  262208.7  571414.9  0.28247  0.314541  0.531479  0.041 
37  821302.3  170296  587486.5  0.188975  0.224729  0.434713    
37  1668869  364662.5  1193760  0.19862  0.233995  0.445668    
37  169756  267125.9  121428.3  0.670713  0.687487  0.818971  0.048 
41  621996.8  319907  444921.2  0.390457  0.418273  0.624866    
41  877168.2  900700.9  627448.1  0.56861  0.589406  0.754062    
41  653960.8  74426.33  467785.3  0.097922  0.137264  0.312926  0.051 
43  706003.4  1150.73  505012  -0.04261  0.002273  0    
43  1000978  742044.4  716010.4  0.48483  0.508928  0.696297    
43  135863.3  109.1333  97184.54  -0.0438  0.001122  0  0.162 
44  743409.4  76105.2  531768.9  0.085362  0.125199  0.292168    
44  1777383  786025  1271381  0.352745  0.382047  0.593923    
44  419956.8  137318.6  300399.7  0.28161  0.313715  0.530669  0.025 
46  553062.9  238169.4  395612  0.346233  0.375791  0.588415    
46  1608463  690014.5  1150552  0.345297  0.374893  0.58762    
46  201428.5  381244.1  144084  0.71052  0.725726  0.842924  0.022 
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TIG   Band A  Band B  Band A* 
x-axis = 
allelic 
ratio 
squared 
y-
axis 
allelic 
ratio  Variance 
3  642089.53  177162.92  459293.71  0.15  0.28  0.38    
3  549464.55  294184.50  393038.04  0.32  0.43  0.56  0.016 
8  12221.21  319054.61  8741.97  0.93  0.97  0.96    
8  8769.50  84856.78  6272.92  0.88  0.93  0.94    
8  16972.46  346759.73  12140.58  0.92  0.97  0.96  0 
9  347687.61  295465.58  248704.77  0.45  0.54  0.67    
9  450500.91  114000.45  322248.26  0.13  0.26  0.36    
9  549440.99  193055.61  393021.18  0.21  0.33  0.45  0.025 
13  14584.78  366950.83  10432.65  0.93  0.97  0.96    
13  7494.71  79617.75  5361.05  0.89  0.94  0.94  0 
22  190984.30  427494.66  136613.17  0.69  0.76  0.83    
22  292690.89  399531.28  209365.01  0.57  0.66  0.76    
22  28757.85  510935.15  20570.80  0.92  0.96  0.96  0.01 
26  18850.31  358287.13  13483.83  0.92  0.96  0.96    
26  7033.08  50378.19  5030.84  0.86  0.91  0.93    
26  20537.76  379713.93  14690.88  0.92  0.96  0.96  0 
28  554685.47  367257.57  396772.62  0.38  0.48  0.61    
28  400189.42  386957.50  286259.90  0.48  0.57  0.69    
28  656161.23  444170.12  469359.35  0.38  0.49  0.62  0.002 
44  530601.12  222952.68  379544.82  0.25  0.37  0.50    
44  321617.40  239106.32  230056.47  0.41  0.51  0.64    
44  205821.55  92631.61  147226.42  0.27  0.39  0.52  0.006 
 
Table_Apx C-45: Results for allelic transcription assay for adipose tissue. 
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Appendix D:  Supplementary Material 
 
Figure_Apx D-1: Patient Questionnaire  
 
 
Patient Follow up Questionnaire 
TIG:______________________ 
Date:______________________ 
 
Study Group ⁪     Control Group⁪ 
 
Number of weeks post op: ________ 
Date of operation:_______________ 
 
Recruitment 
 
How do you feel about the way you were recruited to the study? 
 
Very satisfied    satisfied  unsatisfied  very unsatisfied 
 
Give reasons why not satisfied:___________________________________________ 
____________________________________________________________________ 
 
Would you take part in clinical studies in the future:   ⁪Yes    ⁪No 
 
Surgery 
 
Did you have any complications from the operation which required you to seek medical 
advice? 
 
⁪No  ⁪Yes-Give details: ______________________________________________ 
  
How long after your surgery were you able to resume your normal daily activity? 
⁪<1 week  ⁪ 1-2 weeks  ⁪ 2-3 weeks  ⁪ 3-4 weeks  ⁪ other:  
 
On the first day after your operation, how sever was your pain? 
 
0 1 2 3 4 5 6 7 8 9 10 
 
On the second day after your operation, how sever was your pain? 
 
0 1 2 3 4 5 6 7 8 9 10 
 
Did you feel that you suffered any ill side effects due to taking part in this study? 
 
⁪No  ⁪Yes, Give Reasons why: _________________________________________   248 
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Patient Information Sheet 
 
Tissue Specific Genetic Regulation of Interleukin-6 Synthesis
1 
 
Introduction: 
You are being invited to take part in a research study.  Before you decide it is 
important that you understand why the research is being done and what it will 
involve.  Please take time to read this information and discuss it with others if 
you wish. 
 
Background Information: 
Various diseases including diseases of the heart are made worse in people who 
produce  too  strong  an  inflammatory  response.    A  chemical  known  as  IL-6  is 
produced at different levels in different tissues in different people, and may be a 
key culprit, contributing to the chance of dying from e.g. a heart attack.  We want 
to  find  out  more  about  IL-6  by  studying  healthy  people.    We  will  undertake 
studies of IL-6 and related chemicals using small samples taken as biopsies from 
routine operations (these samples would normally be removed and discarded at 
the  time  of  operation).    In  the  laboratory  we  will  study  the  time  course  of 
production of our possible culprit: IL-6 - in response to specific noxious stimuli. 
With  such  a  strategy,  using  samples  from  healthy  individuals  producing  the 
various types of IL-6, we will have a much clearer idea of the role of IL-6 and 
how best to design drugs that could combat its harmful effects and thus help 
prevent people dying. 
 
Why have I been chosen? 
You are already scheduled to undergo an operation on the varicose veins that 
are currently causing you problems.  Other than the trouble with your varicose 
veins you are deemed medically fit and stable.  Therefore you would be an ideal 
candidate for this research on normal individuals free from significant disease. 
 
 
What the study involves: 
Patients  under  the  care  of  Consultant  Vascular  Surgeons,  from  Southampton 
General Hospital and the Royal South Hants Hospital will be considerer for the 
inclusion in this study. 
You  will  continue  to  receive  all  the  standard  care  normal  for  patients  with 
varicose  vein  disease  and  your  surgery  will  be  performed  by  your  vascular 
surgeon in exactly the same manner as in routine with all other patients. 
If you agree to take part in the study and have read and signed the consent form, 
then at the time of your operation confirmation of your medical history and any 
drugs that you are currently taken will be obtained.  A blood test will also be 
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required for us to ascertain your profile for these inflammatory markers. During 
your operation to remove the varicose vein a portion of the excised tissue will be 
made available for cell culture and for analysis at the molecular level. A biopsy of 
skeletal muscle and fat will also be taken for similar analysis. Specific cell types 
isolated form the blood sample will also be grown short term in culture.  With 
your  permission  blood  and  tissue  samples  will  be  frozen  and  stored 
anonymously  for  future  studies  relating  to  cardiovascular  and  inflammatory 
disease. 
 
 
What are the risks / benefits in taking part in this study? 
Your operation will be carried out as normal.  The material made available for 
study is material that would normally be excised and disposed of.  An additional 
sample  of  blood  will  be  required  but  that  should  not  cause  any  additional 
significant  discomfort.    Skeletal  muscle  and  fat  samples  will  only  be  taken  if 
appropriate. 
The benefits of this work will not be realized immediately.  You individually will 
not receive any benefit as a result of your participation in the study.  The impact 
of the study will only be realized when all the data from our normal individual 
study population is analysed as a whole. 
 
Is there anything else I should do? 
If you agree to be part of this study there are no specific requirements for you to 
do anything other than to allow the use of the biopsy material and additional 
blood sample. 
 
Will my taking part in this study be kept confidential? 
If you consent to take part in the study your medical records may be inspected by 
a member of the research team for the purpose of analysing the results.  They 
may also be looked at by the regulatory authorities to ensure that the study is 
being carried out correctly.  All information that is collected about you during the 
course  of  the  research  will  be  kept  strictly  confidential.    Any  information  and 
samples that leave the hospital will have your name and contact details removed 
so that you cannot be recognized from it. 
With your permission we will inform your GP on your behalf that you are taking 
part  in  this  study.    As  you  know  you  GP  will  also  keep  this  information 
confidential. 
 
What happens if something goes wrong?   
Compensation  for  any  injury  caused  by  taking  part  in  this  study  will  be  in 
accordance  with  the  guidelines  of  Southampton  General  Hospital  Indemnity 
Policy. 
   257 
Who has reviewed this study? 
This study has been reviewed and approved by Southampton and South West 
Hampshire  Local  Research  and  Ethics  Committed  submission  number 
040/04/W. This is a group of people not involved in this study, which reviews the 
science and ethics of the study before it is allowed to start. 
 
If there is anything that is not clear or if you would like more information please 
contact: 
 
                 
Consultant Vascular Surgeons       
E level West Wing           
Southampton General Hospital       
Tel: 023 8079 8801          
 
Professor I Day           
Division of Human Genetics       
Duthie Building           
Southampton General Hospital       
Tel: 023 8079 4116 
 
Jenny Williams 
Sabine Sonnenberg 
Vascular Research 
F level Centre Block 
Southampton General Hospital 
Tel.: 023 8079 8558 
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Patient Identification for Study 
 
CONSENT FORM
2 
 
Title of Project:      Tissue Specific Genetic Regulation of  
Interleukin-6 Synthesis 
 
Name of Researchers:  Professor C Shearman, Professor I Day 
        Dr H Montgomery, Dr D Cumming 
 
PLEASE INITIAL BOXES IF YOU AGREE WITH EACH SECTION. 
 
1.  I  confirm  that  I  have  read  the  information  sheet  dated  04/01/05 
(version  3)  for  the  above  study,  have  had  the  opportunity  to  ask 
questions,  understand  why  the  research  is  being  done  and  any 
possible risks have been explained to me. 
 
 
2.  I understand that my participation is voluntary and that I am free to 
withdraw at any time by contacting Professor Shearman or a member 
of  the  research  team,  without  giving  any  reason  and  without  my 
medical care or legal rights being affected.  If I withdraw I understand 
that  any  unused  donated  tissue  will  be  disposed  of,  in  the  case  of 
unlinked anonymised samples. 
 
 
3.  I understand that sections of my medical notes may be looked at by 
responsible  individuals  of  the  research  team  of  from  regulatory 
authorities where it is relevant to my taking part in this study.  I give 
permission for these individuals to have access to my records. 
 
 
4.  I understand that my own GP will be informed if any of the results of 
the medical tests done as part of the research are important for my 
health. 
 
 
5.  I agree to take part in the above study for collection of blood and tissue 
biopsies 
6.   
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Unlinked Anonymised Samples: 
 
7.  I  give  permission  for  the  samples  to  be  used  for  investigations  of 
medical  conditions  relating  to  inflammatory  and  cardiovascular 
disease. 
 
 
8.  I  give  permission  for  the  samples  to  be  stored  for  use  in  other 
unrelated  research  studies  the  precise  nature  of  which  will  depend 
upon future scientific advances but excluding germ line research. 
 
 
9.  I understand that future research using samples I give may include 
genetic research aimed at understanding the genetic influences on the 
susceptibility and progression of disease, particularly inflammatory and 
cardiovascular disease. 
 
 
10.  I  understand  that  the  samples  my  be  used  for  Commercial 
development,  without  financial  or  other  benefit  to  myself  for  the 
investigation  of  medical  conditions,  potentially  leading  to  new 
preventative measures against such conditions in keeping with the gift 
nature of my sample 
 
 
 
 
 
 
____________________    ___________  _____________________ 
 
NAME OF PATIENT    DATE     SIGNATURE 
 
 
____________________    ___________  _____________________ 
 
NAME OF PERSON    DATE     SIGNATURE 
TAKING CONSENT IF  
DIFFERENT FROM 
RESEARCHER 
 
 
____________________    ___________  _____________________ 
NAME OF RESEARCHER   DATE     SIGNATURE 
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Appendix E:  Technical Notes 
a:  Standard Curve 
When making a standard curve it is important to avoid overspill from one well to the 
next as this would alter the intensity of the measured fluorescence. Several point will 
help ovoid this error. 
1.  Use of high concentration loading dye 
2.  Allowing the surface of the gel to dry slightly before filling the well 
3.  Ensuring the well is empty by aspiration with a pipette before inserting the 
sample 
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